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Summary
The aim of this thesis was to characterise further the lipoprotein abnormalities present 
in the St Thomas’ Mixed Hyperlipidaemic (SMHL) rabbit, assess the suitability of this 
strain as an animal model for the human disorder familial combined hyperlipidaemia, 
and to investigate the genetic defect giving rise to the disorder.
The SMHL rabbit colony was derived from the original St Thomas’ Hospital rabbit 
colony, first described in 1987 as exhibiting elevated plasma cholesterol, plasma 
triglyceride or both. Indirect evidence for overproduction of VLDL and LDL apoB as 
the underlying metabolic defect was obtained. To investigate lipoprotein metabolism in 
these rabbits further, we made use of techniques already in place in our laboratory, 
developed a liver perfusion method and took advantage of new molecular biological 
techniques for mRNA quantitation.
All studies were performed on rabbits fed a 0.08% cholesterol diet, which was found to 
exaggerate an already dyslipidaemic phenotype in the SMHL rabbits. Plasma 
cholesterol levels were found to be elevated in both young and mature male SMHL 
rabbits in comparison to NZW controls (p < 0.001, p = 0.04 respectively). Plasma 
triglyceride levels were elevated in young SMHL rabbits compared to young NZW (p 
< 0.001), but there was no difference between the strains in mature rabbits. These 
changes were found to be as a result of an increased mass of each of the lipoproteins 
studied: very low density lipoprotein (VLDL)i, VLDL2, intermediate density
lipoprotein (IDL) and low density lipoprotein (LDL), (Sf 60 - 400, Sf 20 - 60, Sf 12 - 
20 and Sf 0 - 12 respectively) but there was no alteration in lipoprotein composition or 
apolipoprotein content. The SMHL rabbits exhibited insulin resistance with 
exaggerated free fatty acid (FFA) and insulin responses to an oral glucose dose. 
Cholesteryl ester transfer protein (CETP) activities were increased 3 fold in the SMHL 
rabbits (p < 0.01), but there were no differences in hepatic lipase (HL) or lipoprotein 
lipase (LPL) activities.
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Investigation of the kinetics of lipoprotein metabolism using stable isotope labelling of 
apoB, yielded poor results due to the assays being at the limit of detection. There were 
no significant differences in production rates or catabolic rates of any of the lipoprotein 
species, however, trends towards increased VLDLi and IDL production, and 
decreased IDL catabolism were seen.
To investigate directly the output of apoB containing lipoproteins from the liver of the 
SMHL rabbits, we developed a method to perfuse the rabbit livers. This involved the 
perfusion of the organ for 3 hours with a recirculating, oxygenated Krebs Henseleit 
buffer at 37°C, and the isolation of lipoproteins from the perfusate at regular intervals 
throughout. We performed these studies in both young and mature NZW and SMHL 
rabbits. In the mature rabbits, total cholesterol output was increased in the SMHL 
rabbits, but not significantly so, and there was no difference in total triglyceride output. 
VLDLi, VLDL2, IDL and LDL were separated by density gradient ultracentrifugation, 
and cholesterol, triglyceride and apoB measured in each fraction. For the analysis of 
results, VLDL2, IDL and LDL were grouped together to form a ‘cholesterol rich’ non 
VLDLi fraction. In the mature rabbits VLDLi and non VLDLi cholesterol output 
rates were increased but not significantly so. There was no difference in VLDLi 
triglyceride output rate, but non VLDLi triglyceride output rate was significantly 
increased in SMHL rabbits (p < 0.05). Output rates of apoB showed much greater 
differences, with non VLDLi apoB output rate exhibiting a 6 fold elevation in the 
SMHL rabbits compared to the NZW rabbits (p = 0.01). In the young rabbits, 
cholesterol output rate was significantly increased 2 fold (p < 0.01) in the SMHL 
rabbits, and triglyceride output rate was increased 3 fold (NS). VLDLi and non 
VLDLi cholesterol output rates were significantly increased (4 fold, p < 0.05 and 5 
fold, p < 0.05 respectively). Non VLDLi triglyceride output rate was significantly 
increased 6.5 fold (p < 0.05) in SMHL rabbits. Again, output rates of apoB showed 
large differences, VLDLi apoB output rate was significantly increased 3.5 fold (p < 
0.05) in SMHL rabbits, and non VLDLi apoB output rate was significantly increased 
13 fold in SMHL rabbits (p < 0.005).
To investigate the genetics of the disorder, based on the information we had collected, 
we identified a group of candidate genes that had the potential to contribute to the
21
phenotype. Using reverse transcriptase polymerase chain reaction, we obtained a 
measure of the relative expression of the candidate genes in hepatic mRNA. We 
examined transcription of apoB, VLDL receptor, LDL receptor, CETP, microsomal 
triglyceride transport protein (MTP), protein disulphide isomerase (PDI) and 
cholesterol 7 alpha-hydroxylase, and found that, in relation to a housekeeping gene, 
glyceraldehyde 3 phosphate dehydrogenase (GAPDH), apoB, CETP and VLDL 
receptor mRNAs were present at significantly higher levels in SMHL rabbits (p = 
0.005, p = 0.002, p = 0.02 respectively) than NZW rabbits. There were no significant 
differences in any of the other genes between the rabbit strains.
Therefore, we concluded that the SMHL rabbits exhibit a number of characteristics in 
common with the disorder familial combined hyperlipidaemia, namely increased plasma 
cholesterol, plasma triglyceride or both, increased apoB production across the 
lipoprotein spectrum, a possible decreased catabolism of apoB containing lipoproteins, 
insulin resistance and increased CETP activity. The driving force is likely to be an 
increased rate of apoB synthesis due to an upregulation of translation of this gene, with 
ancillary effects on the VLDL receptor and CETP activity. Consequently, SMHL 
rabbits are, it appears, an excellent model for the human disorder familial combined 
hyperlipidaemia.
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Chapter 1. Introduction
7 know what we 've got to do, ’ said Hazel, ‘but I  still can 7 see how. ’ ‘We ’re going 
to need some new ideas, ’ agreed Blackberry. They knew that it was on these and on 
nothing else that their lives, and the lives o f  their children, depended.
Richard Adams, Watership Down
1.1. The prevalence of Coronary Heart Disease
Coronary heart disease (CHD) is the most common cause of death in the Western 
world, with rates in the United Kingdom, and particularly Scotland, being amongst the 
highest (Marmot, 1988). Keys (1957,1970) first suggested that this could be due to 
differences in diet, and showed that although the Japanese have one o f the lowest 
cholesterol levels and CHD prevalence at home, when they emigrated to California 
they took on the lifestyle and subsequently the CHD risk of an American (Keys, 
Minnesota, Kimura, el al, 1957).
Indeed, countries such as the USA and Finland have undertaken successful education 
programmes, recommending dietary and lifestyle changes that have more than halved 
their CHD deaths (Stamler and Stamler, 1984, Puska, Vartiainen, Tuomilehto, et al, 
1998). In 1992 the Secretary of State for Health in the United Kingdom proposed 
that by the year 2000, death rates from CHD should be reduced by 40% in the under 
65s, and by 30% in those aged 65 - 74, by making lifestyle changes such as a 
reduction in smoking, obesity, plasma cholesterol and blood pressure.
However, not all lipid related CHD risk is due to diet. There is a strong genetic 
component which for affected individuals increases risk. A number of common 
genetic hyperlipidaemias have been described which affect up to 0.5% of the 
population but are found in 10% of subjects who have had a myocardial infarction 
(MI). The characterisation of the metabolic basis of genetic hyperlipidaemia will 
assist not only in understanding the specific problem but will offer general insight into 
the regulation of lipoprotein metabolism and new approaches to lipid lowering 
treatments.
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1.2. Lipids
The term lipid defines a heterogeneous group of substances which contain fatty acids 
(FA) or are of steroid derivation. They require organic solvents to solubilise them as 
they are immiscible in water. Cholesterol (and cholesteryl ester), triglyceride and 
phospholipid are the major lipids in the human body.
1.2.1 Cholesterol
Cholesterol is an essential component of cell membranes and plays a major role in 
controlling their fluidity. It is the main sterol in the human body and is the precursor 
o f bile acids, oestrogens, androgens, vitamin D and other steroid hormones. It can 
exist as free cholesterol, or as cholesteryl ester when complexed with a fatty acid. 
Cholesterol is synthesised de novo in the body from acetyl Coenzyme A (acetyl-CoA), 
in a series of steps regulated by the enzyme 3-hydroxy, 3-methylglutaryl-Coenzyme A 
reductase (HMG CoA reductase). The other source of cholesterol is the diet.
The liver is of central importance in cholesterol transport in the body. It regulates 
lipoprotein production and much of the catabolism of these lipid: protein complexes. 
Hepatic cholesterol homeostasis is regulated via the activation of key enzymes such as 
HMG CoA reductase (cholesterol synthesis), acyl coenzyme A:cholesterol 
acyltransferase (ACAT) (cholesterol esterification) and cholesterol 7 alpha- 
hydroxylase (conversion of cholesterol to bile acids for excretion). The function of 
cholesterol of greatest interest for the present discussion is as a component of plasma 
lipoproteins.
1.2.2 Triglyceride
Triglycerides, also called triacylglycerols, are formed by esterifying the hydroxyl 
groups of glycerol with FA. Fatty acids are hydrocarbon chains of varying length, and 
can be saturated (no double bonds) or unsaturated (one or more double bonds). Long 
chain FA circulate bound to albumin in the plasma (Spector, 1975), while short chain 
FA are soluble. Triglycerides are the major energy store in mammals, providing 9 
kcal/g, and are the form in which most FA are stored, with 95% of the body’s
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triglyceride being found in the adipose tissue. Triglycerides are synthesised by many 
tissues, with the liver being the main site, using circulating free fatty acids (FFA). 
Ingested fat provides the FA for triglyceride synthesis in the gut. Circulating 
triglycerides in lipoproteins are hydrolysed to provide FA supplies for energy 
production by the muscle or for storage in the adipose tissue (reviewed in Coppack, 
Jensen and Miles, 1994). De novo synthesis from acetyl-CoA derived from glucose 
and other dietary carbohydrates, is also a source of FA for triglyceride synthesis.
1.2.3 Phospholipid
Phospholipids, like triglycerides, are derived from glycerol. Fatty acid chains are 
esterified to the glycerol backbone at positions 1 and/or 2, and a phosphoric acid is 
found at position 3, attached to another small molecule, that gives the phospholipid 
specific features and contributes to its amphipathic nature. The majority are 
synthesised by the liver, but all tissues can make phospholipids. These lipids act as 
emulsifiers, enabling hydrophobic molecules such as cholesteryl ester and triglyceride 
to exist in aqueous solutions. They form a protective barrier by lining up with their 
polar head groups towards the aqueous environment, and their non polar hydrocarbon 
chains towards the hydrophobic inside. Because of these properties, phospholipids 
are an essential component (40-50%) of biological membranes.
1.3. Lipoproteins
1.3.1 Human lipoproteins
Mammals and many other higher species transport neutral lipids (cholesteryl ester and 
triglyceride) in aqueous solutions such as plasma in the form of lipoprotein particles. 
These consist of a hydrophobic core of neutral lipid, surrounded by a hydrophilic 
monolayer of phospholipid, free cholesterol and protein. Plasma lipoproteins vary 
between species, with the most detailed investigations having been performed on 
human lipoproteins. There are five discrete populations of human lipoproteins that 
can be distinguished by composition, size and density (Table 1.1.). These are 
chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins
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(HDL). These can be grouped into two main families on the basis of their 
apolipoprotein (apo) content - apoA containing lipoproteins (HDL), and apoB 
containing lipoproteins (VLDL, IDL and LDL containing apoB-100 and chylomicrons 
containing apoB-48). Each lipoprotein class can be further subdivided into discrete 
subpopulations with different functions.
Table 1.1. % composition by weight, density and size of human plasma
lipoproteins
Chylo VLDL IDL LDL HDL
CE 2 7 8 10 4
Triglyceride 84 55 32 9 4
FC 5 12 23 38 14
Phospholipid 7 18 21 22 28
Protein 2 8 16 21 50
Density (g/ml) <0.95 <1.006 1.006 - 
1.019
1.019-
1.063
1.063 - 
1.021
Flotation Rate 
(Sf value, F 
value for HDL)
>400 20 - 400 12 - 20 0 -  12 0 - 9
Diameter (A) >800 300 - 800 250 - 300 200 - 250 75 - 200
Chylomicrons (chylo), cholesteryl ester (CE), free cholesterol (FC)
S f  values (Svedberg Flotation Units measured against a density o f  1.063 g/ml), and  
F  values (Svedberg Flotation Units measured against a density o f  1.21 g/ml). 
(Warwick, 1991)
Lipoprotein fractions can be separated by centrifugation on the basis of their density 
and flotation value (Alaupovic, Gustafson, Sanbar, et al, 1964), by electrophoresis 
(paper or gel) on the basis of charge (Fredrickson, Levy and Lees, 1967a) or by size 
(Mills, Lane and Weech, 1984). Each class has a specific role in the transport of lipid, 
but all act coordinately to control lipid flux throughout the body.
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1.3.2 Chylomicrons
Chylomicrons are very large triglyceride rich lipoprotein particles, formed exclusively 
in the mucosal cells of the small intestine from absorbed dietary fat (Figure 1.1.). 
Chylomicrons are distinguishable from the other lipoproteins as they are the only class 
to contain apoB48 (see section 1.4.3). ApoAI, All and AIV, apoCs and apoE are 
also associated with chylomicrons (Table 1.3.). In humans, chylomicron levels peak 2- 
4 hours after a meal and then return to fasting levels within 8 hours and so the 
particles are usually absent in the fasting state. In the rabbit the study of chylomicrons 
is complicated by the fact that they take longer to fast due to their coprophagic 
behaviour.
1.3.3 Very low density lipoprotein
VLDL are triglyceride rich lipoproteins, similar to chylomicrons but with two major 
differences - the apoB is the full length apoBlOO, and the triglycerides are from an 
endogenous source. VLDL are synthesised in the liver, with their lipid content 
reflecting that of the hepatocyte. VLDL contain apoBlOO, apoCs and apoE on their 
surface (Table 1.3.).
VLDL particles are commonly subfractionated into two groups - large triglyceride 
rich VLDLi (Sf 60 - 400), and small, relatively cholesteryl ester rich VLDL2 (Sf 20 - 
60). These subfractions have distinct metabolic properties; both can be synthesised by 
the liver, but VLDL2 can also be formed as a result of catabolism of VLDLi. Kinetic 
studies have shown that VLDLi and VLDL2 are metabolised down parallel lipolytic 
pathways and generate LDL products o f differing properties (Packard, Munro, 
Lorimer, et al, 1984).
1.3.4 Intermediate density lipoprotein
IDL are also known as VLDL remnants, however they are a distinct subspecies which 
are important in their own right and are believed to be atherogenic. They are thought 
to be directly synthesised by the liver, as well as being formed as a result o f catabolism
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Figure 1.1. Overview oflipoprotein metabolism
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Lipid is absorbed into the body from  the diet in the form  o f  chylomicrons. Triglyceride 
(TG) from  these particles is hydrolysed by LPL and stored in adipose tissue, and 
apolipoproteins and phospholipid from  chylomicrons are transferred to newly forming  
HDL particles. These newly forming HDL obtain cholesterol from  peripheral tissues, 
and CETP exchanges cholesterol in the HDL particles with triglyceride in the 
chylomicron particles, form ing chylomicron remnants (chylo remn). In this way, 
cholesterol is transferred from  peripheral tissues to the liver, with chylomicron 
remnants being taken up by the liver via the apoE recognising LRP. Triglyceride in the 
adipose tissue is transported to the liver as FA bound to albumin, and is secreted from  
the liver as VLDL], VLDL2, IDL or LDL. These particles can be taken back up into the 
liver by the LRP or the LDL receptor, or can be delipidated by the action o f  LPL and 
HL. FA liberated by these enzymes is delivered to adipose tissue or skeletal muscle. 
Additionally, VLDL or IDL particles can be taken up by adipose tissue o f  skeletal 
muscle via the apoE recognising VLDL receptor. Cholesterol is also transported to 
VLDL, IDL and LDL particles from  HDL in exchange fo r  triglyceride, a process 
mediated by CETP. Cholesterol from  peripheral tissues can be delivered to these 
apoBlOO containing particles and hence to the liver, via HDL, in processes that involve 
LCAT and CETP.
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of VLDL. IDL can be cleared from the circulation by the liver, or can be further 
catabolised by hepatic lipase (HL) to LDL. Humans have relatively low levels of IDL 
compared to other subfractions, however rabbits have much more substantial IDL 
concentrations. IDL contains apoBlOO, apoC and apoE (Table 1.3.), and has been 
shown to consist of two subpopulations on gradient gel electrophoresis (Musliner, 
Giotas and Krauss, 1986, Meyer, Caslake and Packard, 1997)
1.3.5 Low density lipoprotein
The majority of cholesterol in the plasma is carried in LDL. LDL are formed from the 
delipidation o f IDL, and may also be directly synthesised by the liver (Huff, Telford, 
Woodcroft, et al, 1985, Ginsberg, 1995, Packard and Shepherd, 1997). ApoBlOO 
constitutes 95% of the protein on LDL, and there is only one apoB per particle. LDL 
are cleared from the plasma by the hepatic LDL receptor, and also by receptor- 
independent mechanisms that are currently poorly characterised, resulting in the 
delivery of cholesterol to peripheral tissues. Subclasses of LDL exist with differing 
atherogenic potential. In normolipidaemic subjects, 3 subclasses can be readily 
identified (LDL I, LDL II and LDL III) (Griffin, Caslake, Yip, et al, 1990). Small, 
dense LDL III is most abundant in subjects with raised plasma triglyceride levels and 
is held to be the most atherogenic. It has a longer residence time in the circulation, is 
more susceptible to oxidation, has been shown to bind more readily to arterial wall 
proteoglycans (Anber, Millar, McConnell, et al, 1997) and due to its small size is 
easily taken up into the arterial wall.
1.3.6 High density lipoprotein
In humans, HDL is synthesised both by the liver and the small intestine. The main 
protein is apoAI, but HDL also contains apoAII, apoC and apoE (Table 1.3.). HDL 
is commonly subdivided into HDL2 (d = 1.063 - 1.125 g/ml) and HDL3 (d = 1.125 - 
1.21 g/ml).
HDL is involved in reverse cholesterol transport. In this process free cholesterol from 
cells and the surface layer of triglyceride rich lipoproteins is captured in HDL and
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esterified by the action of LCAT. Cholesteryl esters from HDL are then either taken 
up directly by the liver (Sherrill, Innerarity and Mahley, 1982, Franceschini, Maderna 
and Sirtori, 1991) or passed to VLDL and LDL by the action of CETP. The acceptor 
lipoprotein is then subject to receptor mediated degradation in the liver. This 
mechanism of transport of cholesterol from the peripheral tissues back to the liver for 
excretion gives the HDL particle its anti-atherogenic properties.
1.3.7 Lipoprotein(a)
Lipoprotein(a) (Lp(a)) is an LDL sized cholesterol rich lipoprotein particle containing 
apoB and apo(a). However, unlike LDL, Lp(a) is not derived from a triglyceride rich 
precursor, it is probably secreted directly from the liver. Increased levels o f Lp(a) 
have been associated with CHD (Dahlen, Guyton, Attar, et al, 1986). Lp(a) has been 
found to accumulate in atherosclerotic plaques (Smith and Cochran, 1990) and to 
have a role in the atherothrombotic process (Chapman, Huby, Nigon, et al, 1994).
1.3.8 Rabbit lipoproteins
The lipoprotein profile of the rabbit is distinguishable from that of the human mainly 
by the fact that there is a significant IDL fraction while generally VLDL and LDL 
fractions are substantially lower than in humans (Chapman, 1980). There is evidence 
(Ghiselli, 1982) that LDL can be directly synthesised in rabbits in addition to being a 
delipidation product. HDL is the dominant lipoprotein class, being present in higher 
concentrations than in humans.
The composition of rabbit lipoproteins (Table 1.2.) is variable as reported in the 
literature (reviewed in Chapman, 1980), due to the variety o f strains and the effects of 
diet on lipoprotein concentrations and compositions. VLDL and IDL have an 
intermediate composition between human VLDL and LDL. Rabbit LDL is 
triglyceride enriched and cholesterol poor in relation to human LDL. However, rabbit 
VLDL, LDL and HDL are of similar size range, structure and surface charge as 
human species.
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Table 1.2. Percentage composition (by weight) and size of plasma lipoproteins 
in New Zealand White (NZW) rabbits
VLDL IDL LDL
CE 6.6 ± 1.1 23.5 19.3 ±3 .5
Triglyceride 62.2 ±0 .4 30.6 26.4 ± 3 .0
FC 3.7 ±0 .4 6.3 5.1 ±0 .5
Phospholipid 15.6 ± 2.1 19.7 20.0 ± 2 .7
Protein 11.9 ± 1.3 19.9 29.3 ±2 .8
Diameter (A) 440 249 222
(Havel, Kita, Kotite, et al, 1982)
Rabbit apolipoproteins are similar to those in humans, although not entirely 
homologous (Shore and Shore, 1976). One aspect o f lipoprotein metabolism in the 
rabbit that makes it a much more suitable model for the human situation than for 
example the rat, is that apoB48 is synthesised solely in the intestine, and apoBlOO in 
the liver. Additionally, hepatic cholesterol synthesis occurs at similar rates in the 
rabbit and the human (20 and 16% of the rat level respectively). Furthermore the 
rabbit has similar properties of LCAT and cholesteryl ester transfer activity in plasma 
to humans (De Parscau and Fielding, 1984).
1.4. Apolipoproteins
Apolipoproteins are the protein ‘couriers’ on lipoprotein particles that help solubilise 
cholesterol and triglyceride for transport (Table 1.3.). They regulate the activities of 
enzymes important in lipoprotein metabolism, and act as ligands for targeting 
lipoproteins to specific cell receptors (Mahley, Innerarity, Rail, et al, 1984). 
Apolipoproteins share many common features and are believed to have evolved from 
a common origin, as their amino acid sequences show striking homologies.
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Table 1.3. Properties of apolipoproteins
Apo Molecular
Weight
Origin Lipoprotein
Association
Functions
Al 28 500 Liver,
intestine
HDL,
chylomicrons
Activates LCAT
a h 17 400 Liver,
intestine
HDL,
chylomicrons
Activates HL, inhibits LCAT
ATV 46 000 Intestine Chylomicrons Activates LCAT, activates 
LPL via apoCII
B100 512 000 Liver VLDL, IDL, 
LDL
Triglyceride transport 
(VLDL), receptor-mediated 
LDL catabolism
B48 241 000 Intestine Chylomicrons Triglyceride transport
Cl 6 300 Liver,
intestine
HDL, VLDL, 
chylomicrons
Activates LCAT, lipase
c n 8 800 Liver,
intestine
HDL, VLDL, 
chylomicrons
Activates LPL
c m 8 800 Liver,
intestine
HDL, VLDL, 
chylomicrons
Inhibits LPL
E 35 000 Liver, brain, 
macrophages
VLDL, IDL, 
HDL
Receptor mediated catabolism
(a) 200 000 - 
700 000
Liver Lp(a) Not known
Lipoprotein lipase (LPL)
Adapted from Schaefer, Eisenberg and Levy (1978) and Laker and Evans (1996).
1.4.1 Apolipoprotein (a)
Apo(a) is highly glycosylated and exists in more than 30 different isoforms which vary 
in size from 200 to 700 kDa. This is due to the presence o f a variable number o f
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kringle 4 repeats. The plasma concentration of Lp(a) in general appears to be 
inversely related to the size of the apo(a) (Gaw, Boerwinkle, Cohen, et al, 1994). 
Apo(a) is synthesised by the liver, and attaches to apoB by a disulphide bond, which 
causes the Lp(a) particle to be cleared less efficiently by the LDL (B/E) receptor. 
However, Lp(a) in familial defective apoB (FDB) and familial hypercholesterolaemia 
(FH) patients is cleared at the same rate as normals, therefore there must be a 
clearance mechanism other than the LDL receptor (Perombelon, Gallagher, Myant, et 
al, 1992). Apo(a) has a high degree of homology with plasminogen and an 
interference with the thrombolysis pathway has been suggested as a potential 
mechanism for the atherogenicity of Lp(a) (Maher and Brown, 1995).
1.4.2 Apolipoprotein A
There are three main forms of apoA - apoAI, apoAII and apoAIV. The intestine is 
capable of synthesising all apoA proteins, but apoAI and apoAII are also synthesised 
in the liver. The genes for apoAI and apoAIV are found on chromosome 11, while 
that for apoAII is found on chromosome 1. ApoAI, the main apolipoprotein on HDL, 
is considered important in reverse cholesterol transport and is also found on 
chylomicrons. ApoAII is found mostly on HDL. Both apoAI and apoAII act as 
cofactors for LCAT. ApoAIV is found on chylomicrons and in small amounts on 
HDL, but the majority is free in plasma. It may also act as an activator o f LCAT.
1.4.3 Apolipoprotein B
The apoB gene was the last of the major human apolipoprotein genes to be cloned. 
(Chen, Yang, Chen, et al, 1986). The apoB gene is approximately 43 kb long, 
containing 29 exons. ApoB is heterogeneous, but exists in two main forms: hepatic 
apoBlOO, a 512 kDa protein and intestinal apoB48, a 241 kDa protein. These 
proteins are synthesised from the same gene situated on chromosome 2, with apoB48 
consisting o f the N-terminal 48% of apoBlOO (Marcel, Hogue, Theolis, et al 1982). 
A novel post-transcriptional modification of the apoBlOO mRNA sequence occurs in 
intestinal cells only, which produces a stop codon at position 2153 so that the 
message when translated produces apoB48 (Powell, Wallis, Pease, et al, 1987). A 
cDNA was cloned and identified (Teng, Burant and Davidson, 1993) as apoB mRNA
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editing enzyme catalytic polypeptide-1 (APOBEC-1), which in the presence o f other 
components of the apoB mRNA editing enzyme, caused the site-specific deamination 
o f a cytosine to a uracil (Davidson, Anant and MacGinnitie, 1995).
ApoB48 is found only on chylomicrons, and does not bind to the LDL (B/E) receptor 
as the receptor binding site of apoB is found in the C-terminal half o f the protein. 
ApoBlOO is the main protein associated with VLDL, IDL and LDL, accounting for 
more than 95% of the protein on LDL, and is necessary for their secretion and uptake 
by the LDL (B/E) receptor. Unlike the other apolipoproteins, apoB is not exchanged 
between lipoproteins.
1.4.4 Apolipoprotein C
There are 3 different apoCs - apoCI, apoCII and apoCIII. They are derived from the 
liver and gut and are found on HDL from where they are transferred to VLDL and 
chylomicrons. The apoCI and apoCII genes are found on chromosome 19, while the 
apoCIII gene is on chromosome 11, in a cluster with apoAI and apoAIV.
ApoCI is an activator of LCAT, and also binds phospholipids. ApoCII is the 
activator of LPL and people deficient in apoCII are severely hypertriglyceridaemic. 
ApoCIII appears to have an inhibitory effect on the hydrolysis and clearance of 
chylomicrons and VLDL via LPL (Thompson, 1994) and is the most abundant o f the 
C apolipoproteins.
1.4.5 Apolipoprotein E
The apoE gene is found on chromosome 19, adjacent to apoCI. The gene has 
similarities to apoAI and apoAIV, suggesting a common ancestral origin. ApoE, a 34 
kDa protein, exists in three different isoforms, apoE2, apoE3 and apoE4, which have 
different avidity for the lipoprotein receptors. ApoE is synthesised in the liver and is 
found on chylomicron remnants, VLDL and large HDL particles. ApoE is involved in 
the hepatic uptake of chylomicron remnants and VLDL via the LDL receptor and the 
LDL receptor related protein (LRP, section 1.5.3).
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1.5. Lipoprotein metabolism
Every day, grams of lipid are both absorbed by the intestine and synthesised by the 
liver and intestine, and require to be transported to peripheral tissues where the lipid is 
stored, or used (Figure 1.1.). The liver is responsible for the packaging of cholesterol 
and triglyceride into apoB containing lipoproteins, preferring to use FA from the diet 
or from adipose tissue stores rather than newly synthesised lipid. ApoA containing 
lipoproteins recycle excess cholesterol from the tissues to apoB containing 
lipoproteins (a process known as reverse cholesterol transport), and these cholesterol 
rich lipoproteins are subsequently cleared by the liver.
1.5.1 Lipoprotein production
Lipoproteins are synthesised in two sites - chylomicrons are synthesised by the 
intestine, and VLDL, IDL and LDL by the liver. The components of chylomicrons 
are synthesised, assembled and secreted by cells of the intestinal mucosa. Absorption 
of fat stimulates intestinal synthesis of apolipoproteins and lipids. Cholesterol from 
bile, the diet or from mucosal cells shed during renewal of the lining of the intestine, is 
also present. Chylomicrons are large, apoB containing, triglyceride rich lipoproteins, 
consisting of 95% triglyceride and 2% cholesterol by weight. They are secreted into 
intestinal lymph and thence into the circulation where they acquire apoE and apoCII. 
ApoCII is the co-factor for LPL which hydrolyses the triglyceride within the 
chylomicron into FA which are taken up by adipose tissue and muscle for storage or 
for use as energy. Cholesteryl ester is transferred from HDL to chylomicrons in 
return for phospholipid and apolipoproteins, and within only a few minutes of the 
chylomicron entering the circulation, it has been converted to a chylomicron remnant 
which is taken up by the LRP in the liver with apoE as the ligand, thereby delivering 
cholesteryl ester to the liver for storage or for the synthesis of VLDL and bile acids 
(Figure 1.1.).
Lipoprotein particles produced by the parenchymal cells of the liver are mainly VLDL, 
the main transporter of triglyceride in the post absorptive state, but there is evidence 
that smaller particles, IDL and LDL are directly secreted from the liver too (Packard, 
et al, 1984, Huff et al, 1985, Packard and Shepherd, 1997). The lipid content of the
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lipoprotein particles reflects that of the hepatocyte. VLDL are synthesised in a two- 
step process (Figure 1.2.) (Schumaker, Phillips and Chatterton, 1994) and secreted 
after approximately 30 minutes. ApoB is co-translationally translocated into the 
rough endoplasmic reticulum (RER) and in the process it is glycosylated and 
associated with lipid to allow the apoB to take on the correct conformation. The lipid 
forms a core around which the apoB can fold. This may possibly involve pauses in 
translocation. The rate of secretion of apoB in lipoproteins is thought to depend on 
the availability of lipid as apoB protein is apparently produced at a constant rate. 
Proper association of the lipid with the apoB is critical for efficient secretion of VLDL 
as lipid and molecular chaperones promote the correct folding of apoB. Factors that 
decrease the availability of lipid can block VLDL secretion and result in degradation 
o f the apoB. Microsomal triglyceride transfer protein (MTP), a heterodimer of 
protein disulphide isomerase (PDI) and a 98kDa specific subunit, is important in 
delivering triglyceride and cholesteryl ester to the RER for this purpose, and PDI 
catalyses the formation of disulphide bonds in apoB. An absence of MTP can cause 
abetalipoproteinaemia (Wetterau, Aggerbeck, Bouma, et al, 1992) and an MTP 
inhibitor has been shown to normalise atherogenic lipoprotein levels in the Watanabe 
rabbit (Section 1.7.1) (Wetterau, Gregg, Harrity, et al, 1998). The second step of the 
assembly process occurs in the smooth endoplasmic reticulum where a large 
triglyceride droplet combines with the LDL sized apoB particle to produce a VLDL 
particle. This is then secreted via the golgi and the space of Disse into the circulation. 
If the apoB fails to associate with sufficient lipid during particle initiation, it is 
internally degraded. Degradation can occur throughout lipoprotein assembly (Dixon 
and Ginsberg, 1993).
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Figure 1.2. Synthesis of VLDL
A. ApoB (shown in red) is cotranslationally translocated into the lumen o f  the RER. 
The N  terminus form s a globule, and as MTP adds lipid to the membrane nearby, 
the globule unfolds. Some apoB associates with the membrane. A poB l 7 is the 
largest apoB found  unassociated with lipid. I f  lipid is not available, as the apoB 
grows larger it becomes unstable and is degraded by molecular chaperones.
B. M TP adds more lipid (mainly TG (E), but also cholesteryl ester) to the 
developing apoB. A t apoB90, enough lipid is added and the particle buds off. 
The remaining 10% o f  apoB form s a bow structure across the lipoprotein 
particle.
C  Small amounts o f  triglyceride are added to this lipoprotein to make VLDL2, or it 
associates with a triglyceride droplet in the smooth endoplasmic reticulum (SER) 
to form  VLDLj. These VLDL particles are secreted from  the cell via the golgi 
apparatus and the space o f  Disse. I f  at any stage there is an insufficiency o f  
lipid, the apoB can become unstable and be internally degraded.
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1.5.2 Lipolysis and interconversion oflipoproteins
Circulating VLDL obtains apoCs and apoE from HDL. More than 90% o f the 
triglycerides are hydrolysed by LPL, and much of the apoC and apoE recycled to 
HDL. The particle becomes smaller in a stepwise manner and forms EDL and 
subsequently through the action of HL (an enzyme found in liver sinusoids), LDL 
(Figure 1.1.). CETP transfers cholesteryl ester from HDL to the VLDL, and by the 
time LDL is formed, all apolipoproteins except apoB are lost. Both IDL and LDL 
can be cleared from the circulation by the liver. Some VLDL may also be cleared by 
the liver. The metabolism of VLDL, IDL and LDL particles can be traced readily as 
apoB stays with each particle throughout its lifetime in the circulation.
HDL particles are important in removing cholesterol from extrahepatic tissues. This 
reverse cholesterol transport mechanism is vital in the return of cholesterol to the liver 
for excretion (Figure 1.1.). Cholesterol from peripheral tissues and from cell 
membranes is transferred to small HDL?. LCAT acts to esterify the cholesterol within 
the HDL, which maintains a gradient for free cholesterol. As the particles enlarge, 
they become HDL2 and some cholesteryl ester is transferred to apoB containing 
lipoproteins by CETP in exchange for triglyceride. Cholesterol can also be returned 
to the liver directly from HDL (Sherrill, et al, 1982, Franceschini, et al, 1991). 
Triglyceride in HDL is hydrolysed by HL and the HDL becomes an HDL3 particle 
again.
1.5.3 Lipoprotein catabolism
Catabolism of lipoproteins is by receptor mediated or receptor independent 
mechanisms. The LDL receptor (Goldstein and Brown, 1977), a transmembrane 
glycoprotein found on chromosome 19, is the main receptor involved in the clearance 
o f apoB containing lipoproteins. This receptor recognises apoB or apoE containing 
lipoproteins via their arginine and lysine rich regions which bind to the receptor and 
facilitate the catabolism of VLDL, IDL and LDL. That the LDL receptor is the main 
method of uptake of LDL is demonstrated by accumulation of the lipoprotein when 
the function of the LDL receptor is lost in FH. The LDL receptor is found mainly in 
the liver and the adrenal cortex, and also to some extent in the intestine and skin
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fibroblasts. In fact the LDL receptor enables uptake of cholesterol by all cells of the 
body when faced with cholesterol depletion.
In rabbits, 90% of LDL is catabolised by the LDL receptor, with the remainder 
catabolised by receptor independent mechanisms. The liver is responsible for the 
catabolism of 50-70% of the total LDL (Pittman, Carew, Attie, et al, 1982).
The LRP binds apoE containing lipoproteins but not LDL. Its activity is promoted by 
LPL and HL, which mediate lipoprotein binding if present on the particle’s surface 
(Beisiegel, 1995). LRP is found on hepatocytes, fibroblasts, neurons, and monocyte- 
derived macrophages. It is thought that this receptor may be involved in 
atherogenesis by causing the accumulation of lipoproteins in macrophages and smooth 
muscle cells (Lupu, Heim, Backman, et al, 1994). Additionally, the abundance of 
LRP in neurons and the presence of apoE in the brain has led to the proposal that the 
LRP may play a role in apoE metabolism in the brain, and hence have a link to 
Alzheimers disease (Ji, Pitas and Mahley, 1998). Through apoE and lipase present as 
a ligand on the particle surfaces, the LRP binds chylomicron remnants, and is the main 
method of clearance of chylomicrons. The LRP also binds VLDL, acting as a back­
up for clearing these particles.
The VLDL receptor (chromosome 9) which is structurally related to the LDL 
receptor, was first described in rabbits and binds apoE containing lipoproteins (VLDL 
and IDL) clearing them from the circulation (Takahashi, Kawarabayasi, Nakai, et al, 
1992). It is expressed mainly in the heart, skeletal muscle, adipose tissue, brain and 
ovary. In rabbit aortic intima-media, expression of the VLDL receptor is upregulated 
by cholesterol feeding. Its basic function is likely to be to provide FA to muscle and 
adipose tissue in a mechanism complementary to that facilitated by LPL. The VLDL 
receptor is only present in very small amounts in the liver.
Receptor mediated clearance by the above mechanisms is in general saturable, due to 
there being a limited number of receptors. Therefore at times of lipoprotein excess in 
the circulation, receptor independent clearance becomes important. Such mechanisms 
include pinocytosis (engulfing of extracellular fluid by invagination o f the plasma 
membrane) or adsorptive endocytosis by cell surface receptors with low affinity for
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LDL. Receptor uptake of modified LDL may also occur by high affinity receptors on 
cells of the reticulo-endothelial system eg the acetyl-LDL receptor. Shepherd, 
Packard and Gibson (1985) demonstrated that the reticulo-endothelial system 
contributes significantly to catabolism of total human LDL in vivo in rabbits. 
However others (Pittman et al, 1982) using different techniques have found no major 
contribution o f the reticulo-endothelial system to receptor independent clearance.
1.5.4 The effects of insulin
Insulin is the major anti-lipolytic hormone (Coppack et al 1994), acting mainly in the 
post-prandial state. In times of FFA and/or glucose plenty it causes adipose tissue or 
muscle to store triglyceride or glycogen, by inhibiting hormone sensitive lipase (HSL), 
thus suppressing FA release from the adipose tissue, or by stimulating glucose uptake 
and glycogen synthesis (Figure 1.3.). Insulin has been shown to decrease VLDL (and 
apoB) production, and to increase LPL activity on the adipose tissue surface 
(Durrington, Newton, Weinstein, et al, 1982, Patsch, Franz and Schonfeld, 1983, 
Sparks, Sparks, Bolognin, et al, 1986).
The role of insulin resistance in a number of metabolic disturbances was first 
described by Reaven (1988). Insulin resistance results in an elevated plasma 
triglyceride and FFA concentration, and a decreased HDL cholesterol concentration. 
There is also a preponderance of small dense LDL. Together these changes are 
known as the atherogenic lipoprotein phenotype (ALP). This loss of ability to 
control glucose and FFA levels results in hyperglycaemia and hypertriglyceridaemia, 
and is a common feature of disorders such as familial combined hyperlipidaemia 
(FCH), familial hypertriglyceridaemia (FHTG), non-insulin dependent diabetes 
mellitus (NIDDM) and obesity (Frayn 1993).
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Figure 1.3. Adipocyte lipolysis
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Glucose is taken up into the adipocyte by the Glut4 transporter. Triglyceride is 
hydrolysed to FFA by LPL and FFA are taken up into the adipocyte. Gucose and FFA 
are both stored as triglyceride in the adipocyte, and in times o f energy surplus, insulin 
promotes the storage of triglyceride and inhibits the action o f HSL which hydrolyses 
triglyceride to glycerol and FFA. Acylation stimulatory protein (ASP) also promotes 
the uptake o f glucose, and its storage as triglyeride. Irregularities in the action o f 
insulin and ASP have both been suggested as contributory factors to the development of 
the FCH phenotype.
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1.6. Common Hyperlipidnemias
Several attempts have been made to form a definitive list o f lipoprotein abnormalities. 
Initially, classification was by phenotype as the underlying cause of the abnormality 
was unknown. However the realisation that the same phenotype could have a 
different underlying cause, meant classification by genotype was necessary. As 
information on the genotypic causes o f the various hyperlipidaemias is still incomplete 
it is easier to observe the phenotype, therefore phenotypic classification is still used 
widely. Originally Gofman, Rubin, McGinley, et al (1954) separated lipoproteins by 
analytical ultracentrifugation and described three patterns of lipoprotein distribution. 
Later Fredrickson, Levy and Lees (1967b) described 5 classes o f 
hyperlipoproteinaemia which were subsequently modified by the World Health 
Organisation to include a 6th class (Table 1.4.).
Table 1.4. World Health Organisation classification of hyperlipoproteinaemia
Type TC LDL-C TG Lipoprotein
abnormality
Underlying genetic 
disorder
I T t Excess chylomicrons LPL deficiency, 
ApoCII deficiency
Ha T-> t -> Excess LDL FH, FCH and others
Hb t t t Excess LDL and VLDL FH, FCH and others
III T 4-> t Excess chylomicron 
remnants and IDL
ApoE2E2 and other 
defects
rv t Excess VLDL FCH, FHTG
V t -> t Excess chylomicrons 
and VLDL
FHTG, Apo CII 
deficiency
Total cholesterol (TC), LDL-cholesterol (LDL-C) 
Beaumont, Carlson, Cooper, et al, 1970
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1.6.1 Familial hypercholesterolaemia
Heterozygous FH (usually expressed as phenotype Type Ha) is seen in approximately 
1 in 500 individuals in the UK, with homozygous FH being much more rare. 
Symptoms of CHD are seen by the mid twenties in heterozygotes, and in childhood in 
homozygotes, leading to premature death.
The molecular fault responsible for FH was first described in 1977 by Goldstein and 
Brown. A defect or deficit in the LDL receptor results in the inefficient catabolism of 
LDL and an increased plasma LDL concentration. A large number of mutations can 
cause the same effect, and can be broadly classified into those that affect receptor 
synthesis, those that affect the transport of the receptor from the RER to the golgi, 
those that interfere with the binding of LDL to the receptor, and those that affect the 
interaction of the LDL receptor with the clathrin coated pit important for its 
internalisation.
Heterozygotes have a plasma LDL fractional catabolic rate (FCR) that is 
approximately half of that in normal individuals, and only 20% of their LDL is cleared 
by receptors. Homozygotes have only trace amounts of LDL cleared by the receptor.
FDB is an example of why dyslipidaemia should be characterised by genotype rather 
than phenotype. It has the same phenotype as FH, but is due to a mutation in the 
apoB gene rather than the LDL receptor gene. Several different mutations have been 
described, all affecting the receptor binding region of apoB, rendering it incapable of 
binding to the LDL receptor (Myant 1993, Gaffney, Reid, Cameron, et al, 1995).
1.6.2 Familial hypertriglyceridaemia
Triglycerides are gaining credibility as an independent predictor of cardiovascular risk 
following results from large studies such as PROCAM (Assman and Schulte, 1992), 
and a meta-analysis of 17 prospective studies (Hokanson and Austin, 1996). 
Triglycerides are associated with atherogenesis by several mechanisms including 
effects on endothelial function, macrophage loading, thrombogenesis and LDL 
particle size. Hypertriglyceridaemic individuals are at an increased risk of type 2
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diabetes. Raised triglycerides in association with small dense LDL and decreased 
levels o f HDL cholesterol (the ALP) is the most common lipoprotein pattern seen in 
individuals who have had an MI.
Within the Fredrickson classification, there are two phenotypes associated with 
FHTG, type IV and type V, which differ in the extent to which triglycerides are 
elevated and can sometimes both occur in the one family. Type IV 
hyperlipoproteinaemia, FHTG, is characterised by increased levels of VLDL, and has 
a population frequency of 0.3%. It is not normally expressed in childhood. VLDL 
are larger than normal, and are triglyceride enriched, due to an increased triglyceride 
synthesis and a decreased FCR which is likely to be caused by saturation o f the 
clearance mechanism. The catabolism of VLDL to LDL is lower than normal, 
therefore plasma cholesterol is not elevated. HDL cholesterol is also decreased. The 
underlying cause of FHTG is not known, but insulin resistance has been implicated in 
a number of studies (reviewed by Taskinen, 1995).
Type V hyperlipidaemia is a rare disease, sharing features of type I 
(chylomicronaemia) and type IV. These individuals are often obese, but evidence 
suggests that following weight loss the type V phenotype may change to type IV. 
The phenotype is not seen until adulthood. VLDL apoB synthesis is increased and the 
FCR is decreased to a greater extent than in type IV hyperlipidaemia. Severe 
hypertriglyceridaemia is a heterogeneous disorder, and is likely to have many causes. 
It may be due to LPL deficiency, the presence of an LPL inhibitor or a paucity of 
apoCII.
1.6.3 Familial combined hyperlipidaemia
FCH is a complex inherited disorder, defined by the presence of multiple phenotypes 
within a single family - elevated plasma cholesterol, elevated plasma triglyceride or 
both. It was first described in 1973 (Goldstein, Schrott, Hazzard, et al, 1973, Nikkila 
and Aro, 1973, Rose, Kranz, Weinstock, et al, 1973) as being the most common 
genetic lipid disorder in a group of MI survivors and their relatives. The population 
frequency is 0.5%, with a frequency of about 10% in MI survivors aged under 60. 
Lipid levels are often normal in childhood, rising in the mid-twenties. FCH is
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genetically distinct from FH and FHTG as the distribution pattern in affected families 
is different; children do not express hypercholesterolaemia in FCH although they do in 
FH, there is no abnormality in bile acid synthesis in FCH which is sometimes seen in 
FHTG, and FCH is a risk factor for premature CHD, whereas FHTG is apparently 
not.
Although FCH is expressed as a heterogeneous lipid phenotype there is thought to be 
an underlying common defect - increased plasma levels o f apoB, probably due to an 
overproduction of this protein. VLDL and/ or LDL apoB can be overproduced 
(Kissebah, Alfarsi and Evans, 1984, Venkatesan, Cullen, Pacy, et al, 1993) in FCH 
and the particles are usually smaller than in normals (Chait, Albers and Brunzell, 
1980, Hokanson, Krauss, Albers, et al, 1995). This makes the hypertriglyceridaemia 
different from that seen in FHTG, where there is a normal amount of VLDL particles, 
but they are large and triglyceride enriched. A subset o f FCH may be due to the 
catabolism of VLDL and LDL at a slow rate (Chait et al, 1980, Aguilar-Salinas, 
Barrett, Pulai, et al, 1997). For example, studies in combined hyperlipidaemics o f 
unknown genetics which may include subjects with FCH, have shown that these 
individuals most commonly exhibit a decreased catabolism of VLDL or LDL with or 
without an increased production (Millar, Watson, Stewart, et al, unpublished 
observations). Aguilar-Salinas et al (1997) have reported an FCH kindred with 
decreased VLDL and LDL apoB FCR, but no alteration in production rates, and 
Castro Cabezas, de Bruin, Jansen, et al, (1993a) have reported delayed postprandial 
chylomicron remnant clearance in combined hyperlipidaemia due to competition for 
lipolysis by LPL and for uptake by hepatic receptors. However when the familial 
form of combined hyperlipidaemia is studied, most investigators are convinced that 
the main defect is overproduction of apoB containing lipoproteins.
The underlying defect that causes overproduction of apoB is not known. It is 
generally accepted that apoB is synthesised at a constant rate, and alterations in 
output are not due to variation in expression of the apoB gene. It is considered likely 
that an increased availability of lipid in the hepatocyte leads to the secretion of more 
apoB with less being internally degraded. A number of investigators have examined 
FA metabolism in FCH and found evidence for specific abnormalities which would 
increase FA flux into the liver.
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Insulin resistance can cause alterations in lipid metabolism (Figure 1.3.) such as those 
seen in FCH. Insulin resistance is often seen in FCH, particularly in obese individuals 
(Aitman, Godsland, Farren, et al, 1997). In his group of 8 FCH patients, Aitman 
reported an impaired insulin-mediated glucose uptake in peripheral tissues, and an 
impaired insulin-mediated suppression of serum FFAs compared to controls. It was 
postulated that a defect exists within the adipocyte, either a failure of insulin to inhibit 
HSL, or to stimulate the re-esterification of triglyceride. Prolonged postprandial 
plasma FFA concentration then results in increased FFA flux to the liver and 
stimulation of VLDL production.
Alternatively, the elevated plasma insulin levels seen in FCH individuals may be 
secondary to an impaired postprandial FFA clearance. This elevation in plasma FFA 
has been postulated to be the result of an impairment of uptake of FFA into the 
adipose tissue (Teng, Forse, Rodriguez, et al, 1988, Cianflone, Maslowska and 
Sniderman, 1990). Acylation stimulatory protein (ASP) mediates the intracellular re- 
esterification of FFA to triglyceride in the adipose tissue for storage and stimulates 
glucose transport in differentiated human adipocytes (Maslowska, Sniderman, 
Germinario, et al, 1997) (Figure 1.3.). ASP levels have been reported to be 
decreased in patients with hyperapobetalipoproteinaemia, a disorder similar to FCH 
(Cianflone et al, 1990, Cianflone, 1994). This may explain the increased plasma FFA 
seen in FCH. Increased FFA in turn may stimulate insulin secretion and therefore in 
FCH, increased fasting plasma insulin concentrations could be secondary to impaired 
postprandial FA metabolism. (Castro Cabezas, de Bruin, de Valk, et al, 1993b). 
Whether insulin resistance causes the elevated FFA or whether an impaired FFA 
metabolism causes increased insulin secretion is unknown, and may in fact vary in 
subsets of patients.
Obligate heterozygotes for LPL deficiency express a phenotype consistent with FCH. 
Approximately one third of patients with FCH have been found to have impaired LPL 
activity (Babirak, Brown and Brunzell, 1992). However severe defects in this gene 
have not been found to be important in FCH patients. Moderate variation in LPL 
activity due to gene polymorphisms may magnify the phenotype by impairing the 
clearance of chylomicrons and VLDL (de Bruin, Mailly, van Barlingen, et al, 1996,
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Pajukanta, Porkka, Antikainen, et al, 1997). Evidence has also been found of a 
linkage between the AI-CIII-AIV gene cluster and FCH, prompting speculation o f an 
association between apoCIII levels (an inhibitor o f LPL) and LPL activity 
(Wojciechowski, Farrall, Cullen, e ta l , 1991, Patsch, Sharrett, Chen, eta l, 1994,) with 
consequent effects on FFA concentration. Similarly, there may be an effect o f a 
mutation in apoAIV. ApoAIV may facilitate the transfer of apoCII to chylomicrons, 
where it promotes the hydrolysis of triglyceride in the chylomicrons by LPL. 
Therefore a defect in apoAIV could cause hypertriglyceridaemia, and may explain the 
defect in chylomicron remnant clearance described above. A defect in HSL has also 
been implicated in the progression o f FCH (Reynisdottir, Eriksson, Angelin, et al,
1995).
There is also a strong association between a preponderance o f small dense LDL and 
FCH (Bredie, Demacker and Stalenhoef, 1997). Recent evidence suggests that 40% 
o f variation in LDL subfraction distribution is due to genetic factors with the 
remainder due to environmental factors. The predominance o f small dense LDL may 
play a large part in the development o f premature cardiovascular disease. This may be 
a consequence of increased levels of CETP.
Therefore, FCH appears to be a heterogeneous disorder, with a variety o f potential 
genetic and molecular defects. It may result from the inheritance of more than one 
minor defect, which combine to produce the FCH phenotype. Further understanding 
of the disease will enable a subclassification of FCH and a more straightforward 
diagnosis.
1.7. Rabbit models of genetic hyperlipidaemias
Lipoprotein metabolism in the rabbit is similar to that in humans, making them a 
suitable model for the study of lipid transport and its relation to atherosclerosis. 
Rabbits like humans have apoB containing lipoproteins as the major carriers of 
cholesterol in plasma (Chapman 1986). They have plasma volumes sufficiently large 
to look at lipoprotein subclasses, and to make turnover studies possible. They also 
have atherosclerotic plaques that are similar to human lesions. Unlike rodents, they, 
like humans express apoB48 in the intestine and apoBlOO in the liver. The principal
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difference from man is that rabbits have relatively greater concentrations of DDL, 
probably due to the fact that they express only low levels of HL.
Rabbits are susceptible to cholesterol feeding and develop atherosclerosis at an 
enhanced rate. Some strains hyper-respond to cholesterol in the diet and have 
substantially elevated plasma lipid levels (Meijer, van der Palen, Geelen, et al, 1992). 
However, rabbits appear to react in different ways to dietary intervention (Harris 
1997), therefore it is important to ensure that the rabbit model mirrors the human 
situation as far as possible.
1.7.1 The W atanabe heritable hyperlipidaemic rabbit
The Watanabe heritable hyperlipdaemic rabbit (WHHL) was first described in 1980 by 
Watanabe as a model for FH since the animal had virtually no active LDL receptors. 
The condition is inherited as an autosomal recessive trait, with slight expression of the 
phenotype being seen in the heterozygous state. LDL are therefore cleared slowly 
from the circulation and accumulate in plasma. VLDL and IDL also appear to be 
cleared slowly, and are thus more likely to be transformed to LDL, also contributing 
to the rise in LDL levels (Kita, Brown, Bilheimer, et al, 1982). Homozygous WHHL 
rabbits have elevated plasma cholesterol (approximately 10 fold), LDL-cholesterol 
(20 - 50 fold) and triglyceride ( 2 - 4  fold) and decreased HDL levels (to one third of 
normal). Heterozygotes have LDL levels between homozygotes and normals 
(Goldstein, Kita and Brown, 1983). WHHL rabbits develop atherosclerosis and 
xanthomas. There are no differences in secretion of apoB containing lipoproteins 
(Homick, Kita, Hamilton, et al, 1983), therefore like in humans, the FH exhibited by 
these animals derives entirely from a catabolic defect.
1.7.2 The St Thomas’ hospital rabbit
This strain of NZW rabbit was first described in 1987 by Agnes La Ville and 
coworkers at St Thomas’ Hospital London, as exhibiting an inherited hyperlipidaemia 
similar to that seen in FCH (La Ville, Turner, Pittilo, et al, 1987). The proband was 
discovered serendipidously when it was found that the addition of a small amount of 
cholesterol to the diet caused a large response in serum lipid levels. On breeding the
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proband it was discovered that plasma cholesterol and triglyceride concentrations 
were elevated and variable, and were inherited. There was no discernible defect in the 
LDL receptor, though in LDL kinetic studies there was an impaired FCR, possibly 
due to saturation of clearance mechanisms. Kinetic studies also revealed increased 
production rates of both VLDL and LDL.
Genetic analyses have not been performed on the St Thomas’ hospital rabbit due to 
the closed nature of the colony, although there is evidence suggesting Mendelian 
inheritance of a major gene defect affecting apoB production and a minor gene acting 
on triglyceride metabolism (Beaty, Prenger, Virgil, et al, 1992).
Investigation of arterial pathology concluded that extensive intimal lesions were 
present in rabbits from 6 months old (Seddon, Woolf, La Ville, et al, 1987). Lesion 
pathology generally resembled that seen in cholesterol-fed rabbits, with some features 
similar to the WHHL rabbit and humans.
1.7.3 Transgenic rabbits
Transgenic animals are providing new methods for the study of genes of interest in the 
development of atherosclerosis, and although rabbits are used rarely in comparison to 
transgenic mice, they are increasingly proving the animal of choice due to the 
similarities of lipoprotein metabolism with the human.
Rabbits overexpressing human apoAI have been shown to have higher plasma HDL 
cholesterol levels than non transgenic rabbits, and to develop a significantly smaller 
area of aortic lesion when compared to controls (Duverger, Kruth, Emmanuel, et al,
1996). Similarly LCAT transgenic rabbits had an increased HDL cholesterol 
concentration, and were protected from diet induced atherosclerosis (Hoeg, 
Santamarina-Fojo, Berard, etal, 1996). Brousseau, Santamarina-Fojo, Vaisman, e ta l 
(1997) showed that high expressors of LCAT had high levels of HDL cholesterol and 
low levels of non-HDL cholesterol when compared to low expressors or non 
expressors, and demonstrated that the mechanism by which LCAT regulates HDL and 
non-HDL cholesterol concentration is by modulating the FCR of these lipoprotein 
species.
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Expression of human apoB in transgenic rabbits has been shown to increase plasma 
cholesterol (mainly LDL cholesterol) and triglyceride concentrations. LDL particles 
produced were smaller and triglyceride enriched compared to control rabbits, and 
contained increased amounts of apoE and apoCIII. HDL cholesterol and apoAI levels 
were decreased (Fan, McCormick, Krauss, et al, 1995).
Transgenic rabbits have been produced expressing apoE3 and apoE2. ApoE3 rabbits 
showed an increased binding affinity of VLDL for the LDL receptor, therefore having 
lower VLDL and triglyceride concentrations. However plasma cholesterol 
concentration was increased as LDL was cleared more slowly in transgenic rabbits 
possibly because VLDL competes for LDL receptor mediated clearance (Fan, Ji, 
Huang, et al, 1998). ApoE2 expressing rabbits had a phenotype similar to type III 
hyperlipoproteinaemia, with increases in plasma cholesterol and triglyceride 
concentration being much greater in males than females. This was shown to be mainly 
due to the effects of oestrogen on lipase and LDL receptor activity (Huang, 
Schwendner, Rail, et al, 1997).
Rabbits expressing human HL (Fan, Wang, Bensadoun, et al, 1994) had decreased 
plasma lipid levels compared to normal rabbits, with a 5-fold decrease in HDL 
cholesterol accounting for a large proportion of the decrease in plasma cholesterol 
concentration. DDL levels were decreased, and LDL was increased slightly, consistent 
with the role of HL in the conversion of IDL to LDL. Transgenic rabbits have also 
been reported expressing human apo(a) and apoB which have been shown to make 
Lp(a) (Rouy, Duverger, Lin, eta l, 1998).
1.8. Methods of study of lipoprotein metabolism
To fully understand the complex system of lipoprotein metabolism, it is necessary to 
be able to study each part both in isolation, and as a part of the global mechanism. 
The use of animal models, especially of the size of the rabbit, allows a number of 
approaches to be investigated and then integrated.
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1.8.1 Whole animal studies
Analysis of the metabolism of lipoproteins in the whole animal provides the most 
physiological model available for study. Early studies of the interconversion and 
catabolism of lipoprotein species involved the isolation of a particular lipoprotein 
species. These lipoproteins were then labelled with a radioactive tracer, reinjected, 
and the tracer was followed as it was cleared from the circulation. Labelling was of 
either protein or lipid moieties, depending on the tracer used. The problem with this 
ex vivo method of labelling was that production of lipoproteins could not be measured 
directly, but had to be inferred. The use of stable isotopes has negated the need for 
the ex-vivo labelling of lipoproteins, as the isotope can be injected and the lipoproteins 
are labelled in vivo. This method is preferable as in vivo labelling of lipoproteins 
means there should be minimal alteration in kinetic behaviour, but also means that all 
new proteins are labelled.
Labelling of apoB provides a handle by which the metabolism of particular lipoprotein 
particles can be followed in the whole animal, as apoB is known not to be transferred 
between particles. Whole animal studies of lipoprotein metabolism can be performed 
in the fed or fasted state. In the fed state, the production of chylomicrons complicates 
the study of VLDL metabolism, but it is the most physiological state. One of the main 
problems with turnover studies is the analysis of the data. Multicompartmental 
modelling, allowing the fitting of a multiexponential curve to the apoB decay is 
currently the method of choice. This requires complex mathematical procedures 
which are handled by computer programmes, such as the Simulation, Analysis And 
Modeling (SAAM) computer programme (SAAM Institute, 1997).
1.8.2 Organ perfusions
Organ perfusions are the most physiological method used to investigate the direct 
output of a particle of interest from an organ of choice and can also be used to 
measure catabolism by the organ. In terms of lipoprotein metabolism, the perfused 
liver gives useful information on the direct production of lipoproteins without the 
effects of lipolytic enzymes. Experiments can be performed in vivo or in vitro, with in 
vitro experiments providing scope for manipulations to the system. Organ perfusions
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are also an ideal way to investigate effects of prior in vivo interventions (Marzolo, 
Amigo and Nervi, 1993).
As with all procedures where the body is not taken as a whole, there are opportunities 
for the system to produce erroneous results due to the inability of the experimental 
operator to maintain conditions for the the perfused organ exactly as in vivo. 
However, organ perfusions provide better results than cell cultures, as the different 
cell types are present in their correct spatial location and are more likely to respond in 
a physiological manner to external stimuli. For an organ like the liver, consisting of 
many different cell types, this topography is important for normal interaction with 
other hepatic cells and results may differ in isolated cell cultures.
The main disadvantage of organ perfusions is that the duration of experiment is 
limited as the organ can usually only be kept patent for a matter of hours. The 
experimental set up is technically demanding. Also a large number of animals are 
needed, compared to hepatocyte cultures where several experiments can be set up 
using cells from one organ.
1.8.3 Cell culture
Cells maintained in culture can be of two types, namely primary cell cultures where 
the cells are prepared from living tissue, and transformed (immortal) cell lines 
(Gibbons, 1994). Rabbit hepatocytes are a good model for human lipoprotein 
metabolism as they produce hepatic apoBlOO only, and they secrete full sized VLDL 
particles.
Primary hepatocyte cultures are useful models of hepatic metabolism in that unlike 
perfused livers they remain viable for a few days and the yield of cells from one liver 
provides enough material for several experiments. In vivo pre-treatment of the animal 
donor can be used to provide different conditions in the cells. However culture of 
cells means the topography of the liver is lost, and usually only one type of hepatic 
cell is cultured, therefore there is no interaction with other hepatic cell types.
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Transformed cell lines are easy to maintain in culture, and are immortal. There is no 
need for an animal donor, therefore the cells are much easier to prepare, and can be 
available whenever required and in whatever quantity. Long term experiments can 
also be performed. Further, laboratories around the world can work on the same 
cells and compare results. However, some differentiated functions o f the cells are lost 
on transformation.
The human cell line HepG2 is the most commonly used model for hepatic metabolism, 
but has several shortfalls. These cells do not produce full sized VLDL particles 
possibly because they have lost the second step in assembly. They also have an 
unusual bile acid secretion, and poor capacity for FA oxidation.
When cell culture studies are performed, it is necessary to remember that results have 
been produced from a system that is not physiological, and vital cofactors or 
substrates may be missing, resulting in a response that is different to that seen from 
the whole organ.
1.8.4 Gene expression studies
Molecular biology provides an alternative to the traditional biochemical and 
physiological investigations into lipoprotein disorders. Discovery o f a mutation in a 
gene o f interest opens up the possibility o f tracing the defect through families, and 
provides the potential o f treatment with gene therapy. I f  the level o f expression o f a 
gene is found to be varied, this can provide information on the protein that is causing 
the disorder, and suggest new treatment strategies.
To measure levels o f gene expression, cells can be transfected with the promoters of 
genes o f interest, ligated to a reporter gene, and the relative expression o f the reporter 
can be measured, thereby highlighting any differences in promoter efficacy. However, 
cell work can give false results due to absent spatial stimuli, or transcription factors.
The current method o f choice involves measuring the levels o f mRNA in the tissue of 
interest for the gene o f interest. This provides information on genes that are 
transcribed at different rates, and narrows down the search for proteins that are
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differentially expressed. However, levels o f mRNA are not always directly associated 
with levels of protein.
1.9. Aims and objectives
The principal aim o f the experiments contained within this thesis was to characterise 
the metabolism of apoB containing lipoproteins in a new colony o f St Thomas’ 
hospital rabbit, named the St Thomas’ mixed hyperlipidaemic rabbit (SMHL). We 
wished to investigate the stability of the phenotype in the SMHL rabbits, and the 
similarities between the phenotype of these rabbits and the human disorder FCH.
We planned to investigate the effects of a low cholesterol diet on the lipids and 
lipoproteins o f these rabbits, as such a diet enhances the expression o f the FCH 
phenotype. We intended to perform liver perfusion experiments to examine the direct 
output o f lipoproteins from the liver in order to define the exact cause o f the increased 
lipoprotein concentrations in these rabbits and, complimentary to this, to study the 
kinetics o f the lipoprotein classes using stable isotope labelling of apoB. And finally, 
using information gathered from the previous experiments, we planned to look at the 
expression levels o f some candidate genes.
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Chapter 2. General Methods
2.1. Materials
All chemicals used were of analytical grade. Names and addresses of suppliers of 
reagents, hardware and software are given in appendix 1.
2.2. Animals
Rabbits were obtained from Froxfield Farm and later from Harlan Interfauna Ltd. 
They were housed individually in cages at 18 - 20°C and 55% humidity, with 12 hours 
light per 24 hours. Unless stated, the rabbits were fed a diet supplemented with a low 
amount (0.075% wt/wt) cholesterol (0.08% total) (Special Diet Service). Food and 
water were freely available. All animal procedures in this thesis were approved by the 
Home Office, and carried out subject to their regulations.
2.3. Lipid and lipoprotein measurements
2.3.1 Preparation of plasma
Blood samples were collected from the marginal ear vein into K3EDTA tubes (1 
mg/ml) and centrifuged at 1780 g  for 10 minutes at 4°C. The supernatant was 
aspirated off as plasma.
2.3.2 Cholesterol
Cholesterol was measured using an enzymatic colorimetric test kit (Boehringer 
Mannheim, Cat number 704121). The principle of the assay is described below:
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cholesterol esterase 
cholesterol esters + H20 2 -> cholesterol + RCOOH
cholesterol + 0 2
cholesterol oxidase 
—^ A4-cholestenone + H20 2
2 H20 2 + 4-aminophenazone + phenol
peroxidase
-» 4-(p-benzo-quinone-monoimino)- 
phenazone + 4 H20
Samples are either measured automatically on the Hitachi 717, or manually with the 
optical density measured at 500 nm on a Beckman DU70 spectrophotometer.
2.3.3 Triglyceride
Plasma triglycerides were measured using an enzymatic colorimetric test kit 
(Boehringer Mannheim, Cat number 704113). The assay is performed either 
automatically on the Hitachi 717, or manually following the manufacturers 
instructions, with the optical density measured at 340 nm. The principle of the test is 
described below:
triglycerides + 3 H20
lipase
-> glycerol + 3RCOOH
glycerol + ATP
glycerol kinase
—» glycerol-3-phosphate + ADP
pyruvate kinase 
ADP + PEP —» pyruvate + ATP
lactate dehydrogenase 
pyruvate + NADH + H+ —» L-lactate + NAD+
PEP phospho-enol-pyruvate
60
Cholesterol and triglyceride were kindly measured by staff o f the routine lipids 
section, Department of Biochemistry, Glasgow Royal Infirmary.
2.3.4 Glycerol
The triglyceride assay involves the conversion o f all triglyceride to glycerol with 
subsequent measurement of glycerol whether derived from triglyceride or not. In 
order to obtain a true triglyeride value, it is necessary to subtract plasma glycerol from 
triglyceride.
Plasma glycerol is measured by a colorimetric kit (Randox Laboratories Ltd., Cat 
number GY105) following the manufacturers instructions, with the optical density 
measured at 520 nm. The principle of the assay is described below:
glycerol kinase 
glycerol + ATP —> glycerol-3-phosphate + ADP
glycerol phosphate oxidase 
glycerol-3-phosphate + O2 —> H 2 O2 + dihydroxyacetone-phosphate
peroxidase
2 H2 O2 + DCHBS + 4-aminophenazone —» ACSB
DCHBS 3,5-dichloro-2-hydroxybenzene sulphonic acid
ACSB n-(4-antipyryl)-3-chloro-5-sulphonate-p-benzoquinoneimine
2.3.5 Free cholesterol
Free cholesterol was measured using an enzymatic colorimetric kit (Boehringer 
Mannheim, Cat number 310328). The reaction is similar to that for cholesterol except 
that the cholesterol esterase is omitted, in order that only free cholesterol in the 
sample is oxidised and measured.
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2.3.6 Phospholipid
Phospholipid was measured using an enzymatic colorimetric kit (Boehringer 
Mannheim, Cat number 691844). The principle of the assay is described below:
phospholipase D 
phospholipid -> choline + phosphatidic acid
choline oxidase 
choline —» betaine + H2 O2
Free cholesterol and phospholipid measurements were performed by Mr Michael 
McConnell of the Department of Pathological Biochemistry, Glasgow Royal 
Infirmary.
2.3.7 Coating of Beckman Ultra Clear centrifuge tubes
To enable salt solutions to gravity feed smoothly down the side of the Beckman Ultra 
Clear centrifuge tubes used for density gradient ultracentrifugation, providing no 
disruption to the formation of density layers, it is necessary to coat the interior surface 
o f the tubes with 2% polyvinyl alcohol in propan-2-ol. The tubes are filled with this 
solution for 15 minutes and dried overnight, and are subsequently washed with 
distilled H20  overnight, rinsed once with H20  and left to dry (Holmquist, 1982).
2.3.8 Separation of VLDLi (Sf 60 - 400), VLDL2 (Sf 20 - 60), IDL (Sf 12 - 20) 
and LDL (SfO -12)
VLDLi, VLDL2, IDL and LDL were prepared from plasma or perfusate by a 
modification (Packard, Clegg, Dominiczak, et al, 1986) of the method of Lindgren, 
Jensen and Hatch (1972). Density (d) solutions were prepared from stock solutions at 
d = 1.006 g/ml (0.195 mol/1 NaCl) and d = 1.182 g/ml (0.195 mol/1 NaCl, 2.44 mol/1
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NaBr). The densities were measured to 3 decimal places in a Paar Scientific density 
meter (model DMA 35).
The density o f 2 ml of the plasma or perfusate was adjusted to 1.118 g/ml by the 
addition of NaCl according to the formula:
Weight o f salt = VTd? - di) 
l-vd2
where V is the volume of solution, di is the density of the solution, d2 is the required 
density and v is the partial specific volume of the salt at the relevant temperature and 
concentration.
In a precoated Beckman Ultra Clear centrifuge tube the sample was layered over a 
cushion of 0.5 ml d = 1.182 g/ml solution using an AAII pump (Technicon), and a 
discontinuous gradient of salt solutions was formed over the top (1 ml d = 1.0988 
g/ml, 1 ml d = 1.0860 g/ml, 2 ml d = 1.0790 g/ml, 2 ml d = 1.0722 g/ml, 2 ml d = 
1.0641 g/ml, 2 ml d = 1.0588 g/ml). This was centrifuged in a Beckman SW40 rotor 
under vacuum at 23°C in a Beckman L8 ultracentrifuge according to the conditions 
described in Table 2.1. The rotors were decelerated without the brake. Lipoprotein 
fractions were removed from the top using a drawn out glass Pasteur pipette. After 
removing the VLDLi fraction, lml o f d = 1.0588 g/ml was overlayered on the existing 
gradient.
Table 2.1. Centrifuge conditions for isolation of VLDLi, VLDL2, IDL and LDL
Fraction Relative centrifugal 
field (#)
Time Fraction volume 
(ml)
VLDLi 272 000 1 hour 38 mins 1
v l d l 2 62 000 15 hours 41 mins 0.5
IDL 272 000 2 hours 3 5 mins 0.5
LDL 160 000 21 hours 10 mins 1
63
2.4. Measurement of protein
2.4.1 Isolation of apoB
ApoB was isolated from preparations of VLDLi, VLDL2, IDL and LDL. The 
samples were brought to room temperature and an equal volume o f propan-2-ol was 
added and immediately mixed (Egusa, Brady, Grundy, et al, 1983). After an 
overnight incubation at 4°C the samples were spun at 1780 g  for 30 minutes at 4°C 
and the supernatant was removed using a finely drawn glass Pasteur pipette. The 
supernatant contained isopropanol soluble proteins which in lipoprotein fractions are 
all proteins except for apoB.
The precipitate was redissolved in 3 ml ethanol/ether (3:1), mixed and incubated at 
4°C overnight. The samples were centrifuged at 1780 g  for 30 minutes at 4°C, and 
the supernatant was removed. Traces of ethanol were removed by redissolving the 
precipitate in 3 ml ether by mixing and incubating the samples for at least 1 hour. The 
samples were centrifuged as above and the supernatant was removed. The apoB 
pellets were air dried.
ApoB protein was measured by the method of Lowry, Rosebrough, Farr, et al (1951) 
(section 2.4.2) by subtracting the isopropanol soluble protein from total protein, or by 
measuring the protein content of the NaOH dissolved apoB pellet.
2.4.2 Modified Lowry protein assay
Protein is measured by a modification (Markwell, Hass, Bieber, et al, 1978) of the 
Lowry protein method (Lowry et al, 1951).
Reagents: Solution A - 2% (wt/v) Na2 C0 3  in 0.1 M NaOH
Solution B - 2% (wt/v) NaK tartrate in deionised H20
64
Solution C - 1% (wt/v) Q1SO4 in deionised H20  
Folin Ciocalteu reagent (BDH, Prod 19058 3Q)
W orking reagents:
Biuret reagent - 1 ml solution B and 1 ml solution C were added to 
100 ml solution A. For apoB samples, 100 ml 2% (wt/v) Na2 C0 3  in 
deionised H20  was used. I f  the samples to be analysed were turbid, 
sodium dodecyl sulphate (SDS) (1 mg/ml) was added to the Biuret 
reagent.
Folin Ciocalteu reagent was diluted 1:1 with deionised H20  (freshly 
made).
S tandards: A standard curve in the range 0 - 50 pg was made from a 1 mg/ml
stock standard of human serum albumin (Sigma A-8763) in a final 
volume of 400 pi. For apoB samples, 0.5 M NaOH was also added. 
Quality Control:
15 pg and 30 pg quality control samples (in 400 pi) were made from 
150 pg/ml and 300 pg/ml stock solutions o f bovine serum albumin 
(Sigma A-4503). For apoB samples, 0.5 M NaOH were also added. 
Samples: Samples were used neat or diluted as necessary. Volumes were made
up to 400 pi with deionised H20 .
Procedure: 2 ml Biuret reagent was added to 400 pi standard, quality control or
sample, mixed and incubated at room temperature for 10 minutes. 
Two hundred pi of working Folin Ciocalteu reagent was added and 
mixed immediately. The optical density was read at 750 nm after 30 
minutes and within 2 hours. From the standard curve, unknown values 
were calculated.
2.5. Routine Biochemical tests
Urea was measured using a urease method on an Olympus 5231. Albumin was also 
measured on an Olympus 5231, using its affinity for bromo-cresol green at a neutral 
pH. Microalbumin was measured by an immunoturbidimetric assay on a Behring 
Laser Nephelometer. The antibody was manufactured by the Scottish Antibody
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Production Unit. Aspartate aminotransferase (AST) was measured on an Olympus 
5231 analyser using IFCC recommendations. The method links the conversion of 
alpha-oxoglutarate through oxaloacetate to malate with associated oxidation of 
NADH to NAD. Gamma glutamic acid (GGT) was measured on an Olympus 5231 
using the conversion of gamma-glutamyl-3-carboxy-4-nitroanilide and glycylclycine to 
gamma glutamyl-glycylglycine and 5-amino-2-nitrobenzate. These measurements 
were performed by staff of the Department of Biochemistry, Glasgow Royal 
Infirmary.
2.6. Measurement of enzyme activities
2.6.1 CETP activity
CETP activity was measured in plasma samples using a fluorescence kit from Roar 
Biomedical, Inc., following the manufacturers guidelines. The assay measures the 
CETP transfer activity by measuring the fluorescence released when the CETP in the 
sample transfers fluorescent neutral lipid from the core of donor particles to acceptor 
particles. The fluorescence is quenched when within the donor core, and fluorescence 
increases as the labelled lipid is transferred from the donor to the acceptor. Briefly, a 
standard curve was prepared from donor particles in isopropanol at a concentration 
range of 0 - 430 pmol/ml. One pi of sample was incubated with 10 pi donor particles 
and 489 pi CETP buffer (10mmol/l, Tris base, 150 mmol/1 NaCl, 2mmol/l Na2EDTA, 
pH 7.4) for 3 hours at 37°C. (If the sample was not of plasma, 10 pi acceptor 
particles were also added in a total volume of 500 pi). The fluorescence was 
measured at excitation 465 nm/ emission 535 nm and the CETP transfer activity was 
calculated using the standard curve.
2.6.2 Measurement of lipase activity
Seventy iU heparin (Leo Laboratories Ltd.)/kg body weight was injected into the 
marginal ear vein. After 12 minutes, a blood sample was withdrawn and placed 
immediately on ice. Post heparin plasma samples were incubated with a 14C-labelled 
triglyceride/gum arabic emulsion. FFA released by lipase activity were captured by
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albumin and extracted into a solvent and the ratio o f radioactivity in the extracted 
fraction to the total present in blank incubations enabled the calculation of the lipase 
activity using the following formula:
Lipase Activity (pmoles FFA released/ml/hour) = (cpmf sample) - cpm(blank))
cpm(total) - background
Each sample was measured under 3 different conditions. The addition o f SDS 
inactivated HL, and serum was added as it contains the LPL activator apoCII. HL 
was measured in the presence of a high salt concentration (1 M NaCl) to inactivate 
LPL. A third tube contained a low salt concentration, and no SDS, and total lipase 
activity was measured here.
CETP, HL and LPL were kindly measured by Mr Michael McConnell from the 
Department of Pathological Biochemistry, Glasgow Royal Infirmary.
2.7. Statistical analysis
Variables were tested for normal distribution. If necessary, samples were transformed 
to a normal distribution by taking the logarithm of their values. Two sample t-tests 
were performed to determine significance. Where the distribution of a variable or a 
series o f variables could not consistently be converted to normal, a Mann-Whitney U 
test was performed. All statistics were carried out using Minitab version 10 (Minitab 
Inc.).
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Chapter 3. The St Thomas’ Mixed Hyperlipidaemic Rabbit
3.1. Introduction
The St Thomas’ hospital rabbit, a strain o f NZW rabbit was first described in 1987 
(La Ville, et al) (Chapter 1) as exhibiting an inherited hyperlipidaemia similar to that 
seen in FCH. Both NZW and Dutch Belt rabbits were introduced into this closed 
colony.
In 1993, the remaining rabbits of the St Thomas’ hospital colony were transferred to 
Froxfield Farm where they were bred to maintain a diversity of lipid levels. This new 
colony was named the St Thomas’ Mixed Hyperlipidaemic rabbit (SMHL). As large a 
pool of rabbits as possible were mated, but some rabbits were poor breeders. The 
high degree of inbreeding, leading to an extremely complicated family tree has made 
the genetics of the disorder difficult to establish at present.
Rabbits were maintained on a vegetarian diet until required for experimental use, 
when they were fed specially prepared diets with varying cholesterol concentrations. 
La Ville et al (1987) had shown no effect on plasma cholesterol levels in St Thomas’ 
hospital rabbits on feeding either a diet containing no cholesterol or a diet containing 
0.053% (wt/wt) cholesterol for 6 weeks. We performed a similar study and looked at 
plasma lipid and lipoprotein parameters in more detail.
To characterise more carefully the hyperlipidaemia in SMHL rabbits, we undertook to 
measure plasma lipids, lipoproteins (and their compositions), insulin resistance status, 
and the levels of HL, LPL and CETP.
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3.2. Methods
3.2.1 Animals
Three separate groups of animals were studied. Group 1 consisted of 60 young (< 4 
months o f age) SMHL, 12 young NZW, 16 mature (> 5 months o f age) SMHL and 
18 mature NZW male rabbits, all fed the 0.08% cholesterol diet since weaning. These 
were the group from which we later selected the rabbits for our perfusion experiments 
(chapters 5,6,7). We measured plasma cholesterol and triglyceride levels (section
2.3.2, 2.3.3) in these rabbits.
In group 2 were 9 SMHL (5 female and 4 male) and 9 age and sex matched NZW 
controls fed a chow diet (0.005% cholesterol wt/wt) (Stanrab diet, Special Diet 
Service) ad libitum for a minimum of 4 weeks, plus 10 SMHL and 10 age and sex 
matched NZW rabbits fed a diet supplemented with a low (0.075% wt/wt) level of 
cholesterol (0.08% total) for 12 weeks. These sets o f animals were used to determine 
the effects o f a diet with a slightly elevated cholesterol content on lipoprotein 
composition and mass. The experiments were carried out as a collaboration between 
Dr G. M. Benson of SmithKline Beecham Pharmaceuticals and Dr M. J. Caslake at 
the Department o f Pathological Biochemistry, Glasgow Royal Infirmary.
A further 12 male and 12 female SMHL rabbits and 7 female NZW rabbits (group 3) 
fed on the 0.08% cholesterol diet since weaning were studied. Plasma cholesterol and 
triglyceride levels were measured at two week intervals from 9 to 27 weeks of age in 
order to determine the effects o f age on plasma lipid levels. These experiments were 
performed by Dr G. M. Benson, Mr D. Grimsditch, Dr P. H. E. Groot and Dr K. E. 
Suckling at SmithKline Beecham Pharmaceuticals.
3.2.2 Glucose tolerance test
Six male SMHL rabbits aged approximately 11 months and 7 age and sex matched 
NZW control rabbits from group 1, fed on the 0.08% cholesterol diet since weaning 
were fasted overnight. A pretreatment blood sample was taken from the marginal ear
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vein, and the animals were subsequently orally dosed with a solution of 1 g glucose/kg 
body weight. Blood samples were withdrawn at 15, 30, 45, 60 and 120 minutes after 
the glucose dose, and cholesterol, triglyceride, glucose, FFA and insulin were 
measured in these samples (sections 2.3.2, 2.3.3, 3.2.3, 3.2.4, 3.2.5). The area under 
the response curves for glucose, FFA and insulin were calculated by subtracting the 
baseline concentration from the concentration of the variable at each time point, and 
summing these values. Cholesterol, triglyceride and glucose concentrations were 
measured by staff of the Department of Biochemistry, Glasgow Royal Infirmary, and 
FFA and insulin concentrations were measured by Mr Michael McConnell o f the 
Department of Pathological Biochemistry, Glasgow Royal Infirmary. The assistance 
of Mr D. Robertson, Mr D. McMurdo, Dr M. J. Caslake and Mrs M. Stewart is 
gratefully acknowledged.
3.2.3 Measurement of blood glucose concentrations
Glucose was measured on an Olympus 5231, using the hexokinase catalysed 
conversion of glucose to glucose-6-phosphate, which is then converted to gluconate- 
6-phosphate causing the reduction of NADP to NADPH, which is measured at 340 
nm. These assays were performed by staff of the Department of Biochemistry, 
Glasgow Royal Infirmary.
3.2.4 Measurement of plasma FFA concentrations
Plasma free fatty acids were measured using an enzymatic colorimetric test kit (Wako 
Chemicals GmbH, Code No. 994-75409 E). The principle o f the assay is described 
below, with the absorbance of the resultant adduct being measured at 550 nm.
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acetyl-CoA synthetase 
RCOOH + ATP + CoA —» acetyl-CoA + AMP + PPi
acetyl-CoA oxidase 
acetyl-CoA + O2 —» 2,3-trans-Enoyl-CoA + H2 O2
peroxidase
2 H 2 O2 + MEHA + 4-aminoantipyrine —> adduct of MEHA and 4-aminoantipyrine
+ 4H20
MEHA 3-methyl-N-ethyl-N-(p-hydroxy-ethyl)-aniline
3.2.5 Measurement of plasma insulin
Insulin was measured using a porcine radioimmunoassay kit (Linco Research, Inc.) 
which has been shown to cross react with rabbit insulin. Fasting plasma samples (100 
pi) were incubated with 100 pi 125I labelled insulin, 100 pi insulin antibody and 100 pi 
assay buffer (0.05 mol/1 phosphosaline, pH 7.4, containing 0.025 mol/1 EDTA, 0.1% 
sodium azide and 1% bovine serum albumin) for 18 hours at 4°C. One ml of 
precipitating reagent was added, mixed and incubated for 20 minutes at 4°C, before 
being centrifuged for 15 minutes at 2500 g. The supernatant was discarded and the 
pellet was counted in a gamma counter. The concentration of insulin was calculated 
with reference to a standard curve in the range of 2 - 200 pUnits/ml. These assays 
were performed with the help of Ms Carolyn Lister o f SmithKline Beecham 
Pharmaceuticals.
3.2.6 SDS glycerol polyacrylamide gel electrophoresis
Half ml samples of lipoprotein fractions (prepared by density gradient 
ultracentrifugation as in 2.3.8), containing up to 1 mg protein (Table 3.1.) were 
shaken with 10 ml diethyl ether for 2 minutes (Mindham and Mayes, 1992); 0.2 ml of
3.6 mM sodium deoxycholate and 0.2 ml o f 4.9 M trichloroacetic acid (TCA) were 
added and mixed briefly, and the top layer of diethyl ether was removed by aspiration
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under a stream of nitrogen. The precipitated apolipoproteins in the lower layer were 
pelleted by centrifugation at 3070 g  for 10 minutes at 4°C, and the supernatant was 
decanted. The apolipoproteins were dissolved in 0.1 ml sample buffer (0.087 M Tris 
base pH 6.8, 4% SDS solution, 0.002% bromophenol blue, 20% glycerol, 10% 2- 
mercaptoethanol), neutralised by the dropwise addition of 5 M NaOH, and incubated 
for 5 minutes at 80°C in a Techne heating block.
Table 3.1. Protein content (mg) loaded on to SDS glycerol polyacrylamide gels
Fraction NZW SM HL
VLDL, 0.29 0.07
v l d l 2 0.43 0.05
IDL 0.28 0.06
LDL 0.03 0.02
The samples were loaded on to SDS polyacrylamide gels (3.5% acrylamide 
(acrylamide : bis-acrylamide ratio of 20 : 1), 18% glycerol, 0.064 M Tris/ phosphate 
pH 6.8, 0.05% tetramethylethylenediamine (TEMED), 0.1% SDS and 0.018% 
ammonium persulphate) prepared 18 hours in advance in order to allow full 
polymerisation and cross linking (Maguire, Lee and Connelly, 1989). The lower 
reservoir was filled with 0.1 M NaH2P 0 4  buffer, pH 7.0, and the upper reservoir was 
filled with the same buffer with 0.1% SDS added. Electrophoresis was carried out at 
a constant current of 20 mA for 30 minutes and then at 60 mA for 4.5 hours at room 
temperature, water cooled. Gels were fixed in 4% formaldehyde for 30 minutes, 
stained overnight in 0.025% coomassie brilliant blue G-250 in 45.4% methanol, 9.2% 
acetic acid, and destained in 7.5% acetic acid, 5% methanol.
High and low molecular weight markers (Table 3.2.) (Pharmacia Biotech) were 
loaded on each gel. Apolipoproteins were distinguished on the basis of their 
molecular weight.
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Table 3.2. M olecular W eight m arkers
High M olecular W eight Low M olecular W eight
Protein M olecular W eight Protein M olecular W eight
Thyroglobulin 669 000 Phosphorylase b 94 000
Ferritin 440 000 Albumin 67 000
Catalase 232 000 Ovalbumin 43 000
Lactate
dehydrogenase
140 000 Carbonic
Anhydrase
30 000
Albumin 67 000 Trypsin inhibitor 20 100
a-lactalbumin 14 400
3.2.7 Statistical analyses
All statistics were performed in Minitab 10. Data was tested for normal distribution, 
and 2 sample t-tests were performed. If the data was not normally distributed, it was 
log transformed prior to 2 sample t-tests being performed (insulin, cholesterol and 
triglyceride concentrations from glucose tolerance tests, CETP). If  the data was still 
not normally distributed, Mann Whitney U  tests were performed (lipoprotein 
composition, lipase concentrations). Missing values in composition data were 
estimated using ratios of components calculated from complete data sets in the group. 
Results are presented as mean ± standard error of the mean (SEM) unless otherwise 
stated.
3.3. Results
3.3.1 Population lipids
A group of 60 young SMHL, 12 young NZW, 16 mature SMHL and 18 mature NZW 
male rabbits were screened for inclusion in the liver perfusion experiments (group 1). 
Plasma cholesterol levels of both young and mature SMHL rabbits were significantly
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elevated (though variable) compared to NZW rabbits (5.97 ± 0.37 (mean ± SEM) vs 
1.79 ± 0.14 mmol/1, p < 0.001 in young rabbits and 3.11 ± 0.95 vs 1.32 ± 0.23 
mmol/1, p = 0.04 in mature rabbits, Figure 3.1.). Plasma triglyceride levels were 
significantly elevated in young SMHL rabbits compared to NZW controls (3.31 ± 
0.25 vs 1.14 ± 0.14 mmol/1, p < 0.001, Figure 3.2.) but not in mature SMHL vs NZW 
animals. In the male SMHL rabbits, mature rabbits showed lower levels o f plasma 
cholesterol (p = 0.006) and plasma triglyceride (p < 0.001) than young rabbits (Figure 
3.1., 3.2.) but NZW rabbits did not.
3.3.2 Effects of age on plasma cholesterol and triglyceride concentrations
To explore further the influence of age on plasma lipids, 12 male and 12 female 
SMHL rabbits and 7 female NZW rabbits (group 3) were fed a diet containing 0.08% 
cholesterol and plasma cholesterol and triglyceride concentrations were followed from 
9 - 2 7  weeks of age (Figure 3.3., 3.4.). Plasma cholesterol concentrations were 
similar for the 9 week old male and female SMHL rabbits (7.3 ± 0.89 and 8.8 ± 1.2 
mmol/1 respectively). However, by 26 (male SMHL) and 27 (female SMHL) weeks, 
plasma cholesterol had risen to 22 ± 2.2 mmol/1 in the females, while in the males it 
had fallen to 2.5 ± 0.7 mmol/1. Cholesterol levels were significantly increased in 
female compared to male SMHL rabbits from 19 weeks of age, and were significantly 
increased in female SMHL compared to female NZW rabbits throughout the 
experiment. Plasma triglyceride concentrations fell from 4.5 ± 0.3 mmol/1 in male and 
4.3 ±0 .3  mmol/1 in female SMHL rabbits to 2.7 ± 0.5 mmol/1 in both sexes of SMHL 
rabbits, but in female SMHL rabbits, triglyceride concentrations remained significantly 
elevated when compared to female NZW rabbits throughout the period of the 
experiment.
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Figure 3.1. Plasma cholesterol concentrations in a population of NZW and
SMHL rabbits
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Figure 3.2. Plasma triglyceride concentrations in a population of NZW and 
SMHL rabbits
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Figure 3.3. Plasma cholesterol concentrations by age in NZW and SMHL
rabbits
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Figure 3.4. Plasma triglyceride concentrations by age in NZW and SMHL 
rabbits
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3.3.3 Effect of 0.08% cholesterol diet on plasma lipids and lipoproteins
To uncover the hyperlipidaemic phenotype in SMHL rabbits it was necessary to add a 
small amount o f cholesterol to the diet (Table 3.3., rabbits from group 2). Cholesterol 
supplementation at this level had no significant effect on plasma lipid levels in NZW 
rabbits, however plasma cholesterol was significantly elevated in SMHL rabbits on the 
0.08% cholesterol diet compared to SMHL on normal chow and NZW fed either 
normal or supplemented diet. There were no significant differences in plasma 
triglyceride concentrations between any o f the groups. However, it was noted that 
despite having normal total lipid levels, chow fed SMHL rabbits were dyslipidaemic. 
VLDL2 and IDL mass levels tended to be elevated compared to NZW rabbits fed the 
same diet (p = 0.08, p = 0.01 respectively). When fed the cholesterol supplemented 
diet all four apoB containing lipoproteins were increased in SMHL compared to NZW 
rabbits fed either normal or supplemented diet.
Table 3.3. Effect of 0.08% cholesterol diet on plasma lipid and lipoprotein levels 
in SMHL and NZW rabbits
Cholesterol diet Chow diet
NZW SMHL NZW SMHL
Number 10 10 9 9
Cholesterol
(mmol/1)
1.6 ± 0.3 3.8 ±0.7a’b 0.8 ±0.1 1.1 ±0.2
Triglyceride
(mmol/1)
0.49 ±0.04 1.3 ±0.46 0.8 ±0.2 1.2 ±0.3
VLDLi mass 
(mg/dl)
16 ± 4 97 ± 35a 38 ± 11 43 ± 16
VLDL2 mass 
(mg/dl)
21 ±5 99 ± 22a,b 10 ± 4 20 ± 4
IDL mass 
(mg/dl)
31 ± 10 108 ± 24a,b 7 ± 1 18 ± 3
LDL mass 
(mg/dl)
15 ± 4 36 ± 6a,b 4 ± 1 7 ± 2
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Plasma lipid and lipoprotein measurements in NZW  and SMHL rabbits fe d  either 
normal chow (0.005% cholesterol) or 0.08% cholesterol diet (mean ±  SEM). 
Significant differencesp < 0.05 using the Mann Whitney U te s ta SMHL vs N ZW  on 
0.08% cholesterol diet, b SMHL on 0.08% cholesterol diet vs SMHL on normal diet.
3.3.4 Lipoprotein composition
The content of protein, cholesterol, free cholesterol, triglyceride and phospholipid 
were measured (sections 2.4.2, 2.3.2, 2.3.5, 2.3.3, 2.3.6) in each lipoprotein fraction 
in the 10 NZW and 10 SMHL rabbits fed the 0.08% cholesterol diet above (section 
3.3.3). Cholesterol ester was calculated by subtracting free cholesterol from total 
cholesterol. The contribution of each component as a percentage of the whole 
lipoprotein was calculated (Table 3.4.). The SMHL rabbits studied had a significantly 
increased plasma cholesterol concentration of 3.8 ± 0.7 mmol/1 compared to 1.6 ± 0.3 
mmol/1 in the NZW rabbits (p < 0.01). The triglyceride concentrations were not 
significantly different (Table 3.3.). Percentage compositions of the lipoproteins were 
varied, but did not differ significantly between the two strains o f rabbit, except in 
phospholipid content, which was significantly increased in SMHL rabbits in all four 
fractions. Additionally, the percentage of free cholesterol in VLDLi in SMHL rabbits 
was decreased compared to NZW controls (5.0 ± 0.7 vs 16.0 ± 6.8, p < 0.05).
3.3.5 Apolipoprotein content
Apolipoprotein content was examined by SDS glycerol polyacrylamide gel 
electrophoresis. Protein isolated from VLDLi, VLDL2 , IDL and LDL fractions 
separated by density gradient ultracentrifugation of plasma was loaded on to the gel 
(see Table 3.1. for protein concentrations) and the apolipoproteins were separated. A 
representative gel picture is shown in Figure 3 .5. There was no discernible difference 
in apolipoprotein content between NZW and SMHL rabbits.
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Figure 3.5. Apolipoprotein content of NZW and SMHL rabbit VLDLi, VLDL2,
IDL and LDL
ApoBlOO
ApoE
Low Mr 
apos
ApoB 100 and apoE bands are clearly seen in NZW and SMHL rabbit VLDL, 
with apoBlOO bands visible in NZW  and SMHL rabbit IDL and LDL, showing 
no difference between the two strains. The protein content loaded on to the gel 
is given in Table 3.1. Lower molecular weight (Mr) apolipoproteins were 
incompletely separated.
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3.3.6 Insulin resistance status
Plasma insulin levels were measured as an index o f the degree o f insulin resistance 
present in 7 NZW and 7 SMHL rabbits from group 1 (aged 5 months), fed the 0.08% 
cholesterol diet (Table 3.5.). Insulin concentrations were variable, particularly in the 
SMHL group, but were significantly increased in the SMHL rabbits compared to the 
NZW (p = 0.048).
Table 3.4. % Composition of lipoproteins in 0.08% cholesterol diet fed SMHL 
and NZW rabbits
NZW SMHL
VLDLj v l d l 2 IDL LDL VLDLj v l d l 2 IDL LDL
Protein 17.1 ± 
4.8
16.8 ± 
1.4
19.2 + 
1.0
19.9 ± 
1.8
8.3 ± 
0.9
14.0 + 
0.3
19.4
±0.6
25.6 
± 1.7
FC 16.0 ± 
6.8
7.0 ± 
1.8
7.9 ± 
1.1
10.0 ± 
2.2
5.0 ± 
0.T
7.2 ± 
1.8
7.1 ± 
1.7
6.0 ± 
1.2
CE 28.1 ± 
9.0
51.6 ± 
4.0
49.1 ± 
2.4
37.4 ± 
5.8
37.5 ± 
5.0
46.1 ± 
3.8
42.4 
+ 3.2
44.6
±3.2
TG 27.7 ± 
5.9
8.5 ± 
1.8
6.7 ± 
1.7
8.3 ± 
0.5
36.5 ± 
5.2
13.8 + 
3.8
11.3
±3.1
11.3
±2.7
PL 11.0 ± 
2.4
16.1 ± 
0.8
17.1 ± 
1.2
24.4 ± 
3.0
12.8 + 
0.4a
18.8 ± 
0.4b
19.8
±0.3b
12.4 
± 1.7°
Mean ± S E M
SMHL significantly different from  NZW  rabbits, a p  < 0.05, b p  < 0.01, c p  < 0.005 
Phospholipid (PL)
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Table 3.5. Plasma insulin concentrations (pmol/1)
Rabbit NZW SMHL
1 9.3 344.3
2 7.3 21.5
3 11.8 83.6
4 18.8 23.3
5 27.4 17.0
6 15.5 49.4
7 14.7 15.5
Mean ± SEM 15.0 ± 2.5 79.2 ± 45. l a
Significant difference a p  < 0.05
This prompted further investigation of the insulin resistance status o f the SMHL 
rabbits, and oral glucose tolerance tests were performed in the same group of rabbits 
(now 6 SMHL and 7 NZW) when aged 11 months (section 3.2.2). Mean fasting 
plasma cholesterol and triglyceride concentrations were 3.5 ± 1.8 vs 1.4 ± 0.4 mmol/1 
(SMHL vs NZW), NS, and 1.3 ± 0.8 vs 0.3 ± 0.01 mmol/1 (SMHL vs NZW), NS, and 
did not vary significantly over the 2 hours of the experiment. There was no difference 
in mean area under the curve for the glucose response (Table 3.6.), however the mean 
areas under the curve for both FFA (Figure 3.6.) and insulin (Figure 3.7.) were 
significantly elevated in the SMHL rabbits compared to the NZW rabbits (FFA area 
under the curve was 1.2 ± 0.2 vs 0.5 ± 0.1 mmol/1, SMHL vs NZW, p < 0.05; insulin 
area under the curve was 62.0 ± 10.0 vs 20.9 ± 4.0 pU/ml, SMHL vs NZW, p < 0.01, 
Table 3.6. Thus there was an abnormal response by the SMHL rabbits to the glucose 
dose, consistent with insulin resistance. Insulin concentrations were significantly 
increased in the SMHL rabbits at 15, 45, 60 and 120 minute time points (p < 0.05).
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Figure 3.6.A Plasma FFA response of NZW rabbits to an oral dose of glucose
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Figure 3.6.B Plasma FFA response of SMHL rabbits to an oral dose of glucose
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Individual rabbit responses are shown in blue (*), and mean values are shown in 
red (0)
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Figure 3.7.A Plasma insulin response of NZW rabbits to an oral dose of glucose
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Figure 3.7.B Plasma insulin response of SM HL rabbits to an oral dose of glucose
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Time (minutes)
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Individual rabbit responses are shown in blue (M), mean values are shown in red (M)
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We tested for correlations between variables within the whole group, and also within 
the NZW and SMHL populations individually. Significant positive correlations were 
seen between the insulin area under the curve and both the glucose area under the 
curve and (log) plasma triglyceride (Figure 3.8.). Additionally, a positive correlation 
was seen between FFA area under the curve and (log) plasma cholesterol but not 
plasma triglyceride (Figure 3.8.).
Table 3.6. Insulin, FFA and glucose area under the curve in response to an oral 
glucose dose
Mean area under 
the curve NZW SMHL p-value
Insulin (pU/ml) 20.9 ±4 .0 62.0 + 10.0 <0.01
FFA (mmol/1) 0.5 ± 0.1 1.2 ±0 .2 <0.05
Glucose (mmol/1) 14.6 ± 1.9 20.2 ±3.1 NS
3.3.7 Lipoprotein lipase and hepatic lipase activities
LPL and HL activities in post heparin plasma were measured (section 2.6.2) in 7 
NZW and 7 SMHL rabbits from group 1 (aged 4 months) fed the 0.08% cholesterol 
diet. There were no significant differences in lipase activities between the two strains 
of rabbit (Table 3.7.) by the Mann Whitney U  test.
3.3.8 CETP activity
Plasma CETP activities were measured (section 2.6.1) in 7 NZW and 7 SMHL rabbits 
fed the 0.08% cholesterol diet from group 1. CETP activity was significantly 
increased in SMHL rabbits when compared to NZW rabbits (128.8 ± 16.9 vs 46.6 ±
9.5 pmoles substrate transferred per 1 pi plasma, p < 0.01, Table 3.7.).
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3.8. Correlations between glucose tolerance test variables
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Table 3.7. Plasma lipase and CETP activities
LPL activity (pmoles 
FFA 
released/ml/hour)
HL activity (pmoles 
FFA 
released/ml/hour)
CETP activity 
(pinoles substrate 
transfer/pl plasma)
Rabbit NZW SMHL NZW SMHL NZW SMHL
1 8.9 3.3 1.0 1.0 51.2 81.0
2 8.2 8.1 0.9 4.1 22.8 88.6
3 19.6 6.1 1.4 1.0 64.0 176.0
4 13.7 16.3 4.6 2.7 80.4 165.6
5 15.2 11.3 1.3 1.0 60.6 133.8
6 20.7 18.6 1.2 3.8 40.1 175.7
7 25.5 23.5 1.4 1.3 7.2 81.0
Mean ± 
SEM
16.0 ±2.4 12.4 + 2.8 1.7 ± 0.5 2.1 ±0.5 46.6 ±9.5 128.8 ± 
16.9a
Significant difference a p  ■ 0.01
3.4. Discussion
The SMHL rabbit is a putative model for the human disorder FCH (La Ville et al, 
1987). We performed some basic investigation to further characterise the phenotype 
shown by the SMHL rabbits.
The large population of male rabbits screened for possible use in the liver perfusion 
experiments showed that plasma cholesterol and triglyceride levels were variable, but 
higher in SMHL rabbits compared to NZW rabbits. Individually, SMHL rabbits 
showed elevated cholesterol or triglyceride levels, or, most commonly, increases in 
both cholesterol and triglyceride concentrations.
Male SMHL rabbits showed a decrease in plasma lipid levels with age, reaching a 
plateau at 14 - 16 weeks, while NZW rabbits did not change (Figure 3.1., 3.2., 3.3.,
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3.4.). In contrast, plasma cholesterol concentrations in female SMHL rabbits 
increased with age (Figure 3.3.), while plasma triglyceride levels decreased (Figure
3.4.). The mechanisms responsible for this gender difference are unclear, however it 
is likely that for some reason the IDL and LDL accumulate to higher levels in the 
female compared to the male SMHL rabbits. Increased hepatic stores of cholesterol 
could lead to a shut down of LDL receptors and a rise in plasma LDL levels.
Appearance o f the hyperlipidaemic phenotype of the SMHL rabbits is dependent on 
supplementing their diet with a small amount of cholesterol. NZW animals fed the 
same diet showed no change in plasma lipid levels. However, even on the chow diet, 
plasma VLDL2 and IDL lipoprotein concentrations were elevated in SMHL rabbits 
indicating the presence of a lipoprotein disturbance. That La Ville et a l did not find a 
difference in plasma lipid levels on feeding a cholesterol supplemented diet could be 
explained by the shorter duration of her study.
The composition of the lipoprotein particles present in plasma in SMHL and NZW 
rabbits was investigated. The content of protein, free cholesterol, cholesterol ester 
and triglyceride was variable, but not significantly different. This is in contrast with 
the original work performed by La Ville et al (1987) who found that free cholesterol 
and cholesterol ester content were significantly increased in VLDL, IDL and LDL 
fractions in the St Thomas’ hospital rabbits compared to NZW controls, and that 
triglyceride content was significantly decreased in IDL and LDL in St Thomas’ 
hospital rabbits compared to NZW controls. This may be explained by the fact that 
the rabbits included in the St Thomas’ hospital study exhibited a greater 
hypercholesterolaemia than did our rabbits. From analysis of the apolipoprotein 
content of the lipoproteins by SDS glycerol polyacrylamide gel electrophoresis, we 
could detect no difference in the apolipoprotein distribution between the two strains 
of rabbit, in accordance with earlier work by La Ville.
The response of the SMHL rabbits to an oral glucose dose was characteristic of a 
degree of insulin resistance. Compared to the NZW rabbits (Figure 3.7.A), the 
response in SMHL rabbits was elevated and highly variable (Figure 3.7.B). In the 
NZW rabbits, insulin secreted in response to the glucose dose will have
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downregulated HSL and reduced FFA release from triglyceride stores in the adipose 
tissue leading to the fall in plasma FFA levels (Figure 3.6.). However in the SMHL 
rabbits, there was resistance to the effects of insulin evidenced by the 
hyperinsulinaemia (Figure 3.7.B), and by the fact that the insulin release failed to 
lower plasma FFA, presumably due to more FFA release from adipose tissue (Figure
3.6.).
Insulin area under the curve was positively correlated with glucose area under the 
curve, demonstrating that an exaggerated insulin response is associated with impaired 
glucose disposal (Figure 3.8.); a correlation in the whole group that was driven by a 
positive correlation in the SMHL group. No correlation was seen between the insulin 
area under the curve and the FFA area under the curve, but there was a positive 
correlation between insulin area under the curve and (log) plasma triglyceride again 
primarily in the SMHL rabbits, explained possibly by an increased FFA delivery to the 
liver in insulin resistant animals which results in an increased triglyceride output. 
However, FFA area under the curve did not correlate with (log) plasma triglyceride as 
is the case in humans (Laws, 1996), but did show a positive correlation with (log) 
plasma cholesterol. This unusual finding may indicate that an increase in FFA due to 
insulin resistance is associated with the hyperlipidaemia but may not be the underlying 
driving force. If it was, we would have expected a tight correlation between FFA and 
plasma triglyceride and little association with plasma cholesterol.
Post heparin LPL and HL activities were measured in both strains of rabbit and did 
not show any significant differences. HL levels were low in both strains, in 
accordance with previous findings (Warren, Ebert, Mitchell, et al, 1991). This 
suggests that there is no underlying defect in the lipolytic cascade in the SMHL 
rabbits (Figure 1.1) and that any differential delipidation of lipoprotein species is due 
to altered affinity of the particles themselves for the lipase enzymes. This provides 
further evidence for the suitability of the SMHL rabbits as a model for FCH, as, 
although LPL activity has been reported to be impaired in approximately one third of 
patients with FCH (Babirak et al, 1992), severe defects in this gene have not been 
shown to be important in FCH patients, and moderate variations in LPL activity may
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merely magnify the phenotype. Therefore LPL deficiency is not an obligate marker 
for FCH.
CETP activity has been documented to be increased in individuals with various forms 
of hyperlipidaemia, including combined hyperlipidaemia (Tato, Vega, Tall, et al, 
1995). Increased CETP activity may result in elevated cholesterol concentrations in 
lipoprotein remnants, which are then cleared less efficiently from plasma. In the 
presence o f hypertriglyceridaemia, an increased CETP concentration can cause 
triglyceride transfer from VLDL to LDL ultimately resulting in the formation of small 
dense LDL particles, a risk factor for CHD. However, CETP deficiency can also be 
atherogenic as a lack of CETP results in large HDL particles that may not have anti­
atherogenic functions, and is also associated with small LDL particles (Yamashita, 
Sakai, Hirano, et al, 1997). Therefore CETP levels require regulation within a 
narrow optimal level to exert anti-atherogenic effects.
Our findings of a significantly elevated CETP activity in the SMHL rabbits is 
intriguing and further confirms the rabbits as being a suitable model for FCH (Table
3.7.). Cholesterol feeding has been shown to increase CETP activity in rabbits 
(Quinet, Agellon, Kroon, et al, 1990) but whether the cholesterol level (0.08%) in the 
diet we fed to our rabbits was sufficient to induce an increase in CETP mRNA levels 
and mass is unclear, as Quinet et al supplemented their diet with 0.5% cholesterol. In 
any case, here we show an increased CETP activity in the cholesterol fed SMHL 
rabbits compared to the cholesterol fed NZW rabbits.
On balance, the SMHL rabbit exhibits many features that have been reported in the 
literature as being associated with FCH. The remainder of this thesis describes a 
series o f experiments designed to take a more in depth look at the metabolic disorder 
in these animals.
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Chapter 4. Stable Isotope Turnover Studies
4.1. Introduction
The use o f stable isotopes to investigate lipid metabolism in vivo in humans was first 
described in 1935 by Schonheimer and Rittenberg. However, it is only recently that 
they have become widely used, due to the increased availability of stable isotopes and 
improvements in gas chromatography - mass spectrometry (GC-MS) detection 
systems.
The basis of the stable isotope turnover technique is the endogenous labelling of 
proteins with the injected tracer, usually a stable isotope enriched amino acid. The 
production and catabolism of the protein of interest can then be followed in several 
plasma samples by isolating the protein, in this case apoB, and analysing its isotopic 
enrichment by GC-MS. However the endogenous labelling of proteins with stable 
isotopes has a number of disadvantages, for example that all newly synthesised 
proteins are labelled with the stable isotope and therefore the one o f interest must be 
purified, and that interconversion and recycling of label must be taken in to account. 
Stable isotopes are difficult to measure, however they are much safer than radio­
isotopes. Endogenous labelling provides much clearer information on production 
rates (PR) o f proteins than does exogenous labelling which infers PR from steady 
state turnover data.
The stable isotope turnover technique has been applied to a wide variety o f lipid 
disorders in humans but has rarely been used in any animal species because radio­
isotopes are cheaper and easier to detect. Nonetheless, we decided to apply the stable 
isotope turnover technique currently used in humans in our laboratory (Demant, 
Packard, Demmelmair, et al, 1996), to our rabbit population. We hoped that, if 
successful, this would enable a better comparison with humans and give a clearer 
picture of lipoprotein production, while proving a safer technique.
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The choice o f tracer depends on the protein of interest. The tracer amino acid must 
be abundant in the protein of interest. For apoB, L-[5,5,5 2H3]-leucine (d3 leucine) is 
the tracer of choice (Figure 4.1.) as leucine is one of the most abundant amino acids in 
apoB, and it can be detected with precision in the mass spectrometer. Additionally, it 
is an essential amino acid, and is metabolised in the muscle, therefore the extent of 
recycling in the hepatic precursor pool is minimised. The stable isotope can be 
administered as a bolus or as a primed constant infusion. Generation o f kinetic rate 
constants from the enrichment data is performed by multicompartmental modelling.
Figure 4.1. Structure of d3 leucine
NH 2
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D
D  = deuterium
We wished to use the stable isotope turnover technique in the SMHL rabbits to 
investigate the kinetics of the apoB containing lipoproteins in these rabbits in 
comparison to NZW controls. La Ville et al (1987) performed exogenous 
radiolabelled kinetic experiments on the St Thomas rabbits, and found that they had 
an increased VLDL and LDL apoB PR and a decreased LDL FCR. We planned a 
more detailed series of experiments to look at the metabolism o f apoB in VLDLi, 
VLDL2, IDL and LDL to find potential mechanisms that could describe the 
hyperlipidaemia seen in these animals.
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4.2. Methods
4.2.1 Selection of animals
Five male SMHL rabbits fed the 0.08% cholesterol diet since weaning and aged 
between 10 and 18 months were selected and five NZW rabbits of the same sex and 
similar age were used as control rabbits.
4.2.2 Calculation of standard apoB % in VLDLi, VLDL2, IDL and LDL
Human studies have demonstrated that the percentage of protein that is apoB in each 
lipoprotein fraction is relatively constant between individuals. Because o f insufficient 
sample throughout the turnover we were unable to calculate apoB mass from the 
turnover samples. Therefore we determined the apoB % in VLDLi, VLDL2, IDL and 
LDL of 3 NZW and 3 SMHL rabbits to use as a standard. Ultracentrifugation of 2 ml 
fasted plasma samples from each rabbit to separate these lipoproteins (section 2.3.8) 
was followed by apoB precipiation (section 2.4.1). Protein content was measured in 
lipoprotein fractions and the isopropanol supernatant (non apoB protein), and this 
value was subtracted from total protein to give a value for apoB. ApoB protein was 
expressed as a percentage of total protein. The values obtained here did not vary 
greatly when compared to those in humans, except in VLDL2 (Table 4.1.), and 
therefore, due to the small sample size we decided to use the widely accepted values 
determined from humans.
Table 4.1. Standard apoB%
VLDL, v l d l 2 IDL LDL
NZW mean 44.5 ±3.1 74.3 ± 1.7 87.3 ±0.7 86.3 ±3.5
SMHL mean 50.4 ± 1.1 72.8 ± 1.7 82.8 ±1.2 86.1
Whole group 46.8 ±2.2 73.5 ± 1.2 84.6 ± 1.3 86.2 ±2.0
Human 45 60 85 90
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4.2.3 Testing of the separation of VLDLi, VLDL2, IDL and LDL from small 
volumes of plasma
Due to the small blood volume o f the rabbits, it was only possible to take 2.5 ml blood 
samples at each time point. Therefore the separation of VLDLi, VLDL2, IDL and 
LDL from 2 ml of sample would have to be done on a 1:1 dilution of plasma with 
saline. To ensure that this was possible and did not affect the separation of the 
lipoproteins, we compared the separation of these lipoproteins (section 2.3.8) from 2 
ml plasma and 1 ml plasma plus 1 ml saline from 1 NZW and 1 SMHL rabbit. We 
measured the content of total cholesterol, free cholesterol, triglyceride, phospholipid 
and protein in each fraction (sections 2.3.2, 2.3.5, 2.3.3, 2.3.6, 2.4.2 respectively).
4.2.4 Stable isotope turnover protocol
The rabbits were fasted overnight (> 15 hours). A 2.5 ml sample of blood was 
withdrawn from the marginal ear vein and subsequently a bolus dose o f 1 0  mg d3 
leucine/kg body weight (Isotec Inc.) was injected. Two and a half ml blood samples 
were withdrawn periodically over 4 - 2 7  hours (Table 4.2.). Timing of samples was 
varied to obtain different levels of information on apoB particle secretion in the rabbit, 
and was a function of the size of the rabbit and the number of samples we were 
permitted to withdraw. One NZW and 1 SMHL rabbit followed protocol 1, 1 SMHL 
followed protocol 2, and the remainder, 4 NZW and 3 SMHL followed protocol 3. 
The majority of these experiments were performed by Mr D. Grimsditch and staff of 
L. A. S., Smithkline Beecham Pharmaceuticals.
Plasma was prepared from each sample and cholesterol and triglyceride 
concentrations were measured at time 0. VLDLi, VLDL2, IDL and LDL were 
separated at each time point (section 2.3.8) from 1 ml plasma plus 1 ml saline. ApoB 
was isolated as described previously (section 2.4.1).
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Table 4.2. Sample protocol (minutes)
Protocol 1 Protocol 2 Protocol 3
0 0 0
15 30 30
30 40 40
40 50 50
50 60 60
60 75 75
75 90 90
90 105 105
105 1 2 0 1 2 0
1 2 0 180 180
180 240 240
240 360 360
1440
1620
4.2.5 Preparation of samples for GC-MS
ApoB pellets from VLDLi, VLDL2, IDL and LDL were hydrolysed by adding 2  ml of 
6  M HC1 and incubating at 110°C for 24 hours. The amino acid hydrolysate was 
concentrated in a vacuum concentrator centrifuge (Howe) and transferred to 
Chromacol vials (Chromacol Ltd.) before being dried completely.
4.2.6 Measurement of plasma leucine
One hundred pi of plasma from each time point was mixed with 1 0 0  pi 10% TCA and 
incubated at room temperature for 30 minutes. The samples were spun at 1780 g  for 
30 minutes at 4°C and the supernatant was loaded on to a cation exchange column 
(Dowex AG® 50W-X8 resin, 100 - 200 mesh, hydrogen form, Bio-Rad Laboratories)
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pre-treated with 1 M HC1. The TCA was washed through with deionised H 2 0 , and 
the amino acids were eluted with 4 M NH4 OH. The samples were concentrated on 
the centrifugal evaporator , transferred to Chromacol vials and taken to dryness.
4.2.7 Sample analysis by GC-MS
The amino acids were converted to fer/-butyl-dimethyl-silyl (TBDMS) derivatives, 
and the specific enrichment of tracer amino acid (the atom percent excess) in these 
derivatives was then measured on a Fisons Trio 1000 quadrupole system (Fisons 
Instruments). This work was performed by Mr J. P. Stewart and Mrs D. K. Bedford. 
The sensitivity o f measurement was increased by comparing the d3 leucine peak with a 
naturally occuring leucine (m + 2 ) peak, instead of the most common leucine (m = 0 ) 
peak The m + 2 peak occurs at a constant ratio with the m = 0  peak. To calculate 
the tracer to tracee ratio (the equivalent to specific activity in radioactive terms) the 
ratio of the sample and the naturally occurring leucine (m + 3) to leucine (m = 0) is 
used (Demant, Packard, Stewart, et al, 1994) (Figure 4.2.). The d3 leucine peak (m + 
3) is much closer in size to the m + 2 peak compared to the m = 0  peak, and this 
allows their ratio to be determined with greater precision.
Figure 4.2. Calculation of tracer/tracee ratios from mass ratios
E = (R-Ro)/[(l + R) + (l + Ro)]
where E is the specific isotopic enrichment, R is the ratio of leucine (m = 3) : leucine 
(m + 0) (in sample), and Ro is the ratio of leucine (m = 3) : leucine (m + 0) (naturally 
occurring).
Z = E/(Et - E)
where Z is the tracer/tracee ratio and Et is the specific enrichment of the d3 leucine 
tracer.
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4.2.8 Multicompartmental modelling
Using the tracer/tracee ratios from the plasma, VLDLi, VLDL2, IDL and LDL, and 
the apoB masses, the rates of production, transfer and catabolism of the lipoprotein 
species were calculated by creating a multicompartmental model.
Multicompartmental modelling was performed using the SAAM II programme. This 
software programme is a tool which creates models, and designs and simulates 
experiments, enabling the analysis of turnover data. The compartmental system is a 
visually interactive module, enabling the operator to graphically create an 
experimental model, from which the programme creates a series o f differential 
equations. Experimental data is associated with specific compartments, and SAAM II 
fits the model to the data, generating rate constants.
Based on physiological knowledge and the ability to fit the data, we created a minimal 
model to express our results (Figure 4.3.). The plasma data is modelled in 3 
compartments. The input of d3 leucine is to the plasma pool (2 ), and this equilibrates 
with a hepatic (3) and an extravascular (1) leucine pool. A delay compartment 
accounts for the intrahepatic synthesis of apoB (4). From there, apoB can be 
channelled in to VLDLi (5), VLDL2 (7), IDL (9) or LDL (10) compartments. 
Additionally there is a delipidation chain representing the stepwise delipidation of 
VLDL through to LDL. Finally, for some animals it was necessary to create 
compartments to describe more slowly metabolising lipoproteins, so called VLDLi 
and VLDL2 remnants (6 ,8 ). We applied constraints to these compartments where the 
rate of catabolism of these remnants was equal (k(0 ,6 ) = k(0 ,8 )).
Plasma data was fitted to the plasma model first. The parameters were then fixed, and 
the lipoprotein data was subsequently fitted, first in the absence of VLDLi and 
VLDL2 remnant compartments, which were only added if they were required for best 
fit.
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Figure 4.3. Compartmental Model
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4.3. Results
4.3.1 Comparison of 2 nil plasma sample with 1 ml plasma sample plus 1 ml 
saline for separation of VLDLi, VLDL2, IDL and LDL
When we separated VLDLi, VLDL2, IDL and LDL from 2 ml plasma and compared 
them to the lipoproteins separated from 1 ml plasma plus 1 ml saline, we found that 
there was no difference in the composition of the lipoproteins, and that the contents 
were approximately half in the diluted sample compared to the neat sample (Table
4.3.). Therefore we concluded that the separation from diluted plasma was 
comparable to that from neat plasma and could be used for the turnover studies.
Table 4.3. Composition of VLDLi, VLDL2, IDL and LDL in samples prepared 
from neat or dilute plasma
NZW
1 ml plasma + 1 ml saline 2  ml plasma
TC FC TG PL Prot TC FC TG  - PL Prot
VI 0.09 0.09 0.07 9.4 4.6 0 . 2 1 0 0.13 4.1 6 . 2
V2 0.29 0.06 0.03 6 . 6 6 . 2 0.62 0.09 0.08 11.9 1 1 . 1
IDL 0 . 6 6 0.06 0.07 15.8 12.9 1.3 0.15 0.13 28.1 25.5
LDL 0.07 0 0 . 0 1 4.02 3.19 0.25 0 0 . 0 2 1 2 . 6 7.0
SMHL
1  ml plasma + 1 ml saline 2  ml plasma
VI 0.28 0.05 0.16 5.3 8 . 0 0.57 0 0.33 1 1 . 1 15.4
V2 0.53 0 0.06 11.3 1 0 . 1 1 . 2 0.24 0.13 19.2 2 2 . 6
IDL 0.51 0.03 0.04 13.0 1 2 . 0 1 . 1 0 . 0 2 0.09 23.36 17.0
LDL 0.08 0 0 . 0 1 3.3 3.6 0.24 0.05 0.03 6 . 0 6.5
TC - total cholesterol (mmol/l), FC - free cholesterol (mmol/l), TG - triglyceride 
(mmol/l), PL - phospholipid (mg/dl), Prot - protein (mg/dl)
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4.3.2 Population lipids
Although there was a trend to higher lipid levels in SMHL rabbits, there was no 
significant difference in plasma cholesterol and triglyceride levels between the NZW 
and SMHL rabbits (Table 4.4.), ie SMHL rabbits in this small group of mature 
animals were not hyperlipidaemic.
Table 4.4. Mean plasma cholesterol and triglyceride concentrations
NZW SMHL
Rabbit
Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
Cholesterol
(mmol/1)
Triglyceride
(mmol/1)
1 0.90 0.45 1.17 0.47
2 2.03 0.99 2.83 1.87
3 0.98 0.54 2.28 2.29
4 1.52 0.67 1.26 0.40
5 0.64 0.78 0.72 0 . 8 6
Mean ± SEM 1.21 ±0.25 0.69 ±0.09 1.65 ±0.39 1.18 ± 0.38
4.3.3 ApoB pool sizes
We calculated the apoB mass (mg) in each lipoprotein species by calculating the 
percentage of protein that was apoB using the standard values of 45, 60, 85 and 90% 
of the total protein in each fraction. IDL apoB mass and total apoB mass were 
significantly elevated in the SMHL rabbits compared to the NZW rabbits (Table 4.5.).
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Table 4.5. ApoB mass (mg) in VLDLi, VLDL2, IDL, LDL and total lipoproteins
VLDLi v l d l 2 IDL LDL Total
Rabbits NZW
1 0.9 1.3 2.5 1 . 8 6.5
2 1.7 3.1 2.9 5.2 12.9
3 4.0 3.0 2 . 6 8.7 18.3
4 1 0 . 2 2 . 0 3.9 2.7 18.8
5 1 . 0 1 . 1 3.8 1 . 2 7.1
Mean ± 
SEM
3.5 ± 1.6 2.1 ±0.4 3.1 ±0.3 3.9 ± 1.3 12.7 ±2 .4
SMHL
1 0.5 1 . 6 9.6 15.7 27.4
2 8.4 14.0 16.7 18.4 57.5
3 9.4 5.4 9.9 3.3 28.0
4 0 . 8 1 . 2 7.4 6 . 2 15.6
5 1.7 5.5 14.7 5.7 27.6
Mean ± 
SEM
4 .2+  1.8 5.5 + 2.1 11.7 ± 1 .6 a 9.9 ±2 .7 31.2 ± 6.3a
Significant differences (NZW vs SMHL) a p  < 0.05
4.3.4 Kinetic parameters - NZW
Multicompartmental modelling was performed using tracer/tracee ratios and apoB 
masses o f VLDLi, VLDL2 , IDL and LDL. Rates o f production, transfer and 
catabolism of each particle were defined (Table 4.6.).
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Table 4.6. Kinetic results - NZW
Rabbits
VLDLi
PR
(mg/d)
VLDL!
FDC
(pools/d)
VLDL!
FTR
(pools/d)
v l d l 2
PR
(mg/d)
v l d l 2
FDC
(pools/d)
v l d l 2
FTR
(pools/d)
NZW1 32.2 0 36.0 29.1 35.6 1 1 . 6
NZW2 61.3 36.7 0 1 2 . 1 3.6 1.55
NZW3 62.0 0 15.7 70.4 44.9 0
NZW4 127.0 1 . 0 40.1 0 56.5 0
NZW5 37.5 39.8 0 17.7 16.6 0
Mean ± 
SEM
64.0 ± 
16.9
15.5 ±9.3 18.4 ± 8 . 6 25.9 ± 
1 2 . 1
31.4 ± 9.5 2.6 ±2.3
Rabbits IDL PR 
(mg/d)
IDL FDC 
(pools/d)
IDL FTR 
(pools/d)
LDL PR 
(mg/d)
LDL FCR 
(pools/d)
NZW1 1 0 . 0 6.4 3.8 4.6 8 . 1
NZW2 2.4 0 1.3 4.8 1 . 6
NZW3 16.8 0 6 . 6 16.8 4.0
NZW4 8.4 2 . 1 0 4.2 1 . 8
NZW5 1 2 . 0 3.1 0 3.5 2 . 8
Mean ± 
SEM
9.9 ±2 .4 2.3 ± 1.2 2.4 ± 1.3 6 . 8  ±2.5 3.6 ± 1.2
FDC - fractional rate o f  direct catabolism 
FTR - fractional transfer rate 
d  - day
A representative fit of the curves (solid lines) describing the kinetic parameters to the 
data points are shown in Figure 4.4. A. A schematic diagram of the kinetic parameters 
is shown in Figure 4.5.A.
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Figure 4.4.A Representative tracer curves from a NZW rabbit
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Figure 4.4.B Representative tracer curves from a SMHL rabbit
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Figure 4.5.A Mean NZW kinetic parameters
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Figure 4.5.B Mean SMHL kinetic parameters
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4.3.5 Kinetic parameters - SMHL
Rates of production, transfer and catabolism of lipoprotein particles in the SMHL 
rabbits were calculated from the multicompartmental model (Table 4.7.).
Table 4.7. Kinetic results - SMHL
Rabbits
VLDL!
PR
(mg/d)
VLDL,
FDC
(pools/d)
VLDL,
FTR
(pools/d)
v l d l 2
PR
(mg/d)
VLDLj
FDC
(pools/d)
VLDLz
FTR
(pools/d)
SMHL1 1 1 . 8 21.5 0 13.9 8.7 0
SMHL2 133.2 7.0 9.0 15.5 3.7 2 . 8
SMHL3 209.4 2 2 . 6 0 16.3 0.4 2 . 6
SMHL4 34.5 40.8 0 12.7 1 0 . 6 0
SMHL5 77.7 45.0 0 . 0 2 27.8 3.4 5.6
Mean ± 
SEM
93.3 ± 
32.5
27.4 ± 
1 1 . 0
1 . 8  ± 1 . 6 17.2 ±2.5 5.4 ±2.1 2.2 ± 0 .9
Rabbits IDL PR
(mg/d)
IDL FDC 
(pools/d)
IDL FTR 
(pools/d)
LDL PR 
(mg/d)
LDL FCR 
(pools/d)
SMHL1 24.3 0 2.5 19.4 2 . 8
SMHL2 4.6 1.5 1 . 2 0 1 . 1
SMHL3 2.3 0 . 2 1.5 4.7 5.9
SMHL4 14.1 0 . 2 1.7 9.9 3.6
SMHL5 6.7 0 1 . 0 0 2 . 6
Mean ± 
SEM
10.4 ±3.6 0.4 ±0.3 1 . 6  ± 0 . 2 6 . 8  ±3.3 3.2 ±0 .7
Curves showing representative fits (solid lines) of the modelled kinetic curves to the 
data produced are shown in Figure 4.4.B. Kinetic parameters are shown in schematic 
form in Figure 4.5.B.
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SMHL rabbits did not show a significant difference in any of the kinetic parameters 
when compared to NZW rabbits. However, there were clear differences in some 
VLDLi PR (for example SMHL 2 and 3), that may have reached significance given a 
larger sample size, or reduced variability.
4.3.6 Correlations
When parameters from both NZW and SMHL rabbits were combined, there were 
significant positive correlations between total apoB pool and plasma cholesterol 
concentration and VLDL2 FTR (Figure 4.6).
4.4. Discussion
The method for human stable isotope turnover, adapted for the rabbit, was basically 
sound, but suffered as the levels o f apoB isolated were small and levels of tracer 
enrichment were at the limit of detection by our GC-MS system. We were confident 
that our method of isolation of lipoproteins by density gradient ultracentrifiigation of 
diluted plasma samples resulted in an accurate separation o f lipoproteins, and that the 
recovery was similar to that from a non diluted plasma sample. However, the fact 
that the plasma was diluted 2  fold, added to the fact that the rabbits have a lower 
concentration of plasma lipid than do humans, meant that there was not much material 
in the samples (especially LDL) from which to isolate apoB. Thus obtaining precise 
enrichments was difficult despite great care being taken that no sample was lost 
during the isolation procedures and the loading o f a larger amount o f sample than 
usual on to the GC-MS.
With the small sample size in each group, and the large variance in kinetic parameters 
within group due partly to the problems with detection by the GC-MS, it was perhaps 
not surprising that there were no significant differences between NZW and SMHL 
rabbits. Also in this group of rabbits there was no significant difference in plasma 
lipids.
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The increased total apoB pool size confirmed work (section 3.3.3) which showed that 
the SMHL rabbits had a greater VLDLi, VLDL2. IDL and LDL mass compared to 
the NZW rabbits. IDL apoB pool size specifically was significantly larger in the 
SMHL rabbits than the NZW rabbits.
Although we did not see any significant differences between the rabbit groups in terms 
of production rates, transfer rates or catabolic rates, there were minor differences that 
would help to explain the difference in apoB pool size. The VLDLi and IDL PR were 
increased in the SMHL rabbits compared to the NZW rabbits. This would cause an 
increased flux of apoB into these compartments which may saturate the clearance 
mechanisms and result in an increased pool size. The VLDLi PR increase seems to be 
balanced by an increase in the direct catabolism of apoB from this fraction. This 
effect does not seem to carry on down the cascade. The NZW rabbits have a large 
proportion of their VLDL2 cleared directly - 65 out of 68 mg/day (the remaining 3 mg 
are transferred to IDL). However, the SMHL rabbits have only 20 out of 32 mg/day 
cleared directly, with the remainder being fed to IDL, contributing to the increased 
IDL apoB pool size. Indeed, although SMHL rabbits transferred more apoB from 
IDL to LDL (17 vs 6 mg/day), this was a smaller proportion o f the IDL pool size (1.6 
vs 2.4 pools/day). Additionally, the IDL FDC was lower in the SMHL rabbits at 0.4 
vs 2.3 pools/day, resulting in the clearance of the same absolute amount of apoB (6 vs 
7 mg/day (SMHL vs NZW). Therefore, the SMHL rabbits were not able to cope with 
the increased amount of apoB entering the IDL compartment (both from direct 
synthesis, and from increased transfer from VLDL2). The LDL apoB pool size is also 
increased in SMHL rabbits despite an identical PR to the NZW rabbits. Transfer from 
IDL is increased, and although the amount of apoB that is cleared per day is more in 
SMHL than in NZW, this is a smaller proportion o f the pool size.
Both Venkatesan et al (1993) and Cortner, Coates, Bennett, et al (1991) found using 
stable isotopes that production rate of VLDL was increased in human patients with 
FCH. Additionally, Janus, Nicoll, Turner, et al (1980) found using exogenously 
labelled VLDL and LDL that there was an increased VLDL and LDL PR compared to 
normal controls in FCH patients. Aguilar-Salinas, et al (1997) described a kindred of 
FCH with an impaired catabolism of VLDL and LDL apoB, but also confirmed an
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overproduction of VLDL apoB with normal FCRs in two FCH individuals from other 
kindreds. Therefore it appears that the human FCH population is heterogeneous, but 
that the main defect is an overproduction of VLDL and LDL apoB. These results 
from the SMHL rabbits neither confirm nor deny the strain as a potential model for 
FCH, exhibiting as they do, tendencies towards both overproduction and under 
catabolism.
In conclusion, while these experiments were probably a little too ambitious with 
respect to the measureable levels o f apoB in the rabbits samples, these results gave 
ample cause for further investigation into the metabolic basis for the dyslipidaemia in 
the SMHL rabbits.
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Chapter 5. Development of rabbit liver perfusion 
methodology
5.1. Introduction
La Ville et al (1987) described an overproduction of VLDL and LDL apoB in the St 
Thomas’ hospital rabbits in association with a decreased LDL apoB FCR. In our 
kinetic studies (Chapter 4), we did not see any significant difference in apoB PR in 
SMHL rabbits. However, these studies were fraught with problems and, based on the 
findings of La Ville and the considerable evidence in the literature (Chait et al, 1980, 
Janus, et al, 1980, Venkatesan et al, 1993) that FCH is associated with an 
overproduction o f apoB containing lipoproteins, we decided to try another approach 
to determine if the SMHL rabbits had a similar defect.
The perfused liver provides a more physiological approach than hepatic cell culture to 
the investigation of the action of the liver cells. It offers a flexible experimental 
system where the effects of various substrates can be studied in a situation where the 
anatomical structure is preserved, but where the confounding effects of other organs 
and plasma constituents are eliminated. Experiments can be performed immediately 
unlike cell culture where it can take days to isolate the cells.
This chapter describes the development of a method to perfuse the livers of the 
SMHL rabbits in order to characterise directly the lipoproteins secreted from the 
isolated liver in a system where there was little contribution o f catabolism of the 
lipoproteins by lipolysis or by receptor clearance. The use of the perfused rabbit liver 
in the study of lipoprotein secretion has been previously documented (Mackinnon, 
Savage, Wishart, et al, 1986, Meijer, Geelen, van Herck, et al, 1990) and has 
provided valuable information on another rabbit model of hyperlipidaemia, the WHHL 
rabbit (Hornick et al, 1983).
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5.2. Methods
The liver perfusion system requires the surgical attachment o f the liver to a 
recirculating system of tubes and pumps, designed to oxygenate the perfusate and 
feed it through the liver. To perfuse the liver we planned to use Krebs Henseleit 
buffer, pH 7.4 (118 mM NaCl, 5 mM KC1, 1.2 mM M gS04.7H20 , 12 mM CaCl2, 1.2 
mM KH2P 0 4, 25 mM NaHCC>3 , 8 mM Glucose) (Krebs and Henseleit, 1932) 
containing a 20% haematocrit o f washed human red blood cells (rbc).
5.2.1 Oxygenation of perfusate
Firstly we wished to find a simple, effective method of oxygenating the perfusate. We 
were offered an unused human integral membrane oxygenator, a device used for the 
extra-corporeal oxygenation of blood during surgery. This consisted of a reservoir 
and a system of fine capillary tubes through which the perfusate passed. A mix of 
95% 0 2, 5% C 0 2 would be passed round these tubes and the oxygen would diffuse 
into the perfusate. A 95% 0 2, 5% C 0 2 mix was used instead of 100% 0 2 as 
continued aeration of a solution containing a bicarbonate buffer with 100% 0 2 can 
cause it to lose C 0 2 and become alkaline.
The integral membrane oxygenator was tested by pumping a mix of Krebs Henseleit 
buffer containing a 20% haematocrit of human rbc through it at 100 ml/minute. The 
partial pressure of 0 2 (p 0 2) in the perfusate was measured using an amperimetric 
electrode system where oxygen diffusing through a gas-permeable membrane is 
reduced at the cathode, and the current generated is proportional to the amount o f 0 2 
reduced and thus to the p 0 2 of the sample. These measurements were performed by 
staff of the Department of Biochemistry, Royal Infirmary, Glasgow. The integral 
membrane oxygenator oxygenated the buffer well, with p 0 2 rising from 25.1 kPa 
before the gas supply was switched on, to 79.8 kPa after 10 minutes of gas supply 
with recirculation of buffer. Unfortunately as the oxygenator was meant to be for 
single use it proved difficult to clean with many capillary tubes becoming blocked, and 
it was also intended for a larger volume of blood than we wished to use. Therefore an 
alternative method of oxygenation had to be found.
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Hamilton, Berry, Williams, et al (1974) described ‘a simple and inexpensive 
membrane lung for small organ perfusion’. This apparatus, the Hamilton lung, was 
made from a jar into which a mix of 95% 0 2, 5% C 0 2 was fed through a tightly sealed 
opening in the lid, and vented through another outlet. Perfusate passed through the 
jar in 5 metres o f gas permeable silastic tubing (OsteoTec Limited) (Figure 5.1.).
Figure 5.1. The Hamilton lung
T o jiv e rFrom  liver
G as ^ 
ou tle t Gas
jn le t
S ilastic tubini
The gas mixture enters the ja r  through the gas inlet and form s an O2 rich 
environment within the sealed jar. Perfusate is pumped from  the liver through 
silastic tubing within the lung, and O2 exchange occurs across the tubing. 
Oxygenated buffer is pumped back in to the liver.
We checked the oxygenation of the perfusate (Krebs Henseleit buffer containing a 
20% haematocrit o f rbc) using the Hamilton lung. After 10 minutes of recirculation 
and gassing, p 0 2 levels in the perfusate rose from 26.6 kPa to 93.1 kPa.
5.2.2 Perfusate composition
The majority of the literature describes the use of washed rbc as an oxygen carrier in 
the perfusate. Washed rbc were prepared from human cells. The cells were mixed 
gently with an equal volume of Krebs Henseleit buffer and centrifuged gently (1780 g ,
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10 minutes). The supernatant was discarded, and the cells were again mixed with 
Krebs Henseleit buffer and spun. The cells were once again mixed with buffer (5 x 
volume) overnight, and then spun and washed again as above.
The washing of rbc in copious amounts of buffer was time consuming and the 
repeated centrifugation of the cells weakened them and caused some haemolysis. This 
haemolysis of rbc increased protein measurements. We compared pC>2 after 
oxygenating buffer and buffer plus rbc for 10 minutes and found there to be no 
difference, with levels rising from 26.6 to 93.1 kPa in the presence of rbc and from 
26.0 kPa to 93.0 kPa in the absence of rbc, therefore potentially negating the need for 
rbc to be a constituent of the perfusate.
5.2.3 Perfusion system
To perfuse the livers we needed to create a system of tubes, pumps and reservoirs in 
series with the Hamilton lung. We experimented with a variety o f systems and found 
that it was necessary to pump the perfusate both directly into the liver to ensure a 
constant speed and pressure, and through the Hamilton lung as the small bore o f the 
silastic tubing, and its long length meant that a substantial pressure had to be given to 
enable the buffer to pass through. The system that was used for the experiments is 
depicted in Figure 5.2. Perfusate was pumped via a peristaltic pump (Watson Marlow 
503U) at 100 ml/minute through the Hamilton lung where it was oxygenated. The 
perfusate gathered in the upper reservoir, where the pH was monitored (Jenway 3050 
portable pH meter), and was then pumped by a second peristaltic pump (Watson 
Marlow MHRE) directly in to the liver. On efflux from the liver, the perfusate was 
collected in the lower reservoir from where samples were taken, and the perfusate 
was recirculated and reoxygenated in the lung. A 3.2 mm internal diameter, 6.4 mm 
external diameter tubing (AlteSil high strength tubing, Altec) was used throughout the 
system.
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Figure 5.2.A Perfusion system
PUMP (g)
ERVOIR
LIVER
LUNG (a)
HPV (d)
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PUMP
IVC
Krebs Henseleit buffer is oxygenated in the Hamilton lung (a), and pumped into the 
upper reservoir (b) where the pH  is monitored. The buffer is pumped (c) directly 
through the HPV (d) into the liver, and exits through the IVC (e) into the lower 
reservoir (f). Buffer is then pumped by a second pump (g) back to the Hamilton lung.
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Figure 5.2.B Overview of a perfusion experiment underway
Photograph o f a perfusion experiment underway demonstrating the layout o f  the 
apparatus described in Figure 5.2. A
Figure 5.2.C Close up view of the perfused liver
Close up view o f the perfused liver showing the inflow cannula into the HPV, the 
outflow cannula from  the IVC and the collection o f  bile. For the purposes o f  the 
photograph, the buffer soaked gauze has been removed from the liver.
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The entire experiment was performed in a thermostatically controlled room, set at 
37°C and perfusate was prewarmed to this temperature, and pre oxygenated. The pH 
was monitored and maintained at 7.4 by the addition of 1M NaHCCb.
5.2.4 Preparation of animals
On the day of the perfusion experiment the animal was terminally anaesthetised by the 
injection of 1 ml Euthatal (Rhone Merieux Ltd.) per 1.4 kg body weight plus 1 ml 
heparin (1000 iU/ml) (Leo Laboratories Ltd.) into the marginal ear vein.
5.2.5 Surgical technique
A thoracotomy/laparotomy was performed along the line of the linea alba. The 
intestines were displaced to the left and the inferior vena cava (IVC) was cannulated 
cranial to the diaphragm using plastic tubing (internal diameter 2 mm, external 
diameter 3.2 mm). The hepatic portal vein (HPV) was cannulated (14 Gauge intra 
venous catheter; Vygon UK Ltd.), the IVC was ligated between the renal and hepatic 
veins (polyamide 66 suture, Ethicon Ltd.) and the common bile duct was cannulated 
(translucent vinyl tubing, internal diameter 0.63 mm, external diameter 1.4 mm, 
Portex Ltd.). We are grateful to Dr M. Hicks, Department of Medical Cardiology, 
Glasgow Royal Infirmary, for advice on the techniques used in this procedure.
5.2.6 Perfusion protocol
Livers were flushed with 750 ml of oxygenated Krebs Henseleit buffer (pH 7.4, 37°C) 
(some containing a 10% haematocrit of washed rbc) at 75 cm hydrostatic pressure 
prior to being connected to the perfusion apparatus. The livers were perfused with 
recirculating perfusate for 180 minutes. A 15 ml sample o f perfusate was withdrawn 
at 0, 60, 120 and 180 minutes and 5 ml samples were removed at 30, 90 and 150 
minutes. Samples were spun (1780 g, 10 minutes) to pellet any cellular material. 
Sample volume was replaced with an equal volume of oxygenated, warmed Krebs 
Henseleit buffer. The liver and intestines were kept moist by covering with gauze 
soaked in buffer. Cholesterol, triglyceride, glycerol, urea, albumin, AST and GGT
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(section 2.3.2, 2.3.3, 2.3.4, 2.5) were measured in each sample. Albumin was below 
the level o f detection, but towards the end of this group of experiments, a 
microalbumin method was used which enabled production of this protein to be 
determined. Samples from 0, 60, 120 and 180 minutes were concentrated 5 times 
(section 5.2.8) and VLDLi, VLDL2, IDL and LDL were isolated by density gradient 
ultracentrifugation of this lipoprotein concentrate. Cholesterol, triglyceride, total 
protein and apoB protein were measured in each fraction. The volume o f bile 
produced was recorded. At the end of the experiment the livers were examined and 
found to be well perfused with no necrotic or hypoxic areas.
5.2.7 Testing of perfusion system
To test the perfusion system and the need for rbc to be part o f the perfusate, livers 
from young (< 4 months) NZW rabbits fed normal rabbit chow, who had had their 
hearts removed for electrophysiology experiments were obtained. Prior to removing 
the heart, the IVC was clamped to maintain vascular pressure. We perfused 3 livers 
with buffer containing rbc (20% haematocrit) and 4 livers with buffer only for up to 3 
hours each.
5.2.8 Concentration of lipoproteins at d = 1.065
From the perfusate samples we wished to isolate apoB containing lipoproteins 
VLDLi, VLDL2, IDL and LDL. However, the concentration o f these lipoproteins in 
the perfusate was very small, so we performed an initial 5 fold concentration step. 
We measured the density of perfusate from each time point (0, 60, 120, 180 minutes) 
and obtained an average from the first 6 experiments, from which we calculated how 
much KBr to add to make the density up to 1.065 g/ml (Table 5.1.) using the 
following formula:
Weight o f KBr (g) = v(d2 - di)/[l - ud2] 
where v - volume of solution 
di - actual density 
d2 - required density
o - partial specific volume of KBr (0.2889)
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Table 5.1. Density of perfusate at sample time points, and weight of KBr 
required to bring the density to 1.065 g/ml
Sample time (minutes) Mean density (g/ml) K Br (g)
0 1.005 0.866
60 1.006 0.851
120 1.007 0.837
180 1.008 0.823
We overlayered 5 ml o f sample (d = 1.065) with 1 ml ofNaCl solution at a density of 
1.065 g/ml in duplicate, and spun in a centrifuge at 83150 g  for 18 hours. The total 
lipoproteins obtained were harvested in 1 ml, and duplicates were combined giving 2 
ml for isolation of VLDLi, VLDL2, IDL and LDL (section 2.3.8). The density of 
these 2 ml fractions of total lipoproteins were checked, and brought to 1.118 g/ml by 
the addition of NaCl using the above equation (substituting 0.3464 as the partial 
specific volume of NaCl). Again the average value from 5 experiments was calculated 
for each sample time point (Table 5.2.).
Table 5.2. Density of lipoprotein concentrate and weight of NaCl required to 
bring the density to 1.118 g/ml
Sample time (minutes) Density (g/ml) NaCl (g)
0 1.050 0.222
60 1.053 0.212
120 1.054 0.209
180 1.054 0.209
5.2.9 Measurement of VLDLi loss during perfusion
Total VLDL was isolated from 50 ml rabbit plasma at d = 1.006 g/ml (62918 g, 18 
hours). From this, VLDLi was prepared by density gradient centrifugation as
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described above. VLDLi was then labelled with Na[125I] (Amersham International 
pic.) as described previously (Bilheimer, Eisenberg and Levy, 1972). Iodination was 
performed by Dr M. Caslake, Glasgow Royal Infirmary.
Livers from 2 NZW rabbits (fed standard rabbit chow) were prepared as above. After 
taking a pre-treatment sample at time 0, 5 pCi of 125I-labelled VLDLi was added to 
the circulating buffer. VLDLi, VLDL2, EDL and LDL were isolated from samples as 
described above, apoB was isolated, resolubilised in 0.1 M NaOH and its specific 
activity was measured.
5.2.10 leucine experiments
To demonstrate that the accumulating lipoproteins in the recirculating perfusate 
represented newly synthesised products, the incorporation o f radioactive leucine into 
apoB was measured during perfusion of livers from 2 mature NZW and 2 mature 
SMHL rabbits. One hundred pCi 3h  leucine (Amersham International pic.) (165 
Ci/mmol) was added to the perfusate at time 0 and further doses o f 100 pCi 3h  
leucine were added at 30 minute intervals, just after each sample was removed for 
lipoprotein isolation. The specific activity of apoB isolated from VLDLi, VLDL2, 
IDL and LDL was then determined by radioactivity measurement in a p scintillation 
counter and assay of apoB protein as described above.
5.2.11 Measurement of lipase activity
To investigate whether lipase activity removed by the heparin flush (1000 iU) on 
anaesthetisation returns during the experiment, we measured lipase activity in a blood 
sample taken 15 minutes after anaesthetisation, and again 15 mins after a dose of 
heparin administered to the perfusate after the final 180 minute sample was taken 
from the perfusion experiment. This experiment was repeated 3 times. Post perfusion 
doses of heparin were 100 iU for NZW1 and NZW2 (based on 70 iU/kg for humans, 
calculated as an overdose for an average 100 g liver), and 5000 iU for NZW3.
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5.2.12 Calculation of data
Raw data was corrected for all concentration factors introduced during the course of 
the experiment. Typically, free glycerol levels were subtracted from total perfusate 
triglyceride levels to give true triglyceride concentrations. VLDLi, VLDL2, IDL and 
LDL cholesterol, triglyceride and apoB levels were corrected to allow for the 5 fold 
concentration step prior to their isolation, and also for their concentration 2 fold 
(VLDLi and LDL) or 4 fold (VLDL2 and IDL) during their isolation. Cholesterol, 
triglyceride and apoB levels in both total perfusate and lipoprotein isolates were 
corrected to allow for the dilution of the perfusate during the experiment. Values for 
VLDLi, VLDL2, IDL and LDL cholesterol, triglyceride and apoB levels at 30, 90 and 
150 minutes which weren’t measured were calculated by taking the mean o f the 
previous and the following time points. Data was found not to be of normal 
distribution, and therefore Mann Whitney U tests were performed to determine 
significance in Minitab 10.
5.3. Results
5.3.1 Liver patency
Livers were kept warm (37°C) and moist during the perfusion by covering with gauze 
soaked in buffer. Only livers that were well perfused, reaching the tips o f all lobes, 
were used for experiments. At the end of the perfusion, livers were examined and 
found to have remained healthy with no necrotic or hypoxic areas. Liver function 
tests were not grossly elevated (Table 5.3.), and urea production was similar to 
previously reported values (6 pmol/l/minute by MacKinnon et al, 1986). GGT and 
albumin were below the level of detection. Bile production was steady (Table 5.3.).
Subsequent to these initial experiments, we found a method to measure albumin on a 
micro scale (section 2.5.), and in the perfusion experiments described in Chapters 6 
and 7, this method was used.
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Table 5.3. Production rates of AST, urea and bile from buffer and rbc perfused
NZW rabbit livers
Buffer perfused rbc perfused
AST (U/l/minute) 0.41 ±0.15 0.8 ±0.49
Urea (pmol/l/minute) 9 ± 2 17 ± 2
Bile (pl/minute) 20 ± 5 37 ± 2
5.3.2 Lipase activity pre and post perfusion
Lipase activity (HL and LPL) was measured in post heparin plasma and post heparin 
perfusate prior to and during 3 liver perfusion experiments. Results are given in Table
5.4. HL levels were low, a common feature of rabbits (Warren et al, 1991), but 
neither enzyme returned in any significant amount over the three hours o f the 
perfusion.
Table 5.4. Pre and post perfusion HL and LPL activities (pmol/ml/hour) in 3 
NZW rabbits
Plasma Perfusion medium
HL LPL HL LPL
NZW 1 1.42 6.39 0 0
NZW 2 0.45 2.58 0 0
NZW 3 0.6 2.15 0.15 0
5.3.3 Cholesterol and triglyceride production from the livers of 4 NZW rabbits 
perfused with buffer, and 3 NZW rabbits perfused with buffer containing a 
20% haematocrit
Cholesterol and triglyeride levels in the perfusate rose in an approximately linear 
manner in all animals studied (Figure 5.3.). When we compared the results from the
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buffer perfused and the rbc perfused livers, there was a significant increase in 
cholesterol output at all time points and a significantly increased cholesterol output 
rate in the rbc perfused livers (Table 5.5.). We attributed this to cholesterol released 
from the membranes o f haemolysed rbc, as it was noticable that the amount of 
haemolysis increased throughout the experiment. Similarly, when we pumped rbc 
round the system in the absence of a liver, there was an increase in the absorbance at 
280 nm, a measure of protein, due to haemolysis. There was no significant difference 
in triglyceride output between the two perfusate contents.
Table 5.5. Cholesterol output (pg/g liver) and output rates (pg/g liver/minute) 
in 4 buffer perfused and 3 rbc perfused NZW rabbit livers
Sample (minutes) Buffer perfused rbc perfused
0 0 19 ± 5.0a
30 0 27 ± 3.5b
60 1.2 ± 1.2 34 ± 6.7a
90 1.2± 1.2 51 ± 4 .9 b
120 3.8 ± 3.8 62 ± 7.8b
150 4.2 ±4.2 82 ± 2.5b
180 4.2 ±4.2 110 ± 11.5b
Output Rate 0.02 ±0.02 0.43 ± 0.09a
Significant differences a t a p  < 0.005, h p  < 0.001
5.3.4 Lipoprotein output from 4 buffer perfused and 3 rbc perfused NZW 
rabbit livers
VLDLi, VLDL2, IDL and LDL were separated by density gradient ultracentrifugation 
of perfusate concentrated 5 fold at a density of 1.065 g/ml. Cholesterol and 
triglyceride levels rose approximately linearly over the 180 minutes of the experiment 
in the VLDLi fraction (Table 5.6., Figure 5.4.A, B). Cholesterol and triglyceride 
values were very low in the VLDL2, IDL and LDL fractions, and were combined to
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Figure 5.3. Cholesterol and triglyceride output in buffer and rbc perfused NZW
livers
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make a non VLDL] fraction (Figure 5.4.A, B). There were no significant differences 
in the amount of cholesterol or triglyceride in any fraction when buffer perfused and 
rbc perfused experiments were compared.
Table 5.6. VLDLi, VLDL2, IDL, LDL and non VLDLi cholesterol and 
triglyceride output rates (ng/g liver/minute) from buffer perfused and rbc 
perfused NZW livers
Buffer perfused rbc perfused
Cholesterol Triglyceride Cholesterol Triglyceride
VLDLi Output 26 ± 7 518 ± 125 65 ±23 640 ± 225
VLDL2 Output 9 ± 4 21 ± 4 9 ± 2 26 ± 5
IDL Output 4 ± 3 11 ± 1 4 ± 1 9 ± 3
LDL Output 8 ± 7 15 ± 7 4 ± 2 5 ± 2
non VLDLi * 21 ± 13 53 ± 12 16 + 4 4 0 +  10
* non VLDLi is the sum ofVLD L2, IDL and LDL cholesterol or triglyceride outputs
5.3.5 VLDLi, VLDL2, IDL, LDL and non VLDLi apoB output in buffer and 
rbc perfused NZW rabbit livers
ApoB levels were measured in VLDLi, VLDL2, IDL and LDL perfusate samples. 
ApoB levels were low in VLDL2, IDL and LDL fractions and these were combined to 
produce a cholesterol rich non VLDLi fraction. ApoB levels rose linearly in both 
VLDLi and non VLDLi fractions (Figure 5.5.). There was no significant difference in 
apoB output rate between buffer perfused and rbc perfused livers in any o f the 
fractions (Table 5.7.), indicating that both types of perfusate were equally good at 
perfusing the liver, but that rbc caused an unrepresentative increase in cholesterol 
concentration (Figure 5.6.).
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Figure 5.4.A VLDLi and non VLDLi cholesterol output in buffer and rbc
perfused NZW livers
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Figure 5.4.B V LDLi and non VLDLi triglyceride output in buffer and rbc 
perfused NZW livers
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Figure 5.5. VLDLi and non VLDLi apoB output from buffer and rbc perfused
NZW livers
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Figure 5.6.A Total cholesterol output from buffer and rbc perfused NZW livers
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Figure 5.6.C Non VLDLi cholesterol output from buffer and rbc perfused NZW
livers
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Total, VLDLi and non VLDLi cholesterol output from  buffer and rbc perfused NZW  
livers demonstrating that the increased production o f  total cholesterol in the rbc 
perfused livers is due to non-lipoprotein cholesterol
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Table 5.7. ApoB output rates (ng/g liver/minute) from 3 buffer perfused and 3 
red blood cell perfused NZW rabbit livers
Output rates Buffer perfused rbc perfused
VLDLi 2.5 ±0 .6 3.4 ± 1.0
v l d l 2 0.23 ±0.01 0.26 ± 0.22
IDL 0.18 ±0.09 0.33 ±0.19
LDL 0 0.21 ±0.21
non VLDLi 0.41 ±0.10 0.81 ±0.59
5.3.6 Measurement of VLDLi loss during perfusion
To examine the extent to which VLDLi was converted to denser lipoproteins during 
the 3 hour perfusion, 125I labelled VLDLi was added to the perfusate (buffer only) of 
2 NZW rabbits 10 minutes prior to the beginning of the experiment. VLDLi, VLDL2, 
IDL and LDL apoB was isolated to follow the fate of the particles. There was no 
difference in the cholesterol and triglyceride output nor in the subfraction cholesterol, 
triglyceride or apoB output in these two experiments from those buffer perfused 
experiments described above.
At time 0, a mean of 93% of apoB radioactivity was found in the VLDLi fraction, 
with 6% in VLDL2 and 1% in IDL. After 3 hours 77% of the counts remained in 
VLDLi, 7.5% were found in VLDL2, 2.5% in IDL and 1.5% in LDL. The lack of 
increase in VLDL2, IDL and LDL radioactivity indicated that delipidation was limited 
in this system.
5.3.7 H leucine experiments
In order to show that the lipoproteins that accumulated were derived by de novo 
production of apoB, 3H leucine was added to the perfusate of 2 mature NZW and 2 
mature SMHL rabbits. Again, cholesterol and triglyceride output and subfraction
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cholesterol, triglyceride and apoB output were not significantly different from buffer 
perfused experiments described above.
By 3 hours, leucine radioactivity in VLDLi apoB rose by an average of 5 fold above 
the zero time value in NZW and 15 fold in SMHL rabbits, in VLDL2 it rose 2 and 6 
fold; in IDL, 2 and 2 fold and in LDL, 2 and 3 fold respectively showing that the liver 
was synthesising these lipoproteins (Table 5.8.).
Table 5.8. % increase in specific activity resulting from de novo production of 
VLDLi, VLDL2, IDL and LDL apoB during 2 mature NZW and 2 mature 
SMHL rabbit liver perfusions
NZW mean SMHL mean
VLDL, 554 1544
v l d l 2 224 640
IDL 178 206
LDL 188 276
5.4. Discussion
The development of the rabbit liver perfusion method described in this chapter was a 
complex and time-consuming process, pooling the knowledge and resources of a large 
number of people. The main difficulty in perfusion studies has been the development 
o f a method of oxygenation of the perfusate without the introduction o f air bubbles. 
Hamilton’s lung, developed for use in rats, is certainly the best method o f oxygenating 
perfusate for small animal organs, having been adapted previously for use in rabbits by 
several investigators (Hornick et al, 1983, De Parscau and Fielding, 1984, Meijer et 
al, 1990). The advantage over other types of oxygenation is that there is no air-liquid 
interface at which gas exchange could occur. This means that there is less 
opportunity for evaporation of the medium, less mechanical trauma, and there are no 
air bubbles introduced into the circulation. It is a cheap and simple device, and can 
handle small volumes of perfusate.
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Only livers that were fully perfused in all lobes were used for experiments. All livers 
were examined on completion of the experiment, and were found to have been well 
perfused with no necrotic or hypoxic areas. Measurement o f AST and GGT revealed 
that, while these enzymes accumulated throughout the perfusion, there was no 
abnormally high secretion indicative of the liver being under stress. Urea levels rose 
at a rate compatible with good liver function. Albumin levels were below the level of 
detection, but towards the end of the trial period, a method for measuring micro 
albumin was used, and this showed an approximately linear increase in albumin o f the 
order of 410 pg/l/minute. The synthesis of albumin is one o f the main functions o f the 
liver, and therefore the secretion of albumin in to the perfusate throughout the 
experiment further demonstrated that the liver was viable. Finally, we measured bile 
flow (Table 5.3.) which was of the same magnitude as previously published data such 
as 45 pl/minute (De Parscau and Fielding, 1984) and 33 pl/minute (Hornick et al,
1983).
Cholesterol and triglyceride accumulated in the perfusate in an approximately linear 
manner (Figure 5.3.). Cholesterol output rate (Table 5.5.) was similar to values in the 
literature of 0.05 - 0.52 pg/g liver/minute (various strains of rabbit) (Meijer et al, 
1990), and 0.5 pg/g liver/minute in NZW rabbits (Hornick et al, 1983). The rate of 
output of triglyceride (0.6 ± 0.2 pg/g liver/minute for buffer perfused and 1.0 ± 0.2 
pg/g liver/minute for rbc perfused livers) is of the same order as that reported by 
Hornick et al (1983) of 4 pg/g liver/minute (NZW rabbits), and 0.6 - 1.8 pg/g 
liver/minute (various strains of rabbit) reported by Meijer et al (1990).
These experiments showed that we were able to isolate VLDLi, VLDL2 , IDL and 
LDL by density gradient ultracentrifugation of perfusate, providing the opportunity to 
look directly at the hepatic output of these lipoproteins. Lipid levels in these 
lipoproteins accumulated linearly throughout the 3 hours of the perfusion. We 
compared total perfusate cholesterol content with VLDLi plus non VLDLi 
cholesterol content in buffer and rbc perfused livers, and found that in buffer perfused 
livers total cholesterol was accounted for by VLDLi and non VLDLi cholesterol. 
However in rbc perfused livers, total perfusate cholesterol was 6 fold higher than 
VLDLi plus non VLDLi cholesterol (Figure 5.6.). Clearly, the cholesterol in the total
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fraction of rbc perfused livers contained non-lipoprotein cholesterol, such as that from 
the haemolysed membranes o f rbc. Therefore we decided that as the buffer perfused 
livers performed as well as the rbc perfused livers, we would perfuse with buffer only 
to eliminate contamination with non-lipoprotein cholesterol.
The liver perfusion and lipoprotein separation techniques were sensitive enough for 
us to be able to isolate apoB in each lipoprotein fraction. Levels of this protein rose 
linearly throughout the experiments, and did not differ between buffer perfused and 
rbc perfused livers.
We found little evidence for extensive delipidation in our perfusion system. HL and 
LPL were removed by the heparin flush during anaesthetisation, and did not return to 
any appreciable extent during the perfusion (Table 5.4.). Furthermore 125I labelled 
VLDLi, when added to the perfusate, was not substantially delipidated (section 
5.3.6). This means that our results are not complicated by the delipidation of 
lipoproteins as is the case in vivo, however it must be borne in mind that we have 
made no measure of lipoprotein catabolism during the experiment. We also 
demonstrated linear 3H leucine incorporation into the apoB of denser lipoproteins 
throughout the 3 hour period (section 5.3.7) indicating that these species did not 
derive from wash out o f the space of Disse as has been previously suggested (Hornick 
et al, 1983). Therefore, although VLDLi was by far the major species produced by 
these rabbit livers during the perfusion, in terms of cholesterol, triglyceride and apoB, 
the small amount of non VLDLi lipoproteins produced were due to direct production 
and not delipidation of VLDLj.
Therefore we developed a method for rabbit liver perfusion that enabled us to study 
the output of lipid from the liver over a period of 3 hours without any noticeable 
degeneration of liver function. This method enabled us to look not only at cholesterol 
and triglyceride output, but more specifically at lipoprotein cholesterol, triglyceride 
and apoB output. The perfused liver provided a method of study of lipoprotein 
metabolism in a physiological system with the option of experimental manipulation, 
and we planned to use the system to investigate the mechanism of the dyslipidaemia in 
SMHL rabbits.
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Chapter 6. Liver perfusion studies in mature NZW and 
SMHL rabbits
6.1. Introduction
The SMHL rabbit is a putative model for FCH, a disorder commonly thought to be 
due to an overproduction of apoB containing lipoprotein particles. To investigate the 
lipoprotein disorder exhibited by the SMHL rabbits in more detail, we performed a 
series of liver perfusion experiments. This method allowed the measurement of the 
direct output of lipoprotein particles from the liver in a system free from FFA flux 
from other tissues, and from lipolytic activity.
We have previously described the effect of age on plasma lipids in the SMHL rabbits 
(Chapter 3). Because of the decrease in plasma lipid concentration that occurs during 
the first 4 - 5  months of life, we decided to first study rabbits in which lipid levels had 
become stable, ie greater than 5 months old.
Studies of the output of apoB-100 containing lipoprotein particles from the liver of 
SMHL rabbits were compared with that of NZW rabbits of the same sex and similar 
age to investigate the hypothesis that, as suggested in FCH, the hyperlipidaemic 
phenotype o f the SMHL rabbits was due to an overproduction of apoB containing 
lipoproteins.
6.2. Methods
6.2.1 Animal selection
Eleven male SMHL rabbits (aged > 5 months) fed the 0.08% cholesterol diet were 
selected on the basis of their moderate (cholesterol range 0.8 - 13.6 mmol/1, 
triglyceride range 0.4 - 4.0 mmol/1) hyperlipidaemia. The rabbit with a cholesterol of
13.6 mmol/1 was an outlier, with all rabbits being below 4.1 mmol/1 except for one at
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7.8 mmol/1 and one at 5.9 mmol/1. Twelve NZW controls of the same sex and similar 
age (cholesterol range 0.6 - 3.8 mmol/1, triglyceride range 0.5 - 2.1 mmol/1) were also 
selected. Mean age at sacrifice was 10.2 vs 9.8 months and mean body weight was
3.6 vs 4.0 kg (SMHL vs NZW, both NS).
6.2.2 Perfusion method
The method used for the perfusion experiments is described in Chapter 5, and is 
summarised here. The animal was terminally anaesthetised. To perfuse the liver, the 
IVC was cannulated cranial to the diaphragm, the HPV and the common bile duct 
were cannulated and the IVC was ligated between the renal and hepatic veins. The 
liver was flushed with 750 ml oxygenated Krebs Henseleit buffer (pH 7.4, 37°C) prior 
to being connected to the perfusion apparatus in a room thermostatically controlled at 
37°C. The buffer was pumped by two peristaltic pumps in a recirculating system at 
100 ml/minute through the liver, with inflow via the HPV and outflow through the 
IVC. The buffer was oxygenated by a Hamilton lung, and the pH was maintained at
7.4. The total volume of the perfusate was 120 ml, and was maintained thus by 
replacing sample volume with an equal volume of oxygenated warmed Krebs 
Henseleit buffer. Samples of perfusate were taken at 0, 30, 60, 90, 120, 150 and 180 
minutes, and cholesterol, triglyceride, glycerol, protein, urea, microalbumin, AST and 
GGT were measured (Chapter 2, sections 2.3.2, 2.3.3, 2.3.4, 2.4., 2.5.). Lipoprotein 
subfractions were separated, and cholesterol, triglyceride and apoB were measured in 
each fraction (Chapter 2, sections 2.3.8, 2.3.2. 2.3.3, 2.4.). The volume o f bile 
produced by the liver was also measured.
6.2.3 Extraction of lipid from liver samples
Samples of liver were removed and frozen immediately after the perfusion 
experiments were completed in 5 mature SMHL and 5 mature NZW rabbits. Once all 
samples were collected, they were thawed and 0.25 - 0.5 g wet weight pieces 
dissected for measurement of lipid content following a modification (Naito and David,
1984) of the method of Folch, Lees and Sloane Stanley (1957). Samples were 
homogenised (Janke & Kunkel KG homogeniser) in small volumes of methanol
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(BDH) and the volume adjusted to 50 ml with methanol. After standing for 30 
minutes with occasional mixing, 100 ml chloroform (BDH) was added. Following an 
overnight extraction at 15°C the samples were filtered (Whatmans No. 1 filter paper) 
and protein precipitated by the addition o f 50 ml 0.05% calcium chloride solution. 
Samples were again maintained overnight at 15°C and the chloroform (bottom) layer 
was removed and dried on a centrifugal evaporator (Howe). The pellet was 
redissolved in isopropanol (2 ml) and total cholesterol, triglyceride, free cholesterol 
and phospholipid contents were measured (Section 2.3.2, 2.3.3, 2.3.5, 2.3.6).
6.2.4 Statistics
Variables were tested for normal distribution. Plasma cholesterol and triglyceride 
concentrations were transformed to a normal distribution by taking the logarithm of 
their values. Two sample t-tests were performed to determine significance. Where 
the distribution of a variable or series of variables could not consistently be converted 
to normal, as was the case with all perfusate concentration measurements, a Mann- 
Whitney U  test was performed. Data are expressed as mean ± SEM unless otherwise 
stated.
6.3. Results
6.3.1 Population lipids and biochemical parameters
In these mature rabbits selected for perfusion experiments, plasma cholesterol was 4.1 
± 1 .3  mmol/1 in SMHL vs 1.4 ± 0.3 mmol/1 in NZW rabbits (p < 0.05) and plasma 
triglyceride was 2.0 ± 0.4 mmol/1 in SMHL vs 1.2 ± 0.1 mmol/1 in NZW rabbits (NS).
Liver function tests were normal throughout the perfusions. The livers remained 
patent and produced bile at 15 + 5 and 34 + 6 pl/liver/minute in SMHL and NZW 
rabbits respectively. Examination of the livers at the end of the experiment revealed 
no necrotic or hypoxic areas. Mean liver weight was not different (92 ± 12 vs 103 ± 
11 g, SMHL vs NZW).
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6.3.2 Cholesterol and triglyceride production
Mean perfusate cholesterol and triglyceride levels rose linearly in both groups of 
rabbits over the 180 minutes of the experiment (Figure 6.1.). Cholesterol levels rose 
from 6 ± 4 to 96 ± 21 pg/g liver in SMHL rabbits and from 7 ± 5 t o 4 1 ± l l  pg/g 
liver in NZW rabbits. The cholesterol content of the perfusate was significantly 
increased in SMHL rabbits in samples taken at 60, 90 and 150 minutes and the 
calculated cholesterol output was 510 ± 101 vs 220 ± 67 ng/g liver/minute in SMHL 
vs NZW rabbits (NS).
Triglyceride levels in the perfusate rose from 0 to 149 ± 29 pg/g liver in SMHL 
rabbits, and from 5 ± 4 to 160 ± 50 pg/g liver in NZW rabbits. Both groups had a 
similar triglyceride output: 860 ± 130 vs 890 ± 246 ng/g liver/minute in the SMHL 
and NZW rabbit groups respectively (NS).
6.3.3 Lipoprotein production during perfusion
The lipoproteins in the perfusate were separated and their cholesterol and triglyceride 
contents were analysed. Data are shown in Table 6.1. Mean perfusate IDL 
triglyceride output was increased in SMHL rabbits compared with NZW rabbits (p < 
0.05), but no other significant differences were observed in individual fractions.
We then compared the output of triglyceride rich and cholesterol rich lipoproteins 
from the liver. The cholesterol and triglyceride contents of VLDL2, IDL and LDL 
(i.e. non VLDLi) were combined as these represent cholesterol rich lipoproteins and 
the values obtained were compared between groups as were those for the triglyceride 
rich VLDLi (Figure 6.2.A,B, Table 6.1.). There was no difference in mean VLDLi 
cholesterol output between the two strains of rabbit (229 vs 160 ng/g liver/minute, 
Table 6.1.). In NZW rabbits, VLDLi perfusate cholesterol levels rose from 0 to 25 ± 
8 pg/g liver (Figure 6.2.A) and in SMHL rabbits from 0 to 46 ± 11 pg/g liver during 
the experiment. Although there was a 3.5 fold increase in SMHL rabbit non VLDLi 
cholesterol output when compared to NZW rabbits, this was not significant (Table
6.1.). Non VLDLi cholesterol levels increased from 0 to 21 ± 7  and 1 ± 1 to 5 ± 2
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Figure 6.1. Cholesterol and triglyceride output from the perfused liver of mature
NZW and SMHL rabbits
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pg/g liver in SMHL and NZW rabbits respectively during the 180 minute experiment. 
SMHL values were significantly different from NZW at 30, 90 and 150 minutes.
Table 6.1. VLDLi, VLDL2, IDL and LDL cholesterol and triglyceride output 
from the livers of 12 mature NZW and 11 mature SMHL rabbits
Cholesterol Triglyceride
(ng/g liver/minute) (ng/g liver/minute)
NZW SM HL NZW SM HL
n = 12 n = 11 n = 12 n = 11
VLDLi 160 + 45 229 ± 52 443 ± 92 439 ± 94
v l d l 2 18 ± 6 65 ± 20 13 ± 3 56 ± 30
IDL 8 ± 2 26 ± 10 5 ± 2 19 ± 6a
LDL 2 ± 1 7 + 3 4 ± 2 8 ± 3
non VLDLi 28 ± 8 98 ±28 22 ± 6 82 ± 34a
a Significant difference between NZW and SMHL rabbits, p  < 0.05
There were no significant differences in VLDLi triglyceride output in mature SMHL 
and NZW rabbits (Table 6.1., Figure 6.2.B). VLDLi triglyceride levels rose from 16 
± 11 to 84 ± 18 vs 5 ± 5 to 76 ± 18 pg/g liver in SMHL and NZW respectively. Non 
VLDLi triglyceride output was significantly increased 4 fold in SMHL compared to 
NZW rabbits (Table 6.1., p < 0.05). Non VLDLi triglyceride levels rose from 6 ± 6 
to 26 ± 11 vs 0 to 4 ± 2 pg/g liver in SMHL vs NZW rabbits, being significantly 
higher (p < 0.05) in SMHL rabbits compared to NZW at 180 minutes.
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Figure 6.2.A VLDLi and non VLDLi cholesterol output from the liver of mature
NZW and SMHL rabbits
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Figure 6.2.B VLDLi and non VLDLi triglyceride output from the liver of m ature 
NZW and SMHL rabbits
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6.3.4 ApoB output from perfused livers
ApoB was measured in the individual lipoproteins secreted into the hepatic perfusate. 
Results are shown in Table 6.2. and Figure 6.3. Although apoB values particularly in 
the LDL fractions were very small, we were confident that they were accurate as 
apoB as a percentage of total lipoprotein protein was similar in SMHL and NZW 
rabbits. In VLDLi it comprised 41% of the total protein in SMHL vs 38% in NZW 
rabbits, in VLDL2 60% vs 64%, in IDL 79% vs 82% and in LDL 75% vs 76%. These 
values were similar to values we determined for use in the kinetic studies (Chapter 4, 
Table 4.1.). VLDLi apoB output was not significantly different between SMHL and 
NZW rabbits, but VLDL2 and IDL apoB outputs were both significantly increased in 
SMHL compared to NZW rabbits (Table 6.2.). Mature NZW rabbits secreted VLDLi 
and non VLDLi apoB at similar rates (Table 6.2., Figure 6.3.). VLDLi apoB output 
from SMHL rabbits was not different from that in NZW rabbits (Table 6.2., Figure
6.3.). However, non VLDLi apoB concentrations were significantly increased in 
SMHL rabbits compared to NZW rabbits at all time points from 30 minutes until the 
end of the experiment (Figure 6.3.). Non VLDLi apoB output was increased 6 fold in 
SMHL rabbits relative to NZW, p = 0.01 (Table 6.2.). In SMHL rabbits the non 
VLDLi apoB output accounted for 75% of the total apoB output (48 ± 14 ng/g 
liver/minute).
Table 6.2. VLDLi, VLDL2, IDL and LDL apoB output rates (ng/g liver/minute) 
in m ature NZW and SM HL rabbits
NZW SM HL
VLDL, 10 ± 3 15 ± 4
VLDL2 2 ± 1 14 ± 5a
IDL 3 ± 1 16 ± 6a
LDL 0 6 + 2
non VLDLi 6 ± 3 36 ± 12b
Significant differences between NZW  and SMHL rabbits, a p  < 0.05, b p  = 0.01
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Figure 6.3. VLDLi and non VLDLt apoB output from the liver of m ature NZW 
and SMHL rabbits
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We calculated the ratio of the gram weight of cholesterol + triglyceride to the gram 
weight of apoB for each of VLDLi, VLDL2, IDL and LDL. This gave an indication 
o f the amount o f lipid (cholesterol and triglyceride) that was associated with an 
amount o f apoB, and therefore a measure of particle size. There were no significant 
differences between the two groups, although SMHL particle size was consistently 
smaller than NZW (Table 6.3.).
Table 6.3. Cholesterol + triglyceride to apoB ratios (g/g)
NZW SMHL
VLDLi 56.1 45.4
v l d l 2 12.4 8.8
IDL 3.8 2.9
LDL /* 2.5
* there was no consistent value fo r  LDL apoB in the NZW  rabbits, therefore a ratio 
has not been calculated.
6.3.5 Liver lipid content
Hepatic lipid concentrations were measured after the perfusion experiments (Table
6.4.). Phospholipid concentrations were significantly higher in mature SMHL rabbits 
compared to NZW rabbits (Table 6.4.), p < 0 .05, but there were no differences in any 
other parameters.
When we compared the amount of lipid in the liver to the amount released into the 
perfusate during the experiments, the amount secreted was approximately 1% or less 
of that stored in the liver. In the SMHL rabbits, on average, 96 ± 21 pg of 
cholesterol were secreted per gram of liver, from a store o f 12.2 ± 2.3 mg 
cholesterol/g liver. In NZW rabbits, 41 ± 11 pg of cholesterol/g liver were secreted, 
from a store of 15.4 ± 1.9 mg/g liver. Similarly for triglyceride, in SMHL rabbits, 149 
± 29 pg/g liver were secreted from a store of 11.4 ± 2.2 mg/g liver, and in NZW
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rabbits 160 ± 50 pg/g liver were secreted into the perfusate from a store of 13.8 ± 1.3 
mg/g liver.
Table 6.4. Liver lipid content (mg/g wet weight liver)
NZW SMHL
Total Cholesterol 15.4 ±1.9 12.2 ±2.3
Free Cholesterol 7.4 ± 1.3 8.2 ± 1.5
Triglyceride 13.8 ±1.3 11.4 ± 2.2
Phospholipid 15.4 ±0.6 17.3 ±0.5a
Significant difference NZW  v.y SMHL a p  < 0.05
6.4. Discussion
The rabbits used for these experiments were more than 5 months of age and had 
stable plasma lipid concentrations. SMHL rabbits were hyperlipidaemic compared to 
the NZW, and as such were representative of the colony as a whole.
Cholesterol, triglyceride and apoB accumulated in the perfusion medium in an 
approximately linear manner over the 180 minutes of the perfusion experiment, 
suggesting that the liver remained patent and fully functioning throughout. Normal 
liver function tests and linear bile production also suggested that the livers were 
functioning in a physiological manner during the perfusion. Output rates for 
cholesterol of 510 ± 101 and 220 ± 67 ng/g liver/minute and for triglyceride o f 860 ± 
130 and 890 ± 246 ng/g liver/minute were of the same order as those previously 
published for perfused rabbit livers of 380 ng/g liver/minute for cholesterol and 4000 
ng/g liver/minute for triglyceride (Hornick et al, 1983). Comparison of hepatic 
triglyceride output in the four apoB containing lipoproteins in SMHL and NZW 
animals revealed no difference in VLDLi despite the fact that this was the most 
abundant triglyceride carrying particle released from the liver. VLDL2 and IDL 
triglyceride outputs tended to be increased in SMHL rabbits, reaching significance in
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the IDL fraction, and overall, non VLDLi triglyceride output was significantly 
elevated (Table 6.1.). Cholesterol output tended to be increased in SMHL rabbits in 
ail fractions with a 3.5 fold increase in non VLDLi output, but these differences did 
not reach statistical significance.
In these mature animals, apoB was overproduced mainly in both the VLDL2 and IDL 
density classes. This is an interesting observation given the marked difference in 
plasma cholesterol but not plasma triglyceride in these animals. Given that 75% of 
apoB released from the livers of the SMHL rabbits appeared in the non VLDLi 
fraction, and that there is minimal lipase activity, this having been removed by the 
initial heparin flush (Chapter 5), this strongly suggests that the SMHL rabbits 
overproduce denser lipoproteins. Output rates of cholesterol, triglyceride and apoB 
were not different in the VLDLi fraction between mature NZW and SMHL rabbits. 
However in the non VLDLi fraction, cholesterol output was increased 3.5-fold, 
triglyceride 3.5 fold and apoB 6 fold, suggesting that an increased number of 
lipoprotein particles were produced. These results are consistent with the metabolic 
studies o f La Ville et al (1987) which showed an increased PR of VLDL and LDL 
apoB; but do not preclude an additional effect from a decreased clearance rate. The 
lipid to apoB ratios in the SMHL rabbits were lower than in the NZW rabbits, 
indicating that the particles secreted from the livers of the SMHL rabbits had a 
tendency to be smaller (Table 6.3.). Therefore like in FCH (Brunzell, Albers, Chait, 
et al, 1983, Hokanson et al, 1995), a larger number of relatively lipid poor lipoprotein 
particles were produced in the SMHL rabbit, further substantiating its use as a model 
for the disorder.
There were no differences in hepatic stores of free cholesterol, cholesteryl ester or 
triglyceride in the two strains of rabbit (Table 6.4.) suggesting that lipid availability is 
not driving lipoprotein production, although critical lipid pools more closely 
associated with lipoprotein assembly were not measured. However the livers of the 
SMHL rabbits were shown by the perfusion experiments to secrete greater amounts 
o f cholesterol and, to a certain extent, triglyceride. In order to maintain hepatic 
cholesterol homeostasis, there must be an alteration in another aspect of its control, 
for example an upregulation in the uptake by the LDL receptor, either due to the
143
receptor itself or an increase in circulating lipoproteins; an upregulation in cholesterol 
synthesis, or a decrease in the conversion of cholesterol into bile acids for excretion.
In conclusion, the results of these experiments suggest that apoB is overproduced in 
the mature SMHL rabbit, particularly in the VLDL2 and IDL density classes. This, 
rather than increased hepatic lipid stores, may be the driving force for the secretion of 
an elevated amount of lipid, resulting in the hyperlipidaemia characteristic of these 
rabbits. The fact that the lipoprotein overproduction in the SMHL rabbits can be seen 
across the range of apoB containing lipoproteins is a possible explanation for the 
inter- and intra-individual variability of the lipid phenotype in these rabbits and in 
FCH.
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Chapter 7. Liver perfusion studies in young NZW and 
SMHL rabbits
7.1. Introduction
Concurrent with the experiments described in Chapter 6, we performed an 
investigation o f the output of apoBlOO containing lipoprotein particles from the liver 
o f a group of young NZW and SMHL rabbits. Preliminary results from experiments 
performed during the development o f the liver perfusion protocol suggested that 
NZW rabbits secrete mainly VLDLi particles when young, and that more mature 
rabbits secrete a greater amount of non VLDLi particles. This fact, combined with 
the effect o f age on plasma lipids in SMHL rabbits reported in Chapter 3, led us to 
believe that there may be some differences between the output of apoB containing 
lipoprotein particles in young and mature SMHL rabbits.
7.2. Methods
7.2.1 Animal selection
We selected 6 SMHL and 7 NZW male rabbits aged between 11 and 16 weeks of age, 
that had been fed the 0.08% cholesterol diet since weaning (for at least 2 weeks 
before sacrifice). SMHL rabbits expressed a moderate hyperlipidaemia compared to 
controls (cholesterol range 2.7 - 5.6 mmol/1, triglyceride range 1.4 - 7.55 mmol/1 in 
SMHL and cholesterol range 0.4 - 2.0 mmol/1, triglyceride range 0.4 - 1.0 mmol/1 in 
NZW). Mean age at sacrifice was 2.8 vs 3.0 months and mean body weight was 2.0 
vs 2.5 kg (SMHL vs NZW, both NS).
7.2.2 Perfusion method
The method used for the perfusion experiments is described in Chapter 5. Briefly, the 
animal was terminally anaesthetised and the IVC was cannulated cranial to the
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diaphragm. The HPV and the common bile duct were cannulated and the IVC was 
ligated between the renal and hepatic veins. The liver was flushed with 750 ml 
oxygenated Krebs Henseleit buffer (pH 7.4, 37°C) prior to being connected to the 
perfusion apparatus in a room thermostatically controlled at 37°C. The buffer was 
oxygenated by a Hamilton lung, and was pumped by two peristaltic pumps in a 
recirculating system at 100 ml/minute through the liver, with inflow via the HPV and 
outflow through the IVC. The pH was maintained at 7.4. The total volume o f the 
perfusate was 120 ml, and was maintained thus, with sample volume replaced with an 
equal volume of oxygenated warmed Krebs Henseleit buffer. Samples of perfusate 
were taken at 0, 30, 60, 90, 120, 150 and 180 minutes, and cholesterol, triglyceride, 
glycerol, protein, urea, microalbumin, AST and GGT were measured (Sections 2.3.2, 
2.3.3, 2.3.4, 2.4.,2.5.). Lipoprotein subfractions were separated by density gradient 
ultracentrifugation, and cholesterol, triglyceride and apoB were measured in each 
fraction (Sections 2.3.8, 2.3.2, 2.3.3, 2.4). Bile production by the liver was also 
measured.
7.2.3 Extraction of lipid from liver samples
Samples o f liver were removed and frozen from 5 young SMHL and 5 young NZW 
rabbits immediately after the perfusion experiments were completed. The lipid 
content of these samples was measured by the method described in section 6.2.3.
7.2.4 Statistics
Variables were tested for normal distribution. Plasma cholesterol and triglyceride 
concentrations were transformed to a normal distribution by taking the logarithm of 
their values. Two sample t-tests were performed to determine significance. Where 
the distribution of a variable or series of variables could not consistently be converted 
to normal, as was the case with all perfusate sample concentrations, a Mann-Whitney 
U  test was performed. Data are expressed as mean ± SEM unless otherwise stated. 
Data was unavailable for SMHL rabbits at 180 minutes due to insufficient samples.
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7.3. Results
7.3.1 Population lipids and biochemical parameters
The plasma cholesterol and triglyceride concentrations in the young SMHL rabbits 
selected for perfusion experiments were significantly elevated compared to NZW 
rabbits (plasma cholesterol 3.7 ± 0.4 mmol/1 in SMHL vs 1.0 ± 0.2 mmol/1 in NZW, p 
= 0.0001; plasma triglyceride 3.6 ± 0.9 mmol/1 in SMHL vs 0.7 ±0.1 mmol/1 in NZW, 
p < 0.005).
Liver function tests were normal throughout the perfusions. The livers remained 
patent and produced bile at 28 ± 4 and 40 ± 5 pl/liver/minute in SMHL and NZW 
rabbits respectively (NS). Examination of the livers at the end of the experiment 
revealed no necrotic or hypoxic areas. Mean liver weight was not different (76 ± 6 vs 
71 ± 7 g, SMHL vs NZW, NS).
7.3.2 Cholesterol and triglyceride production
Mean perfusate cholesterol and triglyceride levels rose linearly in both groups of 
rabbits over the 180 (150) minutes of the experiment (Figure 7.1.). Cholesterol levels 
rose from 5 ± 5 to 58 ± 31 pg/g liver at 150 minutes in SMHL rabbits and from 0 to 2 
± 0 .5  pg/g liver after 180 minutes in NZW rabbits. The cholesterol content of the 
perfusate was significantly elevated in SMHL rabbits in all samples from 60 to 150 
minutes and the calculated cholesterol output was 380 ± 170 vs 10 ± 6 ng/g 
liver/minute in SMHL vs NZW rabbits (p < 0.01).
Triglyceride levels in the perfusate rose from 0 to 144 ± 63 pg/g liver at 150 minutes 
in SMHL rabbits and from 0 to 48 ± 24 pg/g liver at 180 minutes in NZW rabbits, 
with SMHL triglyceride levels being significantly higher at 90, 120 and 150 minutes 
when compared to NZW rabbits. Mean triglyceride output was 810 ± 290 vs 270 ± 
100 ng/g liver/minute in SMHL vs NZW rabbits, p = 0.12.
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Figure 7.1. Cholesterol and triglyceride output from the liver of young NZW
and SMHL rabbits
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7.3.3 Lipoprotein production during perfusion
The lipoproteins in the perfusate were separated and their cholesterol and triglyceride 
contents were analysed (Table 7.1.). Mean perfusate VLDLi, VLDL2 and IDL 
cholesterol and VLDL2 triglyceride outputs were significantly increased in SMHL 
rabbits compared with NZW.
Table 7.1. VLDLi, VLDL2 , IDL and LDL cholesterol and triglyceride output 
from the livers of 7 young NZW and 6 young SMHL rabbits
Cholesterol (ng/g liver/minute) Triglyceride (ng/g liver/minute)
NZW SMHL NZW SMHL
n = 7 n = 6 n = 7 n = 6
VLDLi 60 ± 19 237 ± 68a 416 + 105 658 ± 177
v l d l 2 10 ± 4 72 ± 25b 20 ± 5 87 ± 44a
IDL 4 ± 2 40 ± 26a 3 ± 2 55 ± 4 0
LDL 5 ± 3 10 ± 7 3 + 2 9 ± 7
non VLDLi 21 ± 8 119 ± 56a 23 ± 7 150 ± 89a
Significant differences between NZW  and SMHL rabbits a p  < 0.05, b p  < 0.005
As in Chapter 6, we compared the output of triglyceride rich VLDLi and cholesterol 
rich non VLDLi between the two strains (Table 7.1., Figure 7.2.A,B). VLDLi 
cholesterol output was elevated 4 fold in SMHL, p < 0.05 (Table 7.1.). In SMHL 
rabbits, VLDLi cholesterol levels rose from l ± 0 . 3 t o 3 8 ± 1 2  pg/g liver after 150 
minutes, and in NZW rabbits, VLDLi cholesterol levels rose from 0 to 13 ± 4  pg/g 
liver after 180 minutes with VLDLi cholesterol levels being significantly higher in 
SMHL rabbits at all time points from 30 to 150 minutes. Non VLDLi cholesterol 
output was elevated 6 fold in SMHL rabbits (Table 7.1., Figure 7.2.A), p < 0.05, 
rising from 1 ± 0.7 to 19 ± 10 pg/g liver in SMHL rabbits and from 0.6 ± 0.4 to 5 ± 2 
pg/g liver in NZW. Levels of non VLDLi cholesterol were significantly higher in 
SMHL rabbits between 90 and 150 minutes.
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Figure 7.2.A VLDLi and non VLDLi cholesterol output from the liver of young
NZW and SMHL rabbits
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Figure 7.2.B VLDLi and non VLDLi triglyceride output from the liver of young 
NZW and SMHL rabbits
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There was no significant difference in VLDLi triglyceride output between the two 
strains o f rabbit, due in part to the large inter-animal variability (Table 7.1., Figure
7.2.B). VLDLi triglyceride levels rose from 1 ± 0.5 to 110 ± 29 pg/g liver at 150 
minutes in SMHL rabbits, and from 1 + 0.6 to 73 ± 18 pg/g liver at 180 minutes in 
NZW rabbits. Non VLDLi triglyceride output was significantly increased more than 
6 fold in SMHL rabbits (Table 7.1.), p < 0.05, rising from 1 ± 0.6 to 27 ± 16 pg/g 
liver at 150 minutes in SMHL rabbits and from 1 ± 0.4 to 5 ± 2 pg/g liver in NZW 
rabbits (Figure 7.2.B). SMHL rabbits had significantly higher non VLDLi triglyceride 
levels from 60 to 150 minutes.
7.3.4 ApoB output from perfused livers
ApoB was measured in each lipoprotein fraction secreted into the perfusate (Table
7.2., Figure 7.3.). VLDLi, VLDL2 and IDL apoB outputs were significantly elevated 
in this group of young SMHL rabbits when compared to young NZW rabbits (Table
7.2.). VLDLi apoB levels rose from 0 to 7 ± 1 pg/g liver at 150 minutes in SMHL 
rabbits and from 0 to 4 ± 0.8 pg/g liver at 180 minutes in NZW rabbits and were 
significantly increased in SMHL rabbits compared to NZW rabbits at 30, 60 and 90 
minutes. Non VLDLi apoB output was increased 13 fold in the SMHL rabbits (Table
7.2.), p < 0.005, rising from 0 to 10 ± 3 pg/g liver at 150 minutes in SMHL rabbits 
and from 0 to 1.3 ± 0.6 pg/g liver at 180 minutes in NZW rabbits. Non VLDLi apoB 
levels were significantly elevated compared to NZW at all time points from 60 to 150 
minutes. Total apoB output was significantly elevated 6 fold in the SMHL rabbits 
( 1 5 9 ± 5 6 v s 2 8 ± 7  ng/g liver/minute, p < 0.01). In the young SMHL rabbits, the 
contribution of VLDLi and non VLDLi apoB to the total apoB output was virtually 
identical, whereas in the young NZW rabbits, 80% of the apoB was in the VLDLi 
fraction.
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Figure 7.3. VLDLi and non VLDLi apoB output from the liver of young NZW
and SMHL rabbits
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Table 7.2. VLDLi, VLDL2, IDL and LDL apoB output (ng/g liver/minute) in 
young NZW and SMHL rabbits
NZW SMHL
VLDLi 22 ± 4 79 ± 29a
VLDLz 3 ± 1 36 ± 13c
IDL 1 ± 1 37 ± 23b
LDL 2 ± 1 7 ± 5
non VLDLi 6 ± 3 80 ± 41°
Significant difference between N ZW  and SMHL rabbits a p  < 0.05, b p  < 0.01, c p  <
0.005
There was no major difference between the cholesterol + triglyceride to apoB ratios 
for each lipoprotein fraction between the NZW and SMHL rabbits (Table 7.3.), 
although as with the mature rabbits, the SMHL rabbits showed a tendency towards 
smaller particles.
Table 7.3. Cholesterol + triglyceride to apoB ratios (g/g) in young NZW and 
SMHL rabbits
NZW SM HL
VLDLi 19.7 11.3
v l d l 2 9.0 4.4
IDL 7.0 2.6
LDL 5.0 2.8
non VLDLi 6.7 3.4
These values give an indication of the relative amount of cholesterol + triglyceride 
present in relation to apoB.
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7.3.5 Liver lipid content
Hepatic lipid concentrations were measured after the perfusion experiments (Table 
7.4.). Young SMHL rabbits had a significantly lower hepatic triglyceride 
concentration than did NZW rabbits (p = 0.05), but no other differences were seen.
Table 7.4. Liver lipid content (mg/g wet weight liver)
NZW SMHL
Total cholesterol 6.0± 1.1 7.9 ±2.1
Free cholesterol 3.3 ±0.8 5.0 ± 1.3
Triglyceride 13.0 ±1.0 9.7 ± 1.0a
Phospholipid 16.2 ±0.8 15.7± 1.5
Significant difference a p  < 0.05
As before we compared the amount of lipid secreted from the liver into the perfusate 
with the amount of lipid in the hepatic store and it was clear that the amount of lipid 
output was a very small fraction (1% or less) of that stored. In SMHL rabbits 58 ± 
31 pg cholesterol/g liver was secreted from a total hepatic store of 7.9 ± 2.1 mg/g 
liver, and in NZW rabbits 2 ± 0.5 pg cholesterol/g liver was secreted from a hepatic 
store o f 6.0 ± 1.1 mg/g liver. In SMHL rabbits, 144 pg triglyceride/g liver was 
secreted from a hepatic pool of 9.7 ±1. 0  mg/g liver, and in NZW rabbits, 48 ± 24 pg 
triglyceride/g liver was secreted from a hepatic store of 13.0 ± 1.0 mg/g liver.
7.3.6 Young versus mature rabbits: cholesterol and triglyceride output
To investigate the effects of age on the output of cholesterol and triglyceride from the 
perfused liver, we compared young and mature rabbits (Chapter 6) of each strain. 
Mature NZW rabbits had a significantly greater cholesterol output compared to young 
NZW of 220 ± 67 vs 10 ± 6 ng/g liver/minute (p < 0.005), with cholesterol levels in 
the perfusate being significantly higher in mature rabbits from 60 minutes onwards.
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Mature NZW also had a significantly greater triglyceride output of 888 ± 246 vs 274 
± 100  ng/g liver/minute (mature vs young), p < 0.05, with perfusate triglyceride levels 
being significantly higher from 120 minutes until the end of the experiment. SMHL 
rabbits did not show any effects o f age.
7.3.7 Young versus mature rabbits: lipoprotein production
There were no differences in VLDLi or non VLDLi outputs with age in either the 
NZW or the SMHL rabbits.
7.3.8 Young versus mature rabbits: apoB production
In contrast to the lipoprotein output, VLDLi apoB output was significantly increased 
in the young NZW compared to the mature NZW (22 ± 4 vs 10 ± 3 ng/g liver/minute 
respectively, p <0.05) with VLDLi apoB levels being significantly elevated in young 
rabbits at 150 and 180 minutes (Table 6.2., 7.2.). Young SMHL also had a 
significantly increased VLDLi apoB output compared to the mature SMHL (79 ± 29 
vs 15 ± 4 ng/g liver/minute respectively, p < 0.01), with VLDLi apoB levels being 
significantly increased at 60 and 150 minutes in the young SMHL rabbits. No 
differences in non VLDLi apoB output were found between the young and mature 
rabbits of either strain.
7.3.9 Young versus mature rabbits: liver lipid content
Liver cholesterol stores showed a significant increase with age in NZW rabbits (Table
6.3., 7.3.). Total and free cholesterol were significantly increased in mature NZW 
compared to young NZW (15.4 ± 1.9 vs 6.0 ± 1.1 mg/g wet weight liver, p = 0.015 
and 7.4 ± 1.3 vs 3.3 ±0 . 8  mg/g wet weight liver, p = 0.017, respectively). There 
were no differences with age in triglyceride and phospholipid concentrations in NZW 
rabbits, and no significant differences in any hepatic lipid concentration in SMHL 
rabbits.
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7.4. Discussion
The young SMHL rabbits used in these experiments were representative of the young 
rabbits in the colony. They were moderately hyperlipidaemic compared to the NZW 
control rabbits and were in good health at the time of sacrifice.
The experiments produced results consistent with those described in Chapter 5 and 6. 
Cholesterol, triglyceride and apoB accumulated in the perfusion medium in an 
approximately linear manner throughout the experiment (Figure 7.1., 7.3.). Indeed, 
cholesterol and triglyceride output rates from the 4 groups o f rabbits were very similar 
in 3 o f those groups (510 ± 101, 220 ± 67, 380 ± 170 ng cholesterol/g liver/minute 
and 860 ± 130, 890 ± 246, 810 ± 290 ng triglyceride/g liver/minute in mature SMHL, 
mature NZW and young SMHL respectively) and comparable to data produced by 
Homick et al (1983) of 380 ng cholesterol/g liver/minute and 4000 ng triglyceride/g 
liver/minute. Liver function tests and bile production were concordant with those 
described in Chapter 5 and 6.
Consistent with the results obtained in the mature rabbits, there was a significantly 
increased cholesterol output in the young SMHL rabbits compared to the young NZW 
rabbits and no significant difference in triglyceride output. However, the triglyceride 
output was actually elevated 3 fold in the young SMHL rabbits, but due to the small 
group numbers, just failed to reach significance. VLDLi, VLDL2 and EDL cholesterol 
and VLDL2 triglyceride outputs were increased in the young SMHL rabbits. Again, it 
was unexpected that the difference in total triglyceride output was explained by an 
increase in VLDL2 and non VLDLi triglyceride production, however this may be 
partially explained by the large inter-animal variability and the fact that most o f the 
triglyceride was found in the VLDLi fraction. VLDLi cholesterol was elevated 4 fold 
and non VLDLi cholesterol was elevated 6 fold in young SMHL rabbits, while 
VLDLi triglyceride was elevated 1.6 fold (NS) and non VLDLi triglyceride was 
elevated 6.5 fold. Together with the data on apoB which showed a significant 4 fold 
increase in VLDLi apoB and a 13 fold increase in non VLDLi apoB in SMHL rabbits, 
this suggests that the young SMHL rabbits overproduce lipoproteins in both the 
VLDLi and non VLDLi density fractions. The cause of this is unclear, but may be
156
driven by the apoB output. Again, similar to the case in the mature rabbits, compared 
to VLDLi, more of the total apoB in the young SMHL rabbits is released from the 
liver in the non VLDLi fraction than in NZW rabbits, and this together with the fact 
that lipase activity is minimal, suggests that the young SMHL rabbits are also able to 
directly produce an increased amount o f these denser lipoproteins compared to the 
young NZW rabbits.
The lipid to apoB ratios for VLDLi VLDL2, IDL and LDL particles were lower in the 
young SMHL rabbits compared to the young NZW rabbits. Additionally, the ratios 
for VLDLi of all the young rabbits were substantially lower in this fraction than in the 
mature rabbits, suggesting, in conjunction with the increased apoB outputs and similar 
lipid outputs in the young rabbits, that the particles resulting in the increased amount 
o f apoB being secreted are perhaps released earlier with less lipid associated. 
Therefore, both young NZW and SMHL rabbits secreted lipid poor VLDLi particles 
as compared to mature rabbits.
When the rabbits in the young and mature groups were pooled together, significant 
positive correlations were seen between plasma cholesterol and triglyceride levels and 
apoB output rates from the perfused livers (Figure 7.4.). Taken with the results o f the 
analyses of the hepatic lipid stores which showed few differences between strains, this 
suggests that an increased apoB output rate is driving the hyperlipidaemia in the 
SMHL rabbits.
When young and mature rabbits of each strain were compared to each other, there 
was a significant increase in both cholesterol and triglyceride output overall in mature 
NZW rabbits compared to young NZW rabbits. This was likely to be due in part to 
the increased hepatic total and free cholesterol content which was seen in mature 
compared to young NZW rabbits. There were no significant differences in cholesterol 
or triglyceride output when young and mature SMHL rabbits were compared, nor did 
they show any differences in hepatic lipid concentrations. There were no significant 
differences in VLDLi and non VLDLi cholesterol and triglyceride outputs with age. 
With a larger sample number, we may have been able to distinguish if the overall 
differences in cholesterol and triglyceride outputs in the NZW rabbits were due to the
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Figure 7.4.A Correlation of plasma cholesterol and apoB output in all perfused
rabbit livers
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VLDLi or non VLDLi fractions. The most striking age difference was in the apoB 
output. In contrast to the lipid outputs which increased in mature NZW rabbits, 
VLDLi apoB output was significantly increased in both the young NZW and SMHL 
rabbits. There was no difference in non VLDLi apoB, but total apoB output was also 
increased in both the young NZW and SMHL rabbits. Therefore, as the NZW rabbits 
matured, the cholesterol and triglyceride output increased, but the apoB output 
decreased. In the SMHL rabbits, there was no change in lipid output, but again, apoB 
output decreased.
These experiments show that there is a common mechanism in both NZW and SMHL 
rabbits that downregulates apoB production with age. This appears not to be due to a 
decreased availablity o f lipid, indeed certainly in NZW, there is more lipid in the 
hepatocyte in mature rabbits, and the lipid to apoB ratios show that particles appear 
to become larger. What causes this downregulation is unclear. However the problem 
in SMHL rabbits is not the lack of downregulation, but the fact that the lipoprotein 
output is set at a much higher rate in both young and mature SMHL rabbits compared 
to NZW rabbits.
In conclusion, mature rabbits (NZW and SMHL) secrete regular sized particles, but in 
lower numbers than young rabbits. However overall, SMHL rabbits, like individuals 
with FCH, secrete an increased number of relatively lipid poor lipoprotein particles 
across the density spectrum, providing a possible explanation for the inter- and intra­
individual variablility of lipid phenotype in these groups.
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Chapter 8. Investigation of potential genetic abberations 
in the SMHL rabbit
8.1. Introduction
In all eukaryotes, DNA contains the information that controls all cell functions 
although only 3% of eukaryotic DNA has been found to encode proteins. The 
synthesis o f protein is a two-step process: transcription, where mRNA is synthesised 
by RNA polymerase using the DNA as a template, and translation, where mRNA is 
the template that directs the correct association o f amino acids into protein, on 
ribosomes. Each of these processes is regulated intra- or inter-cellularly and can be 
tissue specific or even cell specific. Control over protein production can be exerted 
transcriptionally, translationally or post translationally.
The polymerase chain reaction (PCR) is a relatively recent (Mullis, Faloona, Scharf, et 
al 1986, Mullis and Faloona 1987) but widely used procedure for the amplification of 
specific DNA and RNA sequences into workable amounts, for example for 
sequencing or testing for polymorphisms. The use of the thermostable DNA 
polymerase from Thermus Aquaticus (Taq) (Chien, Edgar and Trela, 1976, Saiki and 
Gelfand, 1989) has enabled the automation of this procedure.
Reverse transcriptase (RT) PCR involves the synthesis and amplification of DNA 
complementary to mRNA (cDNA) and has been shown to be extremely sensitive, 
enabling the detection of rare mRNA species (Byrne, Li, Sninsky, et al 1988, Wang, 
Doyle and Mark, 1989). RT PCR is documented as being thousands of times more 
sensitive than other methods of RNA detection such as Northern Blot Hybridisation 
or ribonuclease (RNase) protection assays (Larrick 1992, Siebert and Larrick 1992).
Rea, DeMattos and Pape (1993) successfully used RNase protection assays to 
investigate relative abundances of various lipid regulating genes in different tissues in 
rabbits. Although RT-PCR can detect small quantities of mRNA, it is difficult to
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precisely quantify. The efficiency of the PCR assay is easily affected by a change in 
the reaction conditions, for example by such a change as would occur in primer or 
deoxynucleoside triphosphate (dNTP) concentration as amplification proceeds 
(Dickover, Donovan, Goldstein, et al, 1990). Because the amplification by PCR is 
exponential, small variations in efficiency can have major effects on the final 
concentration of amplicon. The use o f an internal standard facilitates quantification. 
Until recently the best method for quantification of mRNA has been slot hybridisation 
(White and Bancroft, 1982) where RNA is bound to a nitrocellulose filter, and probed 
with a radiolabelled DNA or RNA probe. Other common methods o f quantitation 
include Primer Extension where PCR products are radiolabelled and counted when 
separated by gel electrophoresis (Noonan, Beck, Holzmayer, et al, 1990); or the 
probing of PCR products on a Southern blot. However these methods are time 
consuming and often require large amounts of RNA to start with.
A relatively new, accurate method of quantification known as ‘5 ’ nuclease PCR” is 
now in use (Gibson, Heid and Williams, 1996, Heid, Stevens, Livak, et al, 1996, 
Wittwer, Herrmann, Moss, et al 1997, Luthra, McBride, Cabanillas, et al, 1998, 
reviewed in Lie and Petropoulos, 1998). This is available in automated form on the 
ABI PRISM 7700 Sequence Detector (Taqman™), with attached Sequence Detection 
software (Perkin Elmer Applied Biosystems) using AmpliTaq Gold DNA polymerase 
which is thermostable and has 5’-3’ nuclease activity, but no 3’-5’ exonuclease 
activity. The basis of the technique is the ability to measure in real time the 
accumulation of a PCR product, by the release of fluorescence from a probe that is 
displaced from its hybridisation point on the cDNA during each amplification cycle. 
Measurement occurs during the linear phase of the reaction, that is during the period 
of exponential growth.
Primers are designed to amplify up a short region of cDNA from the gene of interest. 
A probe is designed to a region of cDNA within the amplicon, but not overlapping 
with the primers. This probe is labelled at its 5' end with a fluorescent reporter dye, 
FAM (6-carboxy-fluorescein), and at the 3' end, with a quencher, TAMRA (6- 
carboxy-tetramethyl-rhodamine). When the quencher is in proximity to the reporter, 
the release o f fluorescence is inhibited. During the annealing phase o f the PCR
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reaction, the primers and probe hybridise to the template strands (Figure 8.1.). As the 
primers are extended the probe is displaced from the template and is cleaved by the 
polymerase. This distances the reporter from the quencher, resulting in an increase in 
fluorescence o f the reporter which is proportional to the amount of product 
accumulated. Fluorescence is measured every 7 seconds, and the cycle number at 
which fluorsescence becomes detectable is recorded, and is defined as the threshold 
cycle, Ct. The Ct value is inversely related to the amount o f cDNA of the gene of 
interest that was present. Using a standard curve of Ct values from a known amount 
o f cDNA, values can be determined for the unknowns. In some cases the use of 
internal standards is beneficial to control for the efficiency of PCR.
We wished to compare the relative amounts o f mRNA in NZW and SMHL rabbits for 
a range o f genes that could contribute to the phenotype of cholesterol and apoB 
overproduction that we have characterised for the SMHL rabbits. In addition to 
apoB, we investigated the expression of MTP and PDI as they are important transport 
proteins involved in the lipidation of apoB (Figure 8.2.) (Jamil, Dickson, Chu, et al, 
1995, Gordon, Jamil, Gregg, et al, 1996, Patel and Grundy, 1996, Gordon, 1997). 
We also investigated VLDL and LDL receptor mRNA, as indices o f catabolism, 
CETP as transfer activity was significantly increased in the SMHL rabbits and 
cholesterol 7 alpha-hydroxylase as the rate limiting enzyme in the conversion of 
cholesterol to bile acids (Figure 8.2.) (Angelin 1995). In addition, we measured the 
expression of three constitutively expressed housekeeping genes, glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) (an important enzyme in glycolysis), 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) (an enzyme involved in the 
salvage pathway of purine bases) and beta actin (a structural protein). By correcting 
the Ct values of the genes of interest to the expression of a housekeeping gene, we 
hoped to eliminate inter-animal variability due to environmental factors or cell cycle 
position.
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Figure 8.1. Principle of TaqMan 5’ nuclease PCR assay
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Figure 8.2. Site of action of candidate genes
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The sites o f  action o f  the genes fo r  which we measured mRNA levels are shown. ApoB 
is transcribed in the liver, MTP and PDI provide the lipid fo r  the production o f  
lipoprotein particles. The VLDL and LDL receptors are involved in the uptake o f  lipid, 
cholesterol 7 alpha-hydroxylase is involved in clearing cholesterol from  the liver as 
bile, and CETP is involved in delivering cholesterol to the liver.
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8.2. Methods
8.2.1 Liver samples
Immediately post-mortem, 1 - 5  gram pieces of liver (11 NZW and 17 SMHL) were 
removed, wrapped in tin foil and snap frozen in liquid nitrogen. These samples were
stored at -70°C  until required.
8.2.2 Isolation of RNA from liver tissue
RNA was extracted from liver using TRIzol™ Reagent (GIBCO BRL, Life
Technologies) following the manufacturers instructions by a modification of the 
method o f Chomczynski and Sacchi (1987). TRIzol™ Reagent contains phenol and 
guanidine isothiocyanate to maintain the integrity of the RNA and dissolve cell 
components while samples are homogenised to break down the tissue. All tubes and 
disposable items used were treated (by baking at 120°C or with 10% hydrogen 
peroxide) so as to be RNAase free, and dH20 was treated with diethyl pyrocarbonate
(DEPC) (0.1%).
Approximately 500 mg of frozen liver tissue was taken and homogenised in 5 ml 
TRIzol™ Reagent in polypropylene tubes. Samples were maintained on ice. The 
samples were incubated at room temperature for 5 minutes and then centrifuged
(12,000 g , 4°C, 10 minutes) to pellet insoluble material such as extracellular
membranes, polysaccharides and high molecular weight DNA. The supernatant was
collected, and 1 ml chloroform was added to isolate RNA. Samples were shaken 
vigorously (15 seconds), incubated at room temperature (10 minutes), centrifuged
(12,000 g , 4°C, 20 minutes), and the aqueous phase (containing RNA) was
transferred to fresh tubes. The RNA was precipitated by the addition of 2.5ml
isopropanol. Samples were mixed and incubated at -20°C (60 minutes), then
centrifuged (12,000 g, 4°C, 20 minutes) to pellet the RNA. The supernatant was 
removed and the pellet washed with 5 ml 75% ethanol. The pellet was resuspended
by mixing and was re-centrifuged (12,000 g, 4°C, 20 minutes). The wash procedure
165
was repeated with 1 ml 75% ethanol, the supernatant removed and the pellet air dried 
before being resuspended in 300 pi DEPC treated water.
A 1.2% agarose gel containing 18% formaldehyde and ethidium bromide, was 
prepared in 1 x MAE buffer (5 x MAE consists of: 0.1 mol/1 3-(N- 
morpholino)propanesulfonic acid (MOPS), 40 mmol/1 sodium acetate, 5 mmol/1 
EDTA). Two pg RNA from each liver preparation was loaded on to the gel in 2 x 
volume sample buffer (SIGMA R-4268). Samples had been previously denatured at
65°C for 10 minutes and immediately cooled on ice. The gel was run at 100 volts for 
75 minutes. In order to check the integrity of the RNA, the gel was placed on an ultra 
violet light box to visualise the ethidium bromide stained RNA, and was then 
photographed.
The optical density at 260 nm of each RNA sample was measured. An absorbance 
of 1.0 was taken to be equivalent to 40 pg RNA/ml.
8.2.3 Reverse transcription
One pg RNA was reverse transcribed to form cDNA. An additional 1 pg RNA 
was prepared in the same manner, with the reverse transcriptase enzyme omitted 
(replaced with an appropriate volume of distilled H 2 O) to act as a negative control.
Samples were initially treated with deoxyribonuclease (DNase) to digest single and 
double stranded DNA. One pg RNA was incubated with DNase reaction buffer 
(20 mmol/1 Tris-HCl, 2 mmol/1 MgCl2, 50 mmol/1 KC1), 1 unit of DNase I (both 
from Gibco BRL) and DEPC treated water (15 minutes, room temperature). The 
DNase I was inactivated by the addition of 2.5 mmol/1 EDTA (10 minutes, 65°C). 
Five hundred ng random primers (Promega) were added (10 minutes, 25°C) followed 
by First Strand Buffer (50 mmol/1 Tris-HCl, Gibco BRL), 0.01pmol/l 
dithiothreitol and 0.5 nmol/1 dNTP mix (2 minutes, 42°C). Two hundred units of 
SUPERSCRIPT II (Gibco BRL) were added and incubated for 50 minutes at 42°C,
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followed by 15 minutes at 70°C to destroy the Superscript II. cDNA was stored at - 
20°C.
8.2.4 Amplification and sequencing of a region of rabbit MTP cDNA
cDNA was reverse transcribed from 1 pg of rabbit liver RNA as described previously 
(section 8.2.3). PCR was carried out in 50 pi reaction volumes containing 5 pi o f 5 x 
diluted cDNA, 1.5 mmol/1 MgCh, 0.5 pmol/1 of each primer, 0.2 mmol/1 o f each 
dNTP and 5 units of Taq polymerase (Gibco BRL). The oligonucleotide primers 
were obtained from Cruachem Ltd. and were designed according to a region of 
human MTP which showed high homology with hamster MTP. The primer pair used 
was 5’ AATGACCGGCTGTACAAGCTCAC 3’ (forward) and 5’ 
CCTTTGAAGATGCTCTTCTCTCC 3’ (reverse) amplifying a 226 base pair (bp) 
product (NIH genetic sequence database GenBANK Accession number X59657, 
Sharp, Blinderman, Combs, et al, 1993). The amplification profile consisted of 30 
cycles of 94°C for 1 minute, annealing at 55°C for 1 minute and extension for 30 
seconds at 72°C, and one final cycle of extension at 72°C for 5 minutes.
An aliquot o f the RT PCR and an amplified RT ‘no template’ blank were subjected to 
agarose gel electrophoresis together with Sigma PCR molecular weight standards. 
The correct size fragments were excised from the gel and purified using a QIAquick 
gel extraction kit according to the manufacturer’s protocol (Quiagen). PCR 
fragments were kindly sequenced by Gene Expression Sciences at SmithKline 
Beecham Pharmaceuticals using the PCR primer pair described above on an A B B 77 
automated sequencer (PE Applied Biosystems). A consensus sequence was obtained 
using Lasergene software (DNASTAR Inc.).
8.2.5 Design of primers and probes
Rabbit sequences o f apoB (Sudarickov and Surguchov, 1988), PDI (Fliegel, Newton, 
Bums, et al, 1990), VLDL receptor (Takahashi et al, 1992), LDL receptor 
(Yamamoto, Bishop, Brown, et al, 1986), CETP (Nagashima, McLean and Lawn, 
1988), cholesterol 7 alpha-hydroxylase (Poorman, Buck, Smith, et al, 1993), GAPDH
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(Applequist, Keyna, Calvin, et al, 1995), and beta-actin (Carter, Umenishi, Matthay, 
et al, 1997) were obtained from the GenEMBL database (Accession numbers 
X07480, J05602, D l l  100, M l 1501, M27486, S67315, L23961 and AF000313 
respectively). A human sequence was found for HPRT (Lightfoot, Joshi, Nuki, et al, 
1992) (Accession number L29383) which cross reacted with rabbit HPRT cDNA. 
Primers and probes were designed using the Primer Express programme (PE Applied 
Biosystems), which selects probes and primers specifically for the TaqMan assay. 
Several criteria must be met when chosing a probe and primer set.
1. The primers and probe must have at least 50% G + C content
2. The primers and probe must not be complimentary to each other, nor capable of 
forming secondary structures, nor must there be more than 4 consecutive identical 
residues
3. The probe and primers must not overlap, but should be in close proximity to each 
other
4. The melting temperature (Tm) of both primers should be identical, and the Tm of 
the probe should be 10°C greater
5. The amplicon should be 70 - 100 bp long
6. The probe must have more C residues than G residues and should be 20 - 30 bp 
long
7. There must not be a G residue at the 5' end of the probe
Primers and probes were synthesised by PE-applied biosystems UK. Sequences are 
given in appendix 2.
8.2.6 Quantitative PCR
cDNA equivalent to 50 ng RNA was incubated for 40 cycles (95°C, 15 seconds,
60°C 1 minute; preceded by 2 minutes at 50°C and 10 minutes at 95°C) with 
Taqman Universal mix containing AmpliTaq Gold DNA polymerase (Perkin Elmer), 
100 nmol/1 probe, 300 nmol/1 forward primer and 300 nmol/1 reverse primer, made up 
to 25 pi with dH20.
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Samples and negative controls were run for each gene, and ‘no template’ controls 
were run to ensure background was minimal.
8.2.7 Calculation of results
For each gene o f interest, Ct values from unknown samples were compared to a 
standard curve o f Ct values generated from 4 fold dilutions o f known concentrations 
o f cDNA. From this, values for the unknown cDNAs could be calculated. To control 
for inter-individual variation, results were expressed relative to a housekeeping gene 
which was shown not to be different between the two rabbit groups. Values were 
expressed on a relative scale rather than as absolute values.
8.2.8 Statistics
Variables were tested for normal distribution. Distribution was normal after the 
logarithm of the values was taken, and two sample t-tests were performed.
8.3. Results
8.3.1 Population data
Plasma lipids
In the animals selected for this study, plasma cholesterol and triglyceride levels were 
significantly elevated in the SMHL when compared to the NZW group (Table 8.1.).
RNA yield
The RNA extracted from the liver samples from these rabbits was generally o f good 
quality (Figure 8.3.) showing intact 28S and 18S ribosomal RNA bands.
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Figure 8.3. Purified RNA
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The amplified rabbit MTP insert is shown to be pure, and o f the correct size (226 bp)
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Table 8.1. Plasma lipids (mmol/l)
NZW SMHL p value
Cholesterol 2.2 ±0.3 6.9 ±0.8 0.0001
Triglyceride 1.0 ±0.2 3.0 ±0.4 0.001
8.3.2 Sequence of rabbit MTP
The size of the band of rabbit MTP cDNA amplified by the human primers was 
estimated by agarose gel electrophoresis (section 8.2.4, Figure 8.4.) and was found to 
be consistent with the known human cDNA size, 226 bp. This was purified, and the 
sequence o f the amplicon of rabbit MTP cDNA was determined (Figure 8.5.).
Figure 8.5. Consensus sequence of rabbit MTP (corresponding to bp 176 - 391 
of human MTP)
ATGCCGGCTG
GTTGATCGAA
TCCGAATTTC
GAATCCTGAT
ATAACAGATG
GAGAGAAGAG
TACAAGCTCA
GCAAAGGAAA
ATCCAATGTG
GGAGATGATG
TAAACGTGGA
CATNTT
CCTACGCCAC
ACTCCAAGAC
AATGTTGTCT
ACCAATTGAT
AAATGTGAAT
TGAAGTCTTT
AGTGTGGGCT
TACTGTGGAG
CCAAATCACG
CCRCARAGAG
This consensus sequence of rabbit MTP was found to be 87% homologous with that 
of human (Figure 8.6.).
8.3.3 Housekeeping genes
Three housekeeping genes were tested for use as an internal reference. GAPDH and 
HPRT were found to show no difference between NZW and SMHL rabbits (GAPDH 
59.0 ± 5.3 vs 52.7 ± 4.0, HPRT 60.2 ±7 . 1  vs 60.4 ± 7.1, NZW vs SMHL, NS, 
arbitrary values). Beta-actin values were significantly increased in SMHL rabbits
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Figure 8.6. Alignment of rabbit MTP sequence with human MTP
Rabbit 4 CCGGCTGTACAAGCTCACCTACGCCACTGAAGTCTTTGTTGATCGAAGCAAAGGAAAACT
! i i m  i i i m  m  n  i m  11 j i > 1 1 1 1 1 1 1 1  11 1 1 1 1 1 1 1  1 1 1 1 1 1 1  i 11 > i i
63
Human 1 7 9 c c  g g c t g t a c  a a g c t c a c g t a c t c c a c t g a a g t t c  t t c t t g a t c g g g g c a a a g g a a a a c t 2 3 8
Rabbit 64 CCAAGACAGTGTGGGCTTCCGAATTTCATCCAATGTGAATGTTGTCTTACTGTGGAGGAA 
1 1 1 I II 1 1 1 1 1 1 I 1 1 H i  1 i 1 1 ! M i l l  M l  I N I  ! M I M i  1 M 1 1 1 II
1 2 3
Human 2 3 9 GCAAGACAGCGTGGGCTACCGCATTTCCTCCAACGTGGATGTGGCCTTACTATGGAGGAA 2 9 8
Rabbit 1 2 4 t c  c t g a t g g a g a t g a t g a c c a a t t g a t c c a a a t c a c g a t a a c a g a t g t a a a c g t g g a a a a  
M I N I M I  M 1 ! n  M M I 1 1 M 1 1 M 11 1 M i l t  1 U l l i l l l  11 l l l l l
1 8 3
Human 2 9 9 t c c t g a t g g t g a t g a t g a c c a g t t c a t c c a a a t a a c g a t g a a g g a t g t a a a t g t t g a a a a 3 5 8
Rabbit 1 8 4 TGTGAATCCRC ARAGA9GAGAGAAGAGCATMTX.^ 1 6  
II 1 1 1 I I 1 + M +11 i i 11 1 I n  1 1 M i II II
Human 3 5 9 TGTGAATCAGCAGAGAGGAGAGAAGAGCATCTT 3 9 1
 indicates the forward and reverse primers used to amplify up the region o f rabbit
MTP. Homology between the two species is 87%.
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(95.7 ± 10.7 vs 174.1 ± 21.4, NZW vs SMHL, p = 0.009) for unknown reasons. Due 
to the fact that the HPRT sequences were of human derivation, we decided to take 
the commonly used GAPDH as our reference gene.
8.3.4 Standard curves
A standard curve was constructed for each gene, using 4 fold dilutions of a NZW 
cDNA (expressed as equivalent ng of RNA) (Table 8.2.). A representative standard 
curve and amplification profile are shown in Figure 8.7.
Table 8.2. Standard curve Ct values for genes of interest
Ct values
Genes 100 ng 25 ng 6.25 ng 1.56 ng 0.4 ng 0.1 ng
GAPDH 16.07 19.41 22.46 24.58 27.14 29.02
ApoB 15.51 17.87 19.28 21.71 24.52 25.86
VLDL-R 26.30 28.01 29.45 33.66 35.14
LDL-R 25.04 26.93 29.75 32.24 33.97
CETP 22.24 24.93 27.78 30.02 31.04 33.64
MTP 22.32 24.41 26.32 28.14 30.11
PDI 17.94 19.69 21.32 23.94 25.67 28.15
7-AH 24.17 25.94 28.52 30.15 32.30 34.39
VLDL receptor (VLDL-R), LDL receptor (LDL-R), cholesterol 7 alpha-hydroxylase 
(7-AH)
Standard curves were linear with correlation coefficients of greater than 0.99. A 4 
fold increase in cDNA concentration causes a shift in Ct value of approximately 2. As 
a general rule, this procedure is sensitive enough to measure a 2 fold difference in 
cDNA concentration.
These data show that apoB, GAPDH and PDI were relatively abundant in the liver 
mRNA population, as they were present in detectable amounts at an early cycle
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Figure 8.7.A Standard curve and amplification curves of apoB
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Figure 8.7.B Representative apoB amplification curves of 2 NZW and 2 SMHL
rabbits
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This figure clearly demonstrates that the SMHL rabbit apoB cDNA (M, ) is amplified 
above threshold at an earlier cycle number than the NZW rabbit apoB cDNA (M, M).
Figure 8.7.C ApoB amplification curves of 1 NZW and 1 SMHL rabbit overlaid 
on the apoB standard curve
o a * & a to ?z u  i t  1* aa aa *4 2 & zz ao aa n  a& *o
CVBlB
This figure shows how the amplification curves o f the SMHL ( ) and NZW (R) rabbits 
are clearly differentiable on the apoB standard curve.
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number, as compared to the VLDL receptor, LDL receptor and cholesterol 7-alpha 
hydroxylase mRNAs which did not amplify to detectable levels until a further 10 
exponential increases in message had occurred. MTP and CETP mRNA were of 
moderate abundance.
8.3.5 Expression levels of genes of interest
To obtain an estimate of the amount of cDNA encoding for the amplified gene that 
was present in each sample, the Ct values from the housekeeping genes and the genes 
of interest from each sample were compared to the standard curves for each gene 
(Sequence Detection Analysis software, Perkin Elmer). The amout of cDNA of the 
gene of interest was divided by the amount of cDNA of GAPDH in each sample, to 
obtain a relative value for the expression of the gene of interest in each sample (Table 
8.3.). Full values are given in appendix 3.
Expression of apoB mRNA was significantly increased in SMHL rabbits when 
compared to NZW (1.3 ± 0.16 vs 0.82 ± 0.08, p = 0.005). VLDL receptor mRNA 
was also significantly increased in SMHL (1.4 ± 0.26 vs 0.67 ± 0.08, p = 0.02), as 
was CETP mRNA (3.2 ± 0.34 vs 1.6 ± 0.3, p = 0.002). There were no differences in 
LDL receptor, MTP, PDI or cholesterol 7 alpha-hydroxylase mRNA between the two 
rabbit groups.
When observed values were related to the other housekeeping gene, HPRT, the 
results were very similar. ApoB mRNA was significantly elevated in SMHL rabbits 
compared to NZW (1.3 ± 0.60 vs 0.85 ± 0.32, p = 0.01, SMHL vs NZW), and 
VLDL-R mRNA was elevated, but this did not quite reach significance (2.5 ± 4.7 vs 
0.74 ± 0.45, p = 0.06, SMHL vs NZW). We did not relate CETP to HPRT as the 
CETP assay was performed at a later date, and we also did not look at any of the 
ratios to beta actin as this gene was differentially expressed between the two groups 
of rabbits and would have skewed the results.
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Table 8.3. Relative expression (to GAPDH) of mRNA of genes of interest
Genes NZW SMHL p value
apoB mean
range
0.82 ±0.08 
0.55 - 1.3
1.3 ±0.16 
0.53-3.1
0.005
VLDL-R mean
range
0.67 ±0.08 
0.22- 1.24
1.4 ±0.26 
0.40-4.78
0.02
LDL-R mean
range
1.8 ±0.32 
0.51 -3.71
2.2 ±0.38 
0.47 - 7.0
NS
CETP mean
range
1.6 ±0.30 
0.52-3.50
3.2 ±0.34 
0.77-5.5
0.002
MTP mean
range
0.71 ±0.08 
0.32- 1.18
0.88 ±0.11 
0.23 - 2.24
NS
PDI mean
range
1.1 ±0.11 
0.46- 1.6
1.4 ± 0.18 
0.59-3.1
NS
7-AH mean
range
13.3 ±4.2 
1.1 -40.8
10.7 ± 2.5 
0.64-36.8
NS
Values given are mean ±  SEM, and the range.
8.3.6 Correlation of plasma triglyceride with apoB mRNA levels
There was a significant positive correlation between plasma triglyceride levels in the 
animals selected for study and the ratio of apoB:GAPDH measure of mRNA 
abundance (Figure 8.8.), suggesting that the increased availability o f apoB mRNA 
could contribute to the elevation of plasma triglyceride levels.
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8.4. Discussion
The SMHL rabbits included in this study were moderately hyperlipidaemic. The 
quality o f RNA isolated from liver tissue from both the NZW and SMHL rabbits was 
variable, but satisfactory, as evidenced by the presence of clear 18S and 28S 
ribosomal RNA bands on agarose gel electrophoresis (Figure 8.3.).
Although only a small portion o f the rabbit MTP was amplified, the consensus 
sequence from forward and reverse sequencing matched the corresponding hamster 
and human sequences sufficiently for us to believe that the sequence was indeed rabbit 
MTP. It was fortunate that this small amplicon contained suitable sequences against 
which to construct a primer pair and a probe.
Housekeeping genes encode proteins vital for the survival of the cell and these are 
believed to be constitutively expressed. Unfortunately the levels of mRNA of these 
genes are not always constant as they have been shown to be affected by the 
differentiation of the cell, or by certain chemicals or growth factors (Siebert and 
Fukuda, 1985, Elder, French, Subramaniam, et al, 1988). Therefore we felt it was 
important to choose a housekeeping gene to use as an internal reference that did not 
show any differences between strains. Both the data normalised to GAPDH and to 
HPRT expression showed the same trends, but we chose GAPDH as it is more 
commonly used, and the probe and primers were species specific.
These results provide further evidence that this automated quantitative PCR technique 
is o f superior sensitivity to any other method. We were able not only to detect 
hepatic VLDL receptor mRNA, but also to find a significantly different expression of 
this gene in the two strains, in a tissue where previous investigators have sometimes 
failed to find any expression (Takahashi et al, 1992, Webb, Patel, Jones, et al, 1994). 
It was surprising to see such a striking 109% upregulation in VLDL receptor mRNA. 
However, whether this is translated into active receptor molecules is unknown. Our 
perfusion studies (Chapter 7) provided evidence that the major disorder present in the 
SMHL rabbits was an overproduction of apoB, with perhaps a secondary defect in 
catabolism as suggested by the identical triglyceride output, but increased plasma
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triglyceride concentration in the SMHL rabbits. If the increased VLDL receptor 
mRNA in the liver were to be translated into active protein, with a resultant increase 
in catabolism of VLDL particles, this would have a confounding effect on the liver 
perfusion experiments. The increase in CETP mRNA seen in the SMHL rabbits 
provides additional evidence for the increase in CETP transfer activity seen in these 
rabbits (Chapter 3, section 3.3.8), and may be in response to the hyperlipidaemic state 
o f these rabbits.
Whilst several models of lipoprotein assembly have been proposed (Boren, Wettesten, 
Rustaeus, et al, 1993, Hamilton, Wong, Cham, et al, 1998) they all support the 
widespread belief that apoB secretion is regulated post translationally in the RER of 
hepatocytes or enterocytes. Post translational control is believed to be exerted by lipid 
availability (Atzel and Wetterau, 1993, Dixon and Ginsberg, 1993, Thompson, 
Naoumova and Watts, 1996) and both cholesteryl ester (Fungwe, Cagen, Wilcox, et 
al, 1992, Sniderman and Cianflone, 1993) and triglyceride (Wu, Sakata, Lui, et al, 
1994, Ginsberg, 1995) have been cited as the driving factor.
ApoB mRNA levels have been shown to remain constant during conditions that affect 
apoB production. Sparks, Zolfaghari, Sparks, et al (1992) showed no change in 
mRNA levels when apoB was decreased in experimental diabetes in rats; likewise 
Pullinger, North, Teng, et al (1989) and Moberly, Cole, Alpers, et al (1990) showed 
an increased apoB secretion due to increased delivery of FFA to HepG2 cells, but no 
change in mRNA levels. However, others have seen a change in apoB mRNA 
abundance. Burnett, Wilcox, Telford, et al (1997) reported a decrease in apoB 
mRNA in response to atorvastatin therapy, and Sparks et al (1992) showed an 
increase o f apoB mRNA in the liver of diabetic rats treated with insulin. When 
HepG2 cells are treated with 25-OH cholesterol (Dashti 1992), small (< 2 fold) 
increases in apoB mRNA levels in HepG2 cells have been reported, and a decrease in 
extracellular amino acid concentration has been shown to have the same effect 
(Zhang, Sniderman, Kalant, et al, 1993). Despite these reports, apoB synthesis is 
generally believed to be in excess of that secreted, however an association between 
apoB mRNA abundance and apoB secretion has been reported (Selby and Yao, 
1995).
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In this study, apoB mRNA was significantly increased by 59% in the SMHL rabbits. 
There were significant positive correlations between plasma cholesterol or triglyceride 
concentrations and apoB: HPRT levels. Correlations with apoB. GAPDH levels were 
not so strong, however there was a significant positive correlation with plasma 
triglyceride (Figure 8.8.) That such a correlation exists is surprising given the number 
o f steps involved between the synthesis o f apoB and the balance between the output 
and catabolism of lipoproteins giving rise to the plasma cholesterol and triglyceride 
concentration. The increase in apoB mRNA levels in SMHL rabbits is consistent with 
the increased production of apoB protein seen in the perfusion studies (Chapter 7).
The Taqman™ procedure showed no difference in expression of LDL receptor 
mRNA between the NZW and SMHL rabbits. This confirms preliminary data (La 
Ville et al, 1987) which showed there was no difference in catabolism of LDL by the 
LDL receptor in these rabbits. There was no difference in the expression o f MTP and 
PDI mRNA. MTP has previously been shown to be partially regulated at the level of 
transcription (Pease and Leiper, 1996). However, here there was no difference in 
MTP expression, although both MTP and PDI correlated strongly with apoB mRNA 
levels, suggesting that lipid availability is not the rate limiting step, and the 
upregulation o f apoB mRNA is driving the apoB overproduction.
We found cholesterol 7 alpha-hydroxylase activity to be very variable. Some values 
were extremely large, but this was probably due to the fact that the rabbit sample used 
for the standard curve was a low expressor. There were no significant differences 
between NZW and SMHL rabbits in our study, but we would have preferred to repeat 
the experiment using a different standard curve. HMG CoA reductase and cholesterol 
7 alpha-hydroxylase control the balance of cholesterol leaving the liver as lipoproteins 
or in bile, and arriving in the liver via lipoprotein receptors. Indeed, cholesterol 7 
alpha-hydroxylase has a role in regulating LDL receptor activity (Dueland, Trawich, 
Nenseter, et al, 1992).
Therefore the automated quantitative PCR technique has proved to be a sensitive tool 
for the investigation of gene expression. It has provided us with novel ideas on the
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regulation of gene expression, that perhaps have been missed in earlier studies due to 
the less sensitive techniques employed. One limitation of the technique is that due to 
its sensitivity, it is necessary to have the gene sequence for the correct species 
available, as even 1 or 2 bp difference can cause the reaction to fail.
These studies have provided good evidence for the role o f transcriptional control of 
apoB, and should provide impetus for the more detailed study of the regulation o f the 
apoB promoter region. Thus the major defect in the SMHL rabbits, an 
overproduction of apoB, is at least partially driven by an increase in apoB mRNA 
levels. Whether there is a common cis or trans acting factor in the SMHL rabbits that 
upregulates the transcription of apoB, CETP and VLDL receptor mRNA is 
speculative, but would explain the overproduction of all of these genes. Alternatively 
upregulation of apoB may have the subsequent effect of upregulating CETP and the 
VLDL receptor. We have also shown that MTP and PDI mRNAs are not different 
between the NZW and SMHL rabbits, suggesting that lipid delivery by the MTP-PDI 
complex is not rate limiting in the production of apoB containing particles.
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Chapter 9. General discussion and future prospects
Hazel fe lt  sure there was some natural explanation, though he had no idea what it 
could be exactly. Holly, are we much nearer to solving our problem? ’ he asked.
Richard Adams, Watership Down
The main aim o f this thesis was to characterise the lipoprotein abnormalities present in 
SMHL rabbits, assess the suitability o f this strain as an animal model for the human 
disorder FCH and investigate the genetic defect involved. At the outset these were 
ambitious objectives, but we have been able to make progress on each point - the 
thesis contains a detailed description of the dyslipidaemia present in the animals, 
additional evidence for the similarity between the hyperlipidaemic phenotype exhibited 
by the SMHL rabbits and FCH, and proposes 3 potential gene candidates which may 
contribute to the disorder.
9.1. Characterisation of the lipoprotein abnormality in the SMHL rabbits
In her seminal paper, based on observations of plasma lipid and lipoprotein levels and 
radioactive kinetic studies, La Ville proposed that the disorder exhibited by the St 
Thomas hospital rabbits showed characteristics of FCH, in particular an 
overproduction of apoB containing lipoproteins (La Ville et al, 1987). To investigate 
the disorder present in the SMHL rabbits further, we developed a method for the 
perfusion of rabbit liver. We tested this method thoroughly, and found that for 
control animals, our results agreed with those previously published (Chapter 5). 
Therefore we performed a series of liver perfusion experiments to investigate the 
direct output of lipoproteins from the liver of both young and mature SMHL and 
NZW control rabbits (Chapters 6,7). Figure 9.1. describes the main findings o f these 
experiments. In both young and old rabbits, apoB containing lipoproteins were 
overproduced by the SMHL rabbits. In particular, in young SMHL rabbits, VLDLi 
cholesterol and VLDLi apoB were overproduced (Chapter 7). In the non VLDLi 
fraction o f the SMHL rabbits, output of cholesterol, triglyceride and apoB were all 
increased compared to NZW controls. These differences between the strains were not
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driven by gross hepatic lipid concentration as there was little difference between 
hepatic lipid levels, and indeed, hepatic triglyceride levels were significantly decreased 
in the young SMHL rabbits compared to the young NZW rabbits. In the mature 
rabbits, there were fewer differences between the strains, partly due to large variability 
in the data (Chapter 6). There were no significant differences between cholesterol, 
triglyceride or apoB in the VLDLi fraction, but significant increases in output of 
triglyceride and apoB were seen again in the non VLDLi fraction of mature SMHL 
rabbits. Again there was no difference in hepatic stores o f cholesterol or triglyceride 
in the mature NZW and SMHL rabbits. When all rabbits studied were grouped 
together there were significant positive correlations between plasma cholesterol and 
triglyceride concentrations and apoB output from the perfused livers, suggesting that 
the increased output of apoB may be driving the hyperlipidaemia seen in the SMHL 
rabbits.
When we looked at the effect of age within each strain, there were important 
differences in VLDLi apoB output, which was significantly decreased in both mature 
NZW and SMHL rabbits compared to their young counterparts. There was no 
accompanying decrease in VLDLi cholesterol or triglyceride outputs, implying that 
VLDLi particle size was larger in the mature rabbits compared to the young rabbits. 
Mature NZW rabbits also showed increased hepatic stores of total cholesterol and 
free cholesterol than young NZW, perhaps indicative of the cumulative effect o f the 
cholesterol supplemented diet, while although mature SMHL rabbits showed trends 
towards increased hepatic cholesterol stores, these did not reach significance.
Thus in the SMHL rabbits there is clearly an increased output of apoB containing 
lipoprotein particles. In young rabbits this is evident in both the VLDLi and non 
VLDLi fractions, while in mature rabbits, this is seen only in the non VLDLi fraction. 
The VLDLi particles are apparently smaller, relatively lipid poor in young rabbits, and 
larger, more lipid rich in mature rabbits. Therefore there may be some regulatory 
mechanism which prevents the secretion of apoB particles before they are fully 
lipidated in mature rabbits but not in young rabbits.
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Figure 9.1. Mean VLDLi and non VLDL] cholesterol, triglyceride and apoB
outputs from the livers of young and mature NZW and SMHL
rabbits
YOUNG MATURE
NZW
VLDL
TC 60 ± 19 
TG 416 ± 105 
apoB 22 ±4
non VLDL
TC 21 ± 8 
TG 23 ± 7 
apoB 6 ± 3
VLDL
TC 160 ±45 
TG 443 ± 92 
apoB 10 ± 3*
non VLDL
TC 28 ± 8 
TG 22 ± 6 
apoB 6 ± 3
SMHL
7.9 r 2 I 
5.0 ± I 
TG 0 .7 :i I ( 
PL 15 7 i I.
VLDL
TC 237 ±68* 
TG 658 ± 177 
apoB 79 ± 29*
non VLDL
TC 119 ±56* 
TG 150 ±89* 
apoB 80 ± 41*
Cholesterol, triglyceride and apoB output is measured in ng/g liver/minute, liver 
lipid content is measured as mg/g wet weight liver. * indicates significant 
differences between young and mature rabbits, p  < 0.05, ** p  < 0.01, * indicates 
significant differences between NZW  and SMHL rabbits, p  < 0.05, * p  = 0.01
VLDL
TC 229 ± 52 
TG 439 ± 94 
apoB 15 ± 4**
non VLDL
TC 98 ± 28 
TG 82 ± 34* 
apoB 36 ± 12**
185
The overproduction of apoB in the SMHL rabbits corroborates the findings of La 
Ville et al from their radioiodinated kinetic studies. They demonstrated an 
overproduction o f VLDL and LDL in the St Thomas’ hospital rabbits. Their 
experiments also showed a decreased LDL FCR, which they attributed to saturation 
o f receptor-mediated catabolism. The perfusion studies described in this thesis do not 
provide any information about catabolism, and indeed, as the catabolic state is 
unknown, this must be borne in mind when interpreting the results. Our own stable 
isotope kinetic studies, while they did not show any significant differences in kinetic 
parameters, showed trends towards impaired catabolism from IDL and LDL, as 
demonstrated by La Ville (Chapter 4), providing a stimulus for further investigation.
9.2. The SMHL rabbits as a model for FCH
As yet there are no generally accepted animal models for FCH. The literature 
describes a strain of swine which exhibits a ‘marked resemblance’ to FCH, but 
recently little has been heard of this model (Hasler-Rapacz, Nichols, Griggs et al,
1994). Based on the results of the wide variety of experiments described in this 
thesis, the SMHL rabbit continues to demonstrate characteristics analagous to those 
o f the human disorder FCH (Table 9.1.). FCH was first described in 1973 as a 
disorder where ‘affected family members characteristically had elevated levels o f both 
cholesterol and triglyceride. However, increased cholesterol or increased triglyceride 
levels alone were also frequently observed’ (Goldstein et al, 1973). This phenotype 
was evident in our SMHL rabbit population (Chapter 3), with the majority of animals 
expressing hypercholesterolaemia and hypertriglyceridaemia. The
hypercholesterolaemia in these animals has previously been shown not to be 
associated with inactive LDL receptors (La Ville et al, 1987).
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Table 9.1. Is the SMHL rabbit an appropriate model for FCH?
Phenotype FCH SMHL rabbits
Multiple lipid phenotype
t  TC
T t g
T TC and TG 
(Goldstein et al, 1973)
T TC
T t g
T TC and TG
ApoB production t  in VLDL and/or LDL 
(Janus et al, 1980, 
Venkatesan et al, 1993)
T in VLDL; and/or non 
VLDLi
ApoB catabolism
'I in a subset 
(Aguilar Salinas et al, 
1997)
Tendency to 
undercatabolism seen in 
kinetic studies
Lipoprotein size
(Brunzell et al, 1983)
■I (not significant)
Insulin resistance Present in 
hypertriglyceridaemic 
individuals 
(Castro Cabezas et al, 
1993)
Hyperinsulinaemic 
response to an oral 
glucose load
CETP levels T concentration 
(McPherson et al, 1991)
T activity and mRNA
LPL levels i  in a subset 
(Babirak et al, 1992)
Kinetic studies have demonstrated that the common feature of FCH is an 
overproduction of apoB from the liver, in either the VLDL or LDL density classes or 
both, and this is what contributes to the multiple phenotypes seen (Janus et al, 1980, 
Venkatesan et al, 1993). Our own stable isotope kinetic experiments did not 
demonstrate any significant differences in apoB PR, however for these experiments, 
the SMHL rabbit group were not hyperlipidaemic compared to the control NZW 
rabbits (Chapter 4). The two SMHL rabbits that were relatively hyperlipidaemic did
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exhibit greater PRs than the rest o f that group or the NZW rabbits, suggesting an 
association between an increased VLDLi apoB PR and hyperlipidaemia. This 
association is strengthened by the findings of La Ville et al (1987) who demonstrated 
an increased VLDL PR in their group of St Thomas’ hospital rabbits. The animals 
that she studied were more severely hyperlipidaemic than any of our SMHL rabbit 
groups. However, we established directly the major defect in the SMHL rabbits as an 
apoB overproduction by the perfusion experiments. ApoB output was significantly 
increased in young hyperlipidaemic SMHL rabbits in both VLDLi and non VLDLi. 
In mature hyperlipidaemic SMHL rabbits only plasma cholesterol levels were 
significantly increased compared to NZW rabbits, and importantly apoB output was 
significantly increased in the non VLDLi fraction only.
An FCH kindred has been described that exhibits an impaired apoB catabolism 
(Aguilar-Salinas e ta l , 1997), but we have not demonstrated this in the SMHL rabbits. 
Our kinetic data showed a tendency towards decreased FDC, FTR and FCRs in the 
SMHL rabbits, although this may be in addition to an increased PR. Had we 
performed these kinetic studies on a larger number of more hyperlipidaemic SMHL 
rabbits, we may well have found significant differences.
Relatively small lipoprotein particles have been described as characteristic o f FCH 
(Brunzell et al, 1983, Franceschini, Cassinotti, Vecchio, et al, 1994, Hokanson et al,
1995). When we calculated the ratio of cholesterol + triglyceride (in grams) to apoB 
(in grams) in our studies, we found that in the SMHL rabbits there was a decreased 
amount of lipid associated with each apoB molecule (i.e. each particle) as compared 
to the NZW rabbits, although this did not reach significance.
Insulin resistance has been associated with FCH (Hunt, Wu, Hopkins et al, 1989). 
Relatives of index patients with FCH with elevated triglyceride levels had increased 
fasting insulin concentrations and elevated FFA concentrations compared to 
normolipidaemic relatives (Castro Cabezas et al, 1993). Additionally, 
hypertriglyceridaemic FCH individuals demonstrated an impaired postprandial FFA 
metabolism, and the resultant increase in plasma FFA levels may be responsible for the 
decreased lipolytic activity in FCH. Whether elevated insulin levels cause the increase
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in FFA or vice versa is unclear. Further confirming their role as an animal model for 
FCH, the SMHL rabbits showed exaggerated insulin and FFA levels in response to an 
oral glucose load when compared to NZW rabbits, however the lack of a correlation 
between FFA levels and plasma triglyceride levels may indicate that the insulin 
resistance is not the driving force in the lipoprotein overproduction seen in these 
rabbits.
Insulin resistance can also result in decreased LPL activity and therefore a reduced 
clearance o f VLDL. Insulin resistance is not necessarily present in each individual 
with FCH, or in each SMHL rabbit. Millar, Watson, Stewart et a l (unpublished 
observations) showed two sub-groups of mixed hyperlipidaemic individuals with 
different VLDLi and VLDL2 triglyceride kinetics. One group had increased VLDLi 
PR similar to diabetic individuals, while the second group had normal PR but 
decreased FCR. A potential mechanism for the difference in these individuals is the 
presence o f insulin resistance in the diabetic-like group, but not in the other group of 
mixed hyperlipidaemics. The rabbit groups which we studied were too small to look 
at this association, but it is a potential explanation for the variability both in kinetic 
parameters and insulin response to the oral glucose dose.
Increased CETP levels are characteristic of combined hyperlipidaemia (McPherson, 
Mann, Tall, et al, 1991). In combined hyperlipidaemics, cholesteryl ester transfer 
from HDL to VLDL is upregulated compared to normals due to an increased level of 
VLDL (acceptor particle), and a decreased affinity of LDL for cholesteryl ester mass 
transfer. (Guerin, Bruckert, Dolphin, et al, 1996). We demonstrated a significant 
increase in plasma CETP activity in SMHL rabbits (Chapter 3, Table 3.5.) compared 
to NZW controls, but did not perform any investigation of cholesteryl ester mass 
transfer. It is possible that the increased CETP activity in the SMHL rabbits was due 
to the presence of an increased amount o f acceptor particles (VLDL) although this 
would not explain the mRNA results.
A subset o f FCH individuals exhibit decreased LPL levels (Babirak et al, 1992). 
However severe defects in LPL have not been found, and it has been suggested that 
this decrease in LPL levels may merely magnify the phenotype, rather than being a
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primary cause. We did not find any significant difference between LPL levels in 
SMHL and NZW rabbits.
Therefore in conclusion, as can be seen from Table 9.1., the SMHL rabbits exhibit 
characteristics entirely consistent with human FCH, and based on the results contained 
within this thesis, can be recommended as an animal model for the disease.
9.3. Genetic defects within the SMHL rabbits
The genetic basis of FCH is as yet unclear, and has been the subject o f much 
speculation. FCH was first described in 1973 as a disorder with a major gene effect 
on plasma triglyceride levels, and a secondary effect on plasma cholesterol levels. 
Since then apoB has been the principal gene candidate, however no known mutations 
have been found to co-segregate with FCH. LPL and the apoAI-CIII-AIV gene 
cluster have also been implicated, but no consistent association has been found 
(Wijsman, Motulsky, Guo, et al, 1992, Gagne, Genest, Zhang, et al, 1994, Yang, 
Nevin, Peng, et al, 1995, Dallinga-Thie, Bu, van Linde-Sibenius Trip, et al, 1996). 
Therefore our data describing a significant increase in the levels of mRNA for the 
VLDL receptor, CETP and apoB in the SMHL rabbits are exciting new targets for 
study. We also investigated the mRNA levels of the LDL receptor, MTP, PDI and 
cholesterol 7 alpha-hydroxylase, but there was no difference in expression o f these 
between NZW and SMHL rabbits. We therefore propose that there is either 
differential expression of a common regulatory element, similar to the sterol response 
element binding protein (Wang, Du, Martin, et al, 1997), or a mutation in the 
promoter region of the apoB, CETP and/or VLDL receptor genes in the SMHL 
rabbits that causes binding of an additional promoter, or prevents binding of a 
repressor protein, and therefore upregulates transcription of these genes. It is 
possible that the major gene effect is on the apoB gene, and that the upregulation of 
the VLDL receptor and CETP is an attempt to clear the increased amount o f apoB 
containing lipoproteins in the circulation. However it must be borne in mind that 
there is no guarantee that an increase in mRNA means an increase in active protein.
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Figure 9.2. Secretion of lipoprotein particles from NZW and SMHL rabbits
promoter
complex
NZW
r *
-LLALA AAAA
apoB mRNA altered
regulatory
element
SMHL
r *
1-TATA AAAA
apoB mRNA
AAA
RER SER
+ TG 
droplet
VLDL
AAA AAA
RER
+ TG 
droplet
VLDL
VLDL
VLDL
Based on the evidence contained within this thesis, it is possible that the defect in the 
SMHL rabbits that causes the FCH phenotype is the presence (or absence) o f  an 
additional regidatory element that causes the upregulation o f  apoB transcription. This 
same element may upregulate CETP and VLDL receptor transcription, or the presence 
o f an increased amount o f  apoB may upregulate these genes.
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We hypothesise that apoB is transcribed and translated at an increased rate in the 
SMHL rabbits. This results in the initiation of a greater number o f lipoprotein 
particles in the RER (see Figure 1.2. for normal synthesis and secretion of lipoprotein 
particles). Each new particle has to associate with a minimum amount o f lipid to 
allow the apoB to take on a viable formation, and this new lipoprotein particle is then 
secreted (Figure 9.2.). The increased number o f particle initiations in SMHL rabbits 
leads to secretion of a greater number o f smaller particles. This would explain the 
increased output of apoB seen in the perfusion studies even when lipid output was not 
significantly changed (as in mature rabbits). Indeed, there are significant positive 
correlations seen between cholesterol and triglyceride concentrations and output rates 
o f apoB from the perfused livers, and between triglyceride concentrations and apoB 
mRNA levels (Figure 8.8.) in the TaqMan studies. It is interesting to speculate that 
there could be a correlation between apoB mRNA levels and apoB output rate from 
the liver, however these experiments would need to be performed in the same rabbit 
group.
9.4. Future prospects
Further characterisation of the SMHL rabbits is necessary. It would be interesting to 
investigate the effect of the 0.08% cholesterol diet on the mRNA levels of apoB, 
CETP and the VLDL receptor, to see if their upregulation is in response to the 
increased cholesterol, or if it is constitutive. Detailed investigation o f the promoter 
region of the apoB gene in the SMHL rabbit may provide some information on the 
reason for the upregulation of the gene, either by looking at the DNA sequence or by 
identifying transcription factors by gel-shift (or other) assays. Culture o f hepatic cells 
would allow the manipulation of the cells for example by drug (statin) treatment, or 
by stimulating VLDL synthesis by loading with FFA. An important question is 
whether the upregulation of apoB output in the whole SMHL rabbit is limited to 
apoBlOO, or whether apoB48 is also upregulated; mRNA levels in the intestine could 
be studied to investigate this. It would be of interest to find out if other genes are 
upregulated like apoB, CETP and VLDL receptor, for example AC AT, LCAT or 
HMG CoA reductase. Further studies to investigate the catabolism of apoB
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containing lipoproteins would be of interest and would aid the interpretation of the 
perfusion results.
9.5. Conclusions
In conclusion, the SMHL rabbit is currently the most likely animal model for FCH. 
We have found no major inconsistencies with the phenotype reported in humans, and 
envisage that in the near future, this strain of rabbit will be widely used to provide 
more information on, and test new drugs for, FCH.
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Appendix 1. Manufacturers addresses
Altec
Unit 4, Riverwey Industrial Park 
ALTON, GU34 2QG 
UK
Amersham International pic
AMERSHAM
UK
Beckman Instruments (UK) Ltd 
Analytical Sales and Service Operation 
Progress Road
HIGH WYCOMBE, HP12 4JL
BDH Laboratory Supplies 
McQuilkin and Co 
21 Polmadie Avenue 
GLASGOW, G5 OBB
Bio-Rad Laboratories 
2000 Alfred Nobel Drive 
HERCULES 
CA 94547, USA
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane
LEWES, BN7 1LG
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Chromacol Ltd 
3 Little Mundells
WELWYN GARDEN CITY, AL7 1EW
Cruachem Ltd.
GLASGOW
DNASTAR Inc.
MADISON 
Wisconsin, USA
Ethicon Ltd.
EDINBURGH
UK
Fisons Instruments 
Crewe Road 
Wythenshaw
MANCHESTER, M23 9BE
Froxfield Farm UK Ltd 
Unit 3, King Lane
FROXFIELD, Nr PETERSFIELD, GU32 1DR
Gibco BRL
Life Technologies Ltd.
3 Fountain Drive, Inchinnan Business Park 
PAISLEY, PA4 9RF 
UK
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Harlan Interfauna Ltd.
Abbots Ripton Road 
Wyton
HUNTINGDON, PE 17 2DT
V. A. Howe & Co. Ltd. 
Beaumont Close 
BANBURY, 0X 16 7RG
Isotec Inc
A Matheson USA Company 
3858 Benner Road 
MIAMISBURG 
OH 45342, USA
Janke & Kunkel 
STAUFENIM BREISGAU 
Germany
Jen way UK,
DUNMOW, UK
Leo Laboratories Ltd.
PRINCES RISBOROUGH, UK
Linco Research, Inc.
14 Research Park Drive 
ST CHARLES 
MO 63304, USA
Minitab Inc.
3081 Enterprise Drive,
STATE COLLEGE 
PA 16801-3008, USA
OsteoTec Limited 
9 Silver Business Park,
Airfield Way
CHRISTCHURCH, BH23 3TA, UK
Paar Scientific Ltd.
594 Kingston Road 
Raynes Park 
LONDON, SW20 8DN
Perkin Elmer Applied Biosystems 
FOSTER CITY 
CA 94404, USA
Perkin Elmer Applied Biosystems UK 
WARRINGTON, UK
Pharmacia Biotech Ltd.
23 Grosvenor Road 
ST ALBANS 
AL1 3 AW
Portex Ltd.
HYTHE, UK
Promega 
MADISON 
W l, USA
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Quiagen
CRAWLEY, West Sussex
Randox Laboratories Ltd. 
CRUMLIN, Co. Antrim, UK
Rhone Merieux Ltd.
HARLOW, UK
Roar Biomedical, Inc.
2840 Broadway, M/S 271 
NEW YORK, NY 10025, USA
SAAM Institute 
University of Washington 
SEATTLE, WA 98195, USA
Scottish Antibody Production Unit 
Law Hospital 
CARLUKE, ML8 5ES
Sigma Chemical Company 
Fancy Road 
POOLE, BH17 7TG
Special Diet Service 
WITHAM, UK
Techne
Scotlab
Kirkshaw Road 
COATBRIDGE, ML5 8AD
Technicon 
MIT Service Inc 
10065 Mesa Ridge Court 
SAN DIEGO 
California 92121, USA
Vygon UK Ltd. 
CIRENCESTER, UK
Wako Chamicals GmbH 
NissanstraOe 2 
D-41468, NEUSS 
Germany
Watson Marlow Ltd.
FALMOUTH
Cornwall, TR11 4RU, UK
Whatman International Ltd. 
St. Leonards Road, 20/20 
MAIDSTONE, ME 16 OLS
Appendix 2. TaqMan primer and probe sequences
Rabbit GAPDH (base pairs 1051 - 1130)
TGGTCCACAT GGCCTCCAAG GAGTAAGAGC CCTCAAACCA 
CCGGCCCCAG CGAGAGCACC AGAGGAGGAC GAGAGGCCCT
Rabbit beta actin (base pairs 1 - 70)
GTCCTTCCTG GGCATGGAGT CCTGCGGCAT CCACGAGACC 
ACCTTCAACT CGATCATGAA GTGCGACGTG
Human HPRT (base pairs 581 - 700)
AAAAGGACCC CACGAAGTGT TGGATATAAG CCAGACTTTG 
TTGGATTTGA AATTCCAGAC AAGTTTGTTG TAGGATATGC 
CCTTGACTAT AATGAATACT TCAGGGATTT GAATCATGTT
Rabbit apoB (base pairs 201 - 280)
CAGTGCAACA ACCAGCTTGA GGTACAGTCC CCTGATGCTG 
GAGAATGAGC TGAACGCAGA GCTTGCCCTT TCTGGGGCAT
Rabbit VLDL receptor (base pairs 2531 - 2610)
CTTGAAGACC ACGGAAGAGG ACCTCTCCAT TGACATCGGC 
AGACACAGTG CTTCTGTTGG AC AC AC GTAC CCAGCAATAT
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Rabbit LDL receptor (base pairs 2371 - 2450)
GGGCGTGCAT GGCGTTTTAG CTTTGCACCT CGCAAGCCGC 
GCGAGTCTGT GACGACATTT GCACTTTGTG CGTTTCTGGA
Rabbit CETP (base pairs 1311 - 1390)
GGGCATCCCG GAGGTCATGT CTCGGCTCGA GGTGGCGTTC 
ACAGCCCTCA TGAACAGCAA AGGCCTGGAC CTCTTCGAAA
Rabbit MTP (base pairs 1 - 80)
ATGCCGGCTG TACAAGCTCA CCTACGCCAC TGAAGTCTTT 
GTTGATCGAA GCAAAGGAAA ACTCCAAGAC AGTGTGGGCT
Rabbit PDI (base pairs 1281 - 1360)
GCAAGCAGCT GGCTCCCATC TGGGACAAGC TGGGCGAGAC 
GTACAAGGAG CACCAGGACA TCGTCATCGC CAAGATGGAC
Rabbit 7 alpha-hydroxylase (base pairs 341-410)
GCTAGCTGAG GGCTTGAAGC ATGACAACCT CCGAACCAGG 
GACCACATCT CAGAACTGAT CCGCCTGCGC ATGTTTCTGA
Sequences in red are the primers, sequences in blue are the probes.
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Appendix 3. TaqMan gene quantification
Ratios of abundance of mRNA of genes of interest to GAPDH. NZW rabbits.
Rabbit ApoB VLDLR LDL-R CETP MTP PDI 7-AH
1 0.69 0.57 0.51 0.52 0.43 0.81 2.4
2 0.55 0.86 2.0 0.72 1.4 2.5
3 0.70 0.54 0.60 0.94 0.55 1.0 5.3
4 0.60 1.2 1.2 0.98 0.72 1.6 7.2
5 0.61 0.64 2.3 1.63 0.82 1.5 1.1
6 0.59 0.22 1.2 2.3 0.45 0.55 4.7
7 0.85 0.53 1.8 0.90 0.32 0.45 5.8
8 0.90 0.88 3.7 2.6 0.97 0.87 33.7
9 1.1 0.39 3.6 1.8 1.1 1.4 26.1
10 1.1 0.84 1.3 3.5 0.86 1.1 16.3
11 1.3 0.67 1.9 1.1 0.76 0.98 40.8
Mean ± 
SEM
0.82 ± 
0.08
0.67 ± 
0.08
1.8 ± 
0.32
1.62 ± 
0.3
0.71 ± 
0.08
1.1 ± 
0.11
14.0 ± 
4.2
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Ratios of abundance of mRNA of genes of interest to GAPDH. SMHL rabbits.
ApoB VLDLR LDL-R CETP MTP PDI 7-AH
1 1.7 0.85 1.7 3.9 0.95 2.5 3.9
2 0.53 4.8 0.50 3.6 0.23 0.60 1.6
3 1.3 0.90 2.3 4.7 0.84 2.2 0.64
4 1.4 2.5 1.1 5.5 0.72 1.7 5.0
5 0.73 2.1 0.47 2.4 0.33 0.94 4.9
6 1.6 1.4 2.7 2.1 1.4 1.8 16.2
7 2.0 0.90 3.2 3.8 1.2 1.7 19.5
8 3.1 1.4 7.0 1.4 2.2 3.1 12.9
9 1.8 1.5 2.8 3.8 0.88 1.6 3.6
10 1.6
11 1.4 0.80 3.5 4.4 0.88 1.2 2.5
12 0.93 0.97 1.8 4.4 0.65 0.96 17.1
13 0.81 0.59 1.4 4.4 0.58 0.58 16.7
14 0.95 1.4 1.4 1.4 0.84 0.84 3.3
15 0.85 0.70 1.5 2.4 0.66 0.79 20.6
16 0.97 0.40 2.0 4.0 0.88 0.99 6.4
17 1.2 0.93 2.2 0.77 0.87 1.5 36.8
Mean ± 
SEM
1.3 ± 
0.16
1.4 ± 
0.27
2.2 ± 
0.39
3.2 ± 
0.34
0.88 ± 
0.11
1.4 ± 
0.18
10.7 ± 
2.5
p value 0.005 0.02 NS 0.002 NS NS NS
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ANIMAL MODELS
1 .P.92 Effect of hypercholesterolemic diet and D2 vitamin on the 
atherosclerosis development in obese and prediabetic Sand 
Rats (Psammomys obesus)
N. Bennani-Kabchi1. M.A. Belabbas2, O. Lemsafer1, G. Marquie3. 1 Unite de 
Nutrition et Metabolisme, Faculte des Sciences, Universite Mohammed V, 
Rabat, Maroc; 2Service d'Anatomie et Cytologie, Institut National 
d ’Oneologie, Rabat, Maroc; 3Laboratoire des Regulations des Metabolismes 
et Nutrition, Universite Paul Sabatier, Toulouse, France
The Sand Rat (P.O) is known as a good model to study obesity and diabetes 
abnormalities, when submitted to hypercaloric diet instead of hypocaloric and 
halophiles plants usually eaten in the biotope. Limited studies have focused 
on the fundamental role of these disorders in the induction of lipid metabolic 
troubles, and of atherosclerosic lesions in these species which are a good 
model for vascular pathology studies, despite their athero-resistance. We have 
experimentally reproduced atherogenic lesions in 32 Sand Rats fed, during 
two months, with hypercholesterolemic diet enriched with cholesterol, some 
of these animals receiving orally high proportions of D2 vitamin. During 
the treatment the early development of obesity and prediabetes (DNID), 
was confirmed by glucose moderated intolerance, and hypercholesterolemia, 
hypertriglyceridemia, with a huge incfease of LDLC without any change 
of HDLC. Histological analysis undertaken before and after two months 
of treatment showed hypertrophy and hyperplasy of pancreatic Langerhans 
islets which proved the diabetic state of these animals, but without skin 
microangiopathy or lipidic liver deposits. Regarding the macroangiopathy, 
only arterial preatheromateous lesions but no heart lesions were observed. 
The addition of. a high oral dose of D2 vitamin, produced more important 
atherosclerotic lesions at various stages: lipidic, calcified, or ulcerus in aortic, 
coronary and renal arteries with consequentially ischemic effects represented 
by myocardial infarctions.
We conclude that Sand Rat living in Morocco, could be selected as model 
for the study of vascular pathology which could allow therapeutic assays for 
new antiatherogenic agents.
1 .P.93 Effects on plasma lipids levels in cholesterol feeding 
male/female heterozygous KHC rabbits
Akira Iizuka, Fumihiko Yoshie, Yasuhiro Komatsu, Akiyo Matsumoto1, 
Kazuo Kondo1, Hirosige Itakura1. Central Research Laboratories, Tsumura 
& Co., Ibaraki, Japan; 1 The National Institute o f Health and Nutrition,
Tokyo, Japan
High serum cholesterol is a major risk factor for coronary heart diseases. For 
a comparison between male and female rabbits; we observed the responsive to 
dietary hypercholesterolemia as regards plasma lipids levels in KHC rabbits, 
which is LDL receptor deficiency.
Male and female Japanese White (JW) or heterozygous KHC rabbits were 
given a standard milled rabbit diet or containing 0.1% cholesterol (CH). All 
male and female JW and KHC rabbits showed no increase in their plasma 
CH levels after being fed a standard milled rabbit diet for 24 weeks. The 
plasma CH levels in male JW rabbits did not increased, but for heterozygous 
KHC rabbits the transitorily increased for 4 to 8 weeks (about 300 mg/dl) 
and gradually decreased after being subjected to the CH diet. On the other 
hand, as regards female JW rabbits, the plasma CH levels were increased for 
4 to 24 weeks (about 300 mg/dl) and in heterozygous KHC rabbits gradually 
increased (about 700 mg/dl after 24 weeks) after being fed the CH diet. Plasma 
phospholipid levels tend to increase the CH levels in each experiment and 
plasma triglyceride levels were not changed in any of the experiments.
These results indicate that female rabbits were high responders for the 
cholesterol diet than the male rabbits and the responsiveness to dietary 
hypercholesterolemia was predominated as regards the genetic factor.
1 .P.94 Characterisation of lipoprotein metabolism in the Froxfield 
mixed hyperlipidaemic rabbit
H.A. Ardern, D. Grimsditch, D.K. Bedford, M.J. Caslake, K.E. Suckling,
C.J. Packard, J. Shepherd. Royal Infirmary, Glasgow, Scotland; SmithKline 
Beecham Pharmaceuticals, Harlow, UK
The Froxfield mixed Hyperlipidaemic rabbit (FMHL) colony was derived 
from the St Thomas rabbit. We investigated the nature of the defect in these 
rabbits who exhibit a lipoprotein phenotype similar to Familial Combined Hy­
perlipidaemia. Ten FMHL and 10 control New Zealand White (NZW) rabbits
were fed a low cholesterol (0.085% w/w) diet. Median plasma cholesterol 
was significantly higher in FMHL than NZW (108 vs 54 mg/dl; p < 0.01). 
Median plasma triglyceride (TG) showed no significant differences between 
groups, but was elevated and highly variable in FMHL (range FMHL 31—403-, 
NZW 31-62 mg/dl). Lipoprotein subfractions, very low density lipoprotein 
1 (VLDLl) Sf 6CM00, VLDL2 Sf 20-60, intermediate density lipoprotein 
(IDL) Sf 12-20 and low density lipoprotein (LDL) Sf 0-12, were separated 
by density gradient ultracentrifugation. Median VLDLl, VLDL2, IDL and 
LDL masses were significantly higher in FMHL than NZW (33.2 vs 12.5, 
71.7 vs 17.9, 82.3 vs 25.2, 36.6 vs 10.8 mg/dl; all p < 0.01). Apolipoprotein 
(apo) B kinetics were investigated by injecting tri-deuterated (d3 ) leucine (10 
mg/kg) into 4 rabbits from each group and the enrichment of d 3 leucine in 
apoB from V LD Ll, VLDL2, IDL and LDL was followed by gas chromatog­
raphy-mass spectrometry. Data was fitted to a multicompartmental model. 
Preliminary analysis shows a positive correlation between TG levels and 
VLDLl-apoB synthesis (r = 0.92; p < 0.005). FMHL, even those without 
raised VLDLl-apoB synthesis rates, have a higher VLDLl TG:apoB ratio 
(18.1 vs 12.2). FMHL have elevated VLDL2 masses due to lower fractional 
catabolic rates (FCR) than NZW (14.6 vs 33.8 pools/day). Cholesterol levels 
showed an inverse correlation with IDL- and LDL-apoB FCR (r = 0.83, p =
0.01; r = 0.72, p < 0.05). We conclude that in FMHL hypertriglyceridaemia 
is due to increased VLDLl-apoB synthesis and hypercholesterolaemia is a 
consequence of decreased LDL-apoB FCR.
1 .P.95 Effects of A5-olefinic acids from Pinus pinaster seed oil on 
lipoprotein metabolism in apoE deficient mice
G. Asset, E. Bauge, R.L. Wolff, J.C. Fruchart, J. Dallongeville. INSERM 
U-325, Institut Pasteur de Lille and ISTAB, France
The aim of the present study was to assess the lipid-lowering potential of oil 
extracted from Pinus pinaster seeds. This oil contains As-olefinic fatty acids: 
all m - 5 ,9 ,12-18:3 and all cA-5,11,14-20:3 acids. The dose response effect 
of As-olefinic oil supplementation at 0%, 5% and 10% wt/wt on lipid and 
lipoprotein levels was evaluated on apoE KO mice. Diets were completed to 
10% wt/wt of fat with lard. Compared to control (10% wt/wt of lard), the 5% 
and 10% P. pinaster regimen were associated to lower levels of total choles­
terol (C) (—25%, p < 0.02; —38%, p < 0.001 respectively), phospholipids 
(-1 7 % , p < 0.05; -2 8 % , p < 0.01) and VLDL-C (-26%, p <  0.05; -38% , 
p < 0.01). In contrast, total triglycerides (TG) and VLDL-TG increased in a 
dose dependent manner in the P. pinaster supplemented mice resulting in a 
significant decrease in the VLDL-C to VLDL-TG ratio (p < 0.0001). This 
suggests that compared to lard P. pinaster oil decrease VLDL remnant levels 
in apoE KO mice. Gel filtration chromatography confirmed these results. 
Finally, apo Al and apo All concentrations were not modified by P. pinaster 
regimen. In conclusion, we have demonstrated that hypercholesterolemia can 
be reduced by A5-olefinic oil supplementation in apo E deficient mice.
1.P.96 Plasma lipids and atherosclerosis in Froxfield mixed 
hyperlipidaemic (previously St Thomas Hospital) rabbits
G.M. Benson1, D.C. Grimsditch1, J. Phillips2, K.E. Suckling1. 1SmithKline 
Beecham Pharmaceuticals Ltd, NFSP, Harlow, Essex; 2 Froxfield Farms, 
Froxfield, Hants, UK
Froxfield mixed hyperlipidaemic (FMHL) rabbits are derived from the remain­
ing colonies of St Thomas Hospital rabbits1. The present study was designed 
to characterise the changes in plasma lipids and atherosclerosis in FMHL 
rabbits that were fed a mildly atherogenic diet until they were 6 months old.
Nine week old male and female FMHL rabbits (n = 12/sex) were selected 
from larger groups on the basis of their elevated plasma cholesterol (>3.6 
mM) and triglyceride (> 2 .6  mM) concentrations after having been fed a 
standard rabbit diet supplemented with 0.075% w/w cholesterol (0.08% total 
cholesterol) and 2% w/w corn oil from weaning. The rabbits continued to 
receive the diet until they were 6 months old. Plasma cholesterol and triglyc­
eride concentrations were measured throughout this period. At the end of the 
study the rabbits were killed and their hearts and aortas were perfuse-fixed in 
situ. The aortas were removed, cleaned of extravascular fat and stained with 
sudan IV. The percentage area of atherosclerotic plaque was measured enface  
using colour video image analysis.
Plasma cholesterol and triglyceride concentrations were similar for nine 
week old male and female rabbits (7.3 vs 8.8 mM and 4.5 vs 4.3 mM re­
spectively). However, at 6 months of age plasma cholesterol in female FMHL 
rabbits had risen to 22 ±  8 mM whilst in the males it had fallen to 2.5 ±  2.2 
mM. Plasma triglyceride concentrations fell to approximately 2.7 mM in both
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Apolipoprotein B is overproduced in the froxfield mixed hyperlipidaemic rabbit
H A . Ardern, C J . Packard, J. Shepherd and K E . Suckling
Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland
The Froxfield Mixed Hyperlipidaemic rabbit (FMHL) is a putative model of familial com­
bined hyperlipidaemia (FCHL). To investigate the pathogenesis of the disease exhibited 
by these animals, we studied apolipoprotein (apo) B secretion in perfused livers. Four 
FMHL (>1 year old) and 5 age matched New Zealand White (NZW) fed a 0.075% cho­
lesterol diet were euthanised (Euthatal), and their livers were perfused for 3 hours with 
recirculating oxygenated Krebs-Henseleit buffer, pH 7.4, maintained at 37°C. Samples 
were taken at time 0, and every 30 minutes throughout the experiment. Cholesterol, 
triglyceride (TG), glycerol, urea, albumin, AST and GGT were measured at each time 
point. Bile flow was recorded. Very low density lipoprotein (VLDL) 1 (Sf 60-200), 
VLDL2 (Sf 20-60), intermediate density lipoprotein (IDL) (Sf 12-20) and low density 
lipoprotein (LDL) (Sf 0-12) were separated by density gradient ultracentrifugation from 
the 0, 1,2 and 3 hour samples. Cholesterol, TG and apoB were measured in each sub­
fraction, and results were calculated for VLDL1 and VLDL2+IDL+LDL. Liver function 
tests indicated that the livers were normal. Total TG production rates (mean ± SE) were of 
the same magnitude in both groups (43±20 vs 40±15 mg/liver/min). FMHL rabbits had a 
moderately raised apoB production rate compared to NZW (4.1 ±0.8 vs 2.2±0.9 
//g/liver/min, p=0.15). VLDLlapoB production was higher in FMHL than NZW (2.6±0.5 
vs 1,2±0.4//g/liver/min, p=0.05), whereas VLDL2+IDL+LDL apoB production was sim­
ilar in both groups (1.5±0.6 vs 0.9±0.5 /!g/liver/min, NS). Young NZW (3-4 months old) 
fed standard chow were studied in a similar manner. Older rabbits produced equal 
amounts of apoB as VLDL 1 and VLDL2+IDL+LDL, whereas young NZW produced 85% 
of their apoB as VLDL1 . In conclusion, as in FCHL, FMHL constitutively overproduce 
apoB containing lipoproteins, particularly in the VLDL1 density range.
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Hypertriglyceridemia in transgenic mice overexpressing human APO A-II is due to 
defective catabolism by lipoprotein lipase
A.-D. Kalopissis, G. Lambert, E. Boisfer, V. Atger, I. Beaucamp, M. Antonucci, M. 
Laplaud, S. Griglio and J. Chambaz
CJF 9508 INSERM, Institut des Cordeliers, Paris; Laboratoire de Biochimie Hopital 
Broussais, Paris; U321 INSERM, Hopital de la Pitie, Paris, France
The metabolic role of apolipoprotein (apo) A-II, the second major apolipoprotein of HDL, 
was studied in transgenic mice expressing human apo A-II at 2 times, (line hAIItgS) or 4 
times (line hAIItgX) the normal concentration. Hemizygous mice fed chow presented 
postprandially an apparent chylomicronemia, with plasma triglyceride (TG) concentra­
tions ranging from 746 (line 5) to 1524 mg/dl (line X), compared with 50 mg/dl in control 
C57BL/6 mice. Plasma TG returned to normal after an overnight fast in hAIItgb mice but 
remained higher in hAIItgX mice. Plasma HDL decreased 2-3-fold in both transgenic 
mice, and were negatively correlated with apo A-II expression. The postprandial accumu­
lation of large VLDL suggested impaired TG hydrolysis by lipoprotein lipase (LPL), the 
first enzyme to act on VLDL upon secretion. Postheparin LPL activity was decreased by 
only 28%, while hepatic lipase (HL) activity decreased by 20% in the higher-expressing
hAIItX line. Adipose tissue and muscle LPL activities were unaffected in transgenic mice, 
indicating that LPL was normally produced in both tissues. On the contrary, VLDL-TG 
hydrolysis by commercial LPL proceeded at much slower rates in transgenic compared 
with control mice, the Vmax decreasing from 96 nmol free fatty acids (FFA) / min in con­
trol VLDL to 46 and 23 nmol FFA/min in hAIItg 8 and X VLDL, respectively. 
Unexpectedly appreciable amounts of human dimeric apo A-II were present in all apo 
Bcontaining lipoproteins of transgenic mice, whereas normally apo A-II is absent from 
VLDL. Our transgenic mice represent a model of postprandial hypertriglyceridemia char­
acterized by accumulation of TG-rich lipoproteins — due to defective catabolism by LPL 
— and concomitantly decreased HDL, thus resembling the proatherogenic profile of 
familial combined hypertriglyceridemia.
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Fasting and postpradial lipids in subjects with familial combined hyperlipidemi 
treated with HMG-CoA reductase inhibitors and combination therapy with fibraU
M. Castro Cabezas1, T.WA de Bruin and D.W. Erkelens
1 Dpts. of Internal Medicine, University Hospital Utrecht and ^Maastricht.The Netherlanc
Patients with Familial Combined Hyperlipidemia (FCH) are characterized by overpr< 
duction of hepatic apolipoprotein (apo) B and impaired postprandial lipemia. Treatmei 
with HMGCoA-reductase inhibitors is usually not sufficient to normalize fasting plasn 
lipids. The effect of monotherapy with reductase inhibitors on fasting plasma lipids an 
postprandial lipemia was evaluated in 7 male, FCH subjects by standardized oral retin 
palmitate (RP)-fat loading tests. Fasting plasma triglycerides (5.6±1.3 mM, mean±SEM 
cholesterol (8.1 ±0.8 mM) and apo B (1.6 g/L) concentrations improved significantly aft 
therapy with Simvastatin (3.9±1.2 mM; 6.8±0.8 mM, and 1.3 g/L, respectively), howe^ 
er fasting HDL-C concentrations (0.60±0.1 mM) did not change significantly (0.63±0 
mM). The clearance of chylomicrons (Sf>1000; chylo) and chylo remnants (Sf<10(X 
was assessed by the areas under the respective RP curves. Single-drug therapy wii 
Simvastatin resulted in improved remnant clearance (24.4±4.1 versus 62.9±11.1 h.mg/1 
P<0.05) without changes in chylomicron clearance (52.8±12.9 versus 51,8±13.4 h.mg/L 
In 3 FCH subjects combination therapy with gemfibrozil resulted in more pronounce 
improvements in fasting plasma triglycerides (64% reduction) and apo B (23% reductioi 
concentrations and significant improvement of chylomicron clearance (chyloRP-AU( 
30.2±1.8 versus 63.4±29.4 h.mg/L; 41% improvement) and remnant clearanc 
(remnantRP-AUC 39.8±11.3 versus 88.0±22.3 h.mg/L; 51% improvement). Howeve 
HDL-C concentrations increased only by 23% (from 0.51±0.04 mmol/L to 0.62±0.C 
mmol/L). In conclusion, single drug therapy with reductase inhibitors in FCH results i  
improved fasting plasma lipids and remnant clearance without changes in HDL-C coi 
centrations. Combination therapy with fibrates results in more pronounced improvemen 
in fasting lipids and significantly improves both chylomicron and remnant clearanc 
which is reflected by a moderate increase of HDL-C concentrations.
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Gene-gene interaction between apo E and apo B in determining plasma levels of ap 
B-containing lipoproteins
C. Anders son, A. Hamsten and F. Karpe
Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, S 
171 76 Stockholm, Sweden
A common apo B gene variant consists of an insertion/deletion polymophism in the sig 
nal peptide, which has been shown to influence apo B-containing lipoprotein levels ii 
several, partly contradicting studies. The apo E gene polymorphism gives rise to threi 
common isoforms (E2, E3 and E4) associated with the low density lipoprotein (LDL) cho 
lesterol concentration.
In order to study the influence of the apo B signal peptide variants and the apo E poly 
morphism on apo B-containing lipoprotein levels, 249 healthy, 50-year-old men wen 
recruited and genotyped for the respective gene variants.
The apo B signal peptide polymorphism influenced total plasma cholesterol and LDL cho 
lesterol (ins: 3.45 vs. del: 3.68 mmol/1, p<0.05) whereas no effect was seen on VLDI 
triglycerides. The influence of the signal peptide polymorphism was further investigate! 
according to apo E genotype. Subjects with the apo E2/3 genotype (n=33) exhibited sig 
nificantly lower LDL cholesterol with the ins variant compared with the del variant (ins 
2.84 vs. del: 3.50 mmol/1 p<0.05). In contrast, apo E3/3 subjects (n=136) showed a sig 
nificant influence by the signal peptide variants on VLDL triglyceride levels (ins: 1.19 vs 
del: 0.84 mmol/1, p<0.05), but no difference in LDL cholesterol (ins: 3.59 vs. del: 3.7( 
mmol/1, ns). Due to the triglyceride phenotype in subjects with the apo E3/3 genotype, fa 
loading tests were performed in a subset (n=103) of the whole group. The baseline dif 
ference in plasma triglyceride concentration was maintained during the test and wa 
attributed to an increased abundance of large VLDL (Sf 60-400) in subjects with the in 
variant. The signal peptide polymorphism did not influence apo B48 containing lipopro 
tein levels. The fasting and postprandial ins/del triglyceride differences did however no 
remain significant after adjustment for BMI.
This investigation shows a gene-gene interaction between apo E and apo B genes in deter 
mining plasma levels of apo B-containing lipoproteins and argues for a role of the apo I 
signal peptide variants in regulation of atherogenic lipoproteins.
A p o l ip o p r o t e in  B  o v e r p r o d u c t io n  b y  t h e  p e r f u s e d
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fAbstract
The St Thomas’ Mixed Hyperlipidaemic (SMHL) rabbit (previously St Thomas’ Hospital 
rabbit) is a putative model o f familial combined hyperlipidaemia (FCH). When fed a low 
(0.08%) cholesterol diet, it exhibits elevations in both plasma cholesterol and triglyceride 
compared to New Zealand White (NZW) controls. To determine the mechanism for this 
hyperlipidaemia we studied the secretion of apolipoprotein B (apoB) containing lipoproteins 
from perfused livers o f both young and mature rabbits. During a 3 hour perfusion we 
measured the total cholesterol and triglyceride content o f the medium and the cholesterol, 
triglyceride and apoB content o f very low density lipoprotein (VLDL)! (Sf 60 - 400), VLDL2
(Sf 20 - 60), intermediate (Sf 12 - 20) and low (Sf 0 - 1 2 )  density lipoproteins (DDL, LDL). 
Lipoprotein concentrations increased linearly throughout the perfusion period. The rate of 
cholesterol output was 3-fold higher (459 vs 137 ng/g liver/min, p = 0.003) in SMHL vs 
NZW rabbits whilst that o f triglyceride was similar (841 vs 662 ng/g liver/min, NS). VLDLi 
cholesterol output was elevated 2-fold (232 vs 123 ng/g liver/min, p < 0.05) and VLDL2 + 
IDL + LDL cholesterol output, 4.5-fold (106 vs 23 ng/g liver/min, p < 0.005) in SMHL vs 
NZW rabbits. ApoB output in VLDLi was 38 ng/g liver/min in SMHL and 14 ng/g 
liver/min in NZW (NS). In SMHL VLDL2  + IDL + LDL apoB was increased 9-fold at 53 
vs 6 ng/g liver/min in NZW (p < 0.001). We conclude that the SMHL rabbit overproduces 
apoB-containing lipoproteins particularly in the VLDL2  + IDL + LDL fraction, a
characteristic consistent with its use as a model o f FCH.
Key words: Liver perfusion, lipoprotein production, VLDL, IDL, LDL, apoB production,
Froxfield Mixed Hyperlipidaemic rabbit, St Thomas Hospital rabbit.
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Introduction
Familial combined hyperlipidaemia (FCH) was first described in 1973 [1,2,3] as a monogenic 
disorder distinct from familial hypercholesterolaemia and familial hypertriglyceridaemia. 
Affected families show a range of phenotypes; elevated cholesterol, triglyceride or both, with 
an underlying increase in apoB concentration. The disorder is estimated to be associated 
with 1 in 10 premature myocardial infarctions and to affect 1-2% of the general population. 
Currently, diagnosis depends on a knowledge of family histories. However, if  a mechanism 
for the disorder could be elucidated, this may facilitate a clearer description and improved 
detection of the condition.
Animal studies may help to identify the pathogenesis o f the disease. The St. Thomas 
Hospital rabbit was first described in 1987 as exhibiting increased though variable plasma 
lipid levels [4]. Elevated very low density lipoprotein (VLDL, Sf 20 - 400), intermediate 
density lipoprotein (IDL, Sf 12 - 20) and low density lipoprotein (LDL, Sf 0 - 12) cholesterol 
and LDL triglyceride levels were seen when compared to New Zealand White (NZW) 
controls. Both the LDL particles and LDL receptors o f these rabbits were shown to be 
normal and on this basis it was proposed that these rabbits have a disorder similar to FCH. 
Little has appeared in the literature in recent years on this animal model except for a report 
from Johns Hopkins University on a strain o f rabbit derived from St Thomas Hospital rabbits 
that, on investigation provided evidence for two distinct genetic mechanisms, one acting on 
triglyceride, and the other on apoB [5]. In 1993 the remaining rabbits were used to establish 
a new colony, whose members have now been renamed the St Thomas’ Mixed 
Hyperlipidaemic (SMHL) rabbit. When fed a low cholesterol diet the rabbits from the colony 
developed mixed hyperlipidaemia. In preliminary studies performed on a group of
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moderately hyperlipidaemic rabbits we found that the lipid elevation was due to an increased 
mass o f VLDLi (S f60 -  400), VLDL2  (Sf 20 -  60), IDL and LDL [6].
Having observed a reproducible phenotype in the SMHL animals we undertook a series of 
liver perfusion experiments to measure hepatic production o f apoB-containing lipoproteins in 
these animals compared to NZW controls. Current concepts o f the aetiology o f FCH in man 
suggests that the underlying defect is an overproduction o f apoB containing lipoproteins by 
the liver [7,8], possibly as a result o f supranormal amounts of fatty acids being delivered to 
the organ from adipose tissue [9,10]. We therefore tested the hypothesis that SMHL rabbits 
have a metabolic abnormality o f apoB overproduction by the liver.
Methods .
Animals
The SMHL rabbits were maintained as an inbred colony at Froxfield Farms (Froxfield, Nr 
Petersfield, Hants., UK). Nine SMHL (5 female and 4 male) and 9 age- and sex-matched 
NZW controls were fed a chow diet (0.005% cholesterol wt/wt) (Stanrab diet, Special Diet 
Service, Witham, UK) for a minimum of 4 weeks and 10 SMHL and 10 age- and sex- 
matched NZW rabbits were fed a diet supplemented with a low (0.075% wt/wt) level o f 
cholesterol (0.08% total) for 12 weeks in order to determine the effects o f a diet with a 
slightly elevated cholesterol content on lipoprotein composition and mass.
Plasma cholesterol and triglyceride levels were measured in the inbred colony on 60 young
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SMHL, 12 young NZW, 16 mature SMHL and 18 mature NZW male rabbits fed the 0.08% 
cholesterol diet. From these animals, 17 SMHL rabbits and 19 age-matched NZW controls 
were selected for liver perfusion experiments on the basis o f their lipid levels. The selected 
rabbits had moderate mixed hyperlipidaemia; plasma cholesterol was 4.0 ± 0.8 vs 1.3 ± 0.2 
mmol/1, p < 0.005 and plasma triglyceride was 2.6 ± 0.4 vs 1.0 + 0.1 mmol/1, p < 0.001 
(SMHL vs NZW). Six SMHL and 7 NZW rabbits were studied between 11 and 16 weeks of 
age (‘young’), and the remainder were studied when more than 5 months old (‘mature’). The 
animals were housed individually in cages under standard conditions and were fed a d  l i b i t u m  
the diet containing 0.08% cholesterol.
The procedures involving animals in these studies were subject to UK Home Office 
regulations.
Surgical procedure
On the day o f the perfusion experiment the animal was terminally anaesthetised by the 
injection o f 1 ml Euthatal (Rhone M6rieux Ltd., Harlow, UK) per 1.4 kg body weight plus 1 
ml heparin (1000 iU/ml) (Leo Laboratories Ltd., Princes Risborough, UK) into the marginal 
ear vein. A thoracotomy/laparotomy was performed along the line o f the linea alba and the 
thoracic aorta was ligated using 2-0 silk (Davis and Geek, Cyanamid o f Great Britain Ltd., 
Gosport, UK). The intestines were displaced to the left and the inferior vena cava (TVC) was 
cannulated superior to the diaphragm using plastic tubing (internal diameter 2 mm, external 
diameter 3.2 mm). The hepatic portal vein (HPV) was cannulated (14G IV catheter; Vygon 
UK Ltd., Cirencester, UK), the IVC was ligated between the renal and hepatic veins 
(polyamide 66 suture, Ethicon Ltd., Edinburgh, UK) and the common bile duct was
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4cannulated (translucent vinyl tubing, internal diameter 0.63 mm, external diameter 1.4 mrr^  
Portex Ltd., Hythe, UK).
V _
Perfusion
Livers were flushed with 750 ml oxygenated Krebs Henseleit buffer [11] (pH 7.4, 37°C) at 75 
cm hydrostatic pressure prior to being connected to the perfusion apparatus. Perfusions were 
performed at 37°C in a thermostatically controlled room. The apparatus consisted of two 
peristaltic pumps (Watson Marlow MHRE and 503U), pumping buffer at 100 ml/minute with 
inflow via the HPV and outflow through the IVC. Oxygenation was by a ‘Hamilton lung’
[12] containing 5 metres o f silastic tubing. The pH was constantly monitored (Jenway 3050 
portable pH meter, Jenway, UK, Dunmow, UK) and maintained at 7.4 by the addition of 1 M 
NaHC03 when necessary. A 3.2 mm internal diameter, 6.4 mm external diameter tubing 
(AlteSil high strength tubing, Altec, Alton, UK) was used throughout the system. The total 
volume o f recirculating perfusate was 120 ml. It was not necessary to have red blood cells in 
the perfusate as preliminary experiments showed no difference in liver function, viability, 
bile output or apoB production when erythrocytes were present or absent. Their presence 
caused an artificial increase in the cholesterol concentration in the perfusate, presumably as a 
consequence o f erythrocyte degradation.
A 15 ml sample o f perfusate was withdrawn at 0, 60, 120 and 180 minutes and 5 ml samples 
were removed at 30, 90 and 150 minutes. Sample volume was replaced with an equal 
volume o f oxygenated, warmed Krebs Henseleit buffer. The liver and intestines were kept 
moist by covering with gauze soaked in buffer. The volume o f bile produced was recorded. 
At the end o f the experiment the livers were examined and found to be well perfused with no
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necrotic or hypoxic areas. Pieces o f liver were taken and stored at -70°C  for analysis o f 
their lipid content.
Analysis of perfusate
Samples o f perfusate were spun (1780 g, 10 minutes) to pellet any cellular material. 
Cholesterol, cholesterol ester, triglyceride, phospholipid (Boehringer Mannheim GmbH, 
Lewes, UK) and glycerol (Randox Laboratories Ltd., Crumlin, UK) were measured with kits
[13]. Urea, albumin, AST and GGT were determined on an Olympus A300 multichannel 
analyser using manufacturers reagents. Protein was measured by a modification [14] o f the 
method o f Lowry e t  a l  [15]. Lipoprotein subfractions were treated by the addition o f an 
equal volume o f isopropanol to precipitate apoB. The apoB content was calculated by 
subtracting isopropanol soluble protein from total protein [16].
Lipoprotein separation
Lipoproteins in the perfusate were concentrated 5 fold by centrifugation at a density o f 1.065 
g/ml (83150 g, 18 hours). The total apoB containing lipoprotein fraction so obtained was 
separated into VLDLi, VLDL2, IDL and LDL by centrifugation in a density gradient
constructed o f layers o f d = 1.0988, 1.0860, 1.0790, 1.0722, 1.0641 and 1.0588 g/ml [17, 
18]. Cholesterol, triglyceride, total protein and apoB were measured in each fraction. 
Concentrations were corrected back to that present in the original perfusate sample.
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Extraction of lipid from liver samples
Immediately on thawing, samples of liver were taken and the wet weight was recorded (0.25 
~ 0*5 g)- Following a modification [19] of the method of Folch [20], samples were 
homogenised (Janke & Kunkel KG homogeniser, Staufen I Breisgau, Germany) in small 
volumes of methanol (BDH) and the volume adjusted to 50 ml with methanol. After 
standing for 30 minutes with occasional mixing 100 ml chloroform (BDH) was added. After 
an overnight extraction at 15°C the samples were filtered (Whatmans No. 1 filter paper, 
Whatman International Ltd., Maidstone, UK) and protein precipitated by the addition of 50 
ml 0.05% calcium chloride solution. Samples were again maintained overnight at 15°C and 
the chloroform (bottom) layer removed and dried on a centrifugal evaporator (Howe). The 
pellet was redissolved in isopropanol (2 ml) and total cholesterol, cholesteryl ester, 
triglyceride and phospholipid contents were measured as above.
Measurement of VLDLi loss during perfusion
Total VLDL was isolated from 50 ml rabbit plasma at d = 1.006 g/ml (62918 g, 18 hours). 
From this VLDLi was prepared by density gradient centrifugation as described above. 
VLDLi was then labelled with Na[l25I] (Amersham International pic, Amersham, UK) as 
described previously [21].
Livers from 2 NZW rabbits (fed standard rabbit chow) were prepared as above. After taking 
a pre-treatment sample at time 0, 5 pCi of 125I-labelled VLDLi was added to the circulating 
buffer. During the perfusion VLDLi, VLDL2, IDL and LDL were isolated as described 
above, apoB was isolated, resolubilised in 0.1 M NaOH and its specific activity was
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measured.
3h  leucine experiments
To demonstrate that the accumulating lipoproteins in the recirculating perfusate represented 
newly synthesised products, the incorporation of radioactive leucine into apoB was measured 
during perfusion o f livers from 2 mature NZW and 2 mature SMHL rabbits. 100 pCi 3h  
leucine (Amersham International pic) (165 Ci/mmol) was added to the perfusate at time 0 and
further doses o f 100 pCi 3h  leucine were added at 30 minute intervals, just after each sample 
was removed for lipoprotein isolation. The specific activity o f apoB isolated from VLDLi, 
VLDL2, IDL and LDL was then determined by radioactivity measurement in a P scintillation 
counter and assay o f apoB protein as described above.
Statistical analyses
Variables were tested for normal distribution. Plasma cholesterol and triglyceride 
concentrations were transformed to a normal distribution by taking the logarithm of their 
values. Two sample t-tests were performed to determine significance. Where the 
distribution of a variable or series o f variables could not consistently be converted to normal, 
as was the case with all perfusate sample measurements, a Mann-Whitney U  test was 
performed. All statistical analyses were carried out using Minitab version 10. Data are 
expressed as mean ± standard error o f the mean (SEM) unless otherwise stated.
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Results
Effect of 0.08% cholesterol diet on plasma lipids and lipoproteins
To uncover the hyperlipidaemic phenotype in SMHL rabbits it was necessary to add a small 
amount o f cholesterol to the diet (Table 1). Cholesterol supplementation had no significant 
effect on plasma lipid levels in NZW rabbits, however plasma cholesterol was significantly 
elevated in SMHL rabbits on the 0.08% cholesterol diet compared to SMHL on normal chow 
and NZW fed either normal or supplemented diet. There were no significant differences in 
plasma triglyceride concentrations between any of the groups. It was noted that despite 
having normal total lipid levels, chow fed SMHL rabbits were dyslipidaemic. VLDL2 and 
IDL mass levels were elevated compared to NZW rabbits fed the same diet (p = 0.08, p = 
0.01 respectively). When fed the cholesterol supplemented diet all four apoB containing 
lipoproteins were increased in SMHL compared to NZW rabbits fed either normal or 
supplemented diet.
Population lipids and lipoproteins
In the male rabbits in the colony screened for plasma lipid levels prior to selection of animals 
for perfusion experiments, plasma cholesterol levels o f both young and mature SMHL rabbits 
were significantly elevated (though variable) compared to NZW rabbits (5.97 ± 0.37 vs 1.79 
± 0.14 mmol/1, p < 0.001 and 3.11 ± 0.95 vs 1.32 + 0.23 mmol/1, p = 0.04, in young and 
mature rabbits respectively (Figure 1A)). Plasma triglyceride levels were significantly
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elevated in young SMHL rabbits compared to NZW controls (3.31 ± 0.25 vs 1.14 + 0.14 
mmol/1, p < 0.001 (Figure IB)) but not in mature SMHL vs NZW animals. SMHL rabbits 
showed a decrease with age in plasma lipid concentrations, p = 0.006 for young vs mature 
cholesterol levels and p < 0.001 for young vs mature triglyceride levels (Figure 1) but NZW 
rabbits did not.
Perfusion experiments
Liver perfusion experiments were performed on young and mature SMHL and NZW rabbits 
that had been fed the 0.08% cholesterol diet from weaning. Liver function tests were normal 
throughout the perfusions. The livers remained patent and produced bile at 27 ,17 ,29  and 15 
pl/liver/minute in young NZW, young SMHL, mature NZW and mature SMHL respectively 
(none o f these was significantly different). Examination o f the livers at the end o f the 
experiment revealed no necrotic or hypoxic areas. Mean age at sacrifice for young NZW vs 
SMHL rabbits was 3.0 vs 2.8 months, mean body weight was 2.5 vs 2.0 kg and mean liver 
weight was 71 vs 74 g, and mean age at sacrifice for the mature NZW vs SMHL rabbits was 
9.8 vs 10.2 months, mean body weight was 4.0 vs 3.6 kg and mean liver weight was 103 vs 
92 g.
In those rabbits selected for perfusion studies the mean plasma cholesterol and triglyceride 
levels were elevated in SMHL compared to NZW controls and similar to the mean values 
seen for the whole colony. Thus in young animals used for perfusion studies plasma 
cholesterol was 3.7 ± 0.4 mmol/1 in SMHL and 1.0 ± 0.2 mmol/1 in NZW (p = 0.001), while 
plasma triglyceride was 3.6 ± 0.9 mmol/1 in SMHL and 0.7 ± 0.07 mmol/1 in NZW (p = 
0.005). In mature rabbits plasma cholesterol was 4.1 ± 1.3 vs 1.4 ± 0.3 mmol/1 (p < 0.05)
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and plasma triglyceride was 2.0 ± 0.4 vs 1.2 ± 0.1 mmol/1 (NS) (SMHL vs NZW 
respectively).
Lipid levels during perfusion
Mean perfusate cholesterol and triglyceride levels rose linearly in all groups of rabbits over 
the 180 minutes o f the experiment (Figure 2). Only data up to 150 minutes were available 
from the perfusate experiments with the young SMHL rabbits. In young rabbits, cholesterol 
content in the perfusate was barely measurable in the NZW group rising to 2.0 ± 0.5 pg/g 
liver after 180 minutes, however in the perfusate from the SMHL rabbits the cholesterol 
content rose from 5 ± 5 t o 5 8 ± 3 1  pg/g liver at 150 minutes, and was significantly higher 
when compared to that from NZW rabbits at all time points from 60 minutes until the end of 
the experiment. In young rabbits the calculated cholesterol output was 380 ± 170 vs 10 ± 6 
ng/g liver/minute (SMHL vs NZW, p < 0.01). Perfusate cholesterol levels in the mature 
rabbits rose from 7 ± 5 to 41 ± 11 pg/g liver in NZW rabbits during the experiment and from 
6 ± 4 to 96 ± 21 pg/g liver in SMHL rabbits. The cholesterol content o f the perfusate was 
significantly increased in SMHL rabbits in samples taken at 60, 90 and 150 minutes and the 
calculated cholesterol output was 510 ± 1 0 1 v s 220 ± 67 ng/g liver/minute in SMHL vs NZW 
rabbits (NS). Mature NZW rabbits had a significantly greater cholesterol output compared 
to young NZW of 220 ± 67 vs 10 ± 6 ng/g liver/minute (p < 0.005). SMHL rabbits on the 
other hand did not show a significant effect o f age.
The mean triglyceride output was higher in young SMHL rabbits compared to young NZW 
but this did not reach significance (810 ± 290 vs 270 ± 100 ng/g liver/minute, p = 0.12). 
Perfusate triglyceride rose from 0 to 48 ± 24 pg/g liver in NZW rabbits and from 0 to 144 ±
12
63 pg/g liver in SMHL rabbits, reaching a significantly higher level when compared to NZW 
rabbits from 90 - 150 minutes. Mature rabbits in both groups showed a similar triglyceride 
output o f 860 + 130 vs 890 ± 246 ng/g liver/minute (SMHL vs NZW respectively, NS). 
Triglyceride perfusate levels rose from 5 ± 4 to 160 ± 50 and 0 to 149 ± 29 pg/g liver in the 
NZW and SMHL respectively. Neither NZW nor SMHL rabbits showed any significant age 
related differences in triglyceride output.
Lipoprotein production during perfusion
The lipoproteins in the perfusate were separated and their cholesterol and triglyceride 
contents were analysed. Data are shown in Table 2. In young rabbits, VLDLi, VLDL2 and 
IDL cholesterol output were significantly increased in SMHL compared to NZW rabbits but 
no difference was seen in LDL cholesterol output. VLDL2 triglyceride output was 
significantly increased in SMHL rabbits. In mature SMHL rabbits mean IDL triglyceride 
was increased compared with NZW rabbits (p < 0.05, Table 2) but no other significant 
differences were observed in individual fractions. We then compared the output of 
triglyceride-rich and cholesterol-rich lipoproteins from the liver. The cholesterol and 
triglyceride contents o f VLDL2, IDL and LDL (i.e. non VLDLi) were combined as these 
represent cholesterol-rich lipoproteins and the values obtained were compared with those for 
the triglyceride-rich VLDLi (Figure 3). In young rabbits perfusate levels o f VLDLi
cholesterol rose from 0 to 12.5 ± 4 pg/g liver in NZW rabbits and from 0.8 ± 0.3 to 37.8 ± 
12.2 pg/g liver in SMHL rabbits (Figure 3A), being significantly higher in SMHL rabbits at 
all time points from 3 0 - 150 minutes. VLDLi cholesterol output was significantly increased 
in young SMHL rabbits compared to NZW rabbits (237 vs 60 ng/g liver/minute respectively, 
Table 2). Non VLDLi perfusate cholesterol levels rose from 0.6 ± 0.4 to 4.7 ± 1 .7  and from
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0.7 ± 0.7 to 18.8 ± 11 pg/g liver in NZW and SMHL rabbits respectively and were 
significantly higher in SMHL rabbits between 90 and 150 minutes. Non VLDLi cholesterol
output rate was elevated in SMHL rabbits compared to NZW rabbits (118 ± 56 vs 21 ± 8 ng/g 
liver/minute respectively, p = 0.01).
In mature rabbits there was no significant difference in mean VLDLi cholesterol output 
between the two strains o f rabbit (160 vs 229 ng/g liver/minute, NZW vs SMHL, Table 2).
In NZW rabbits, VLDLi perfusate cholesterol levels rose from 0 to 25 ± 8 pg/g liver (Figure
)
3B), and in SMHL rabbits from 0 to 46 ± 11 pg/g liver over the three hours o f the 
experiment. Although there was a 5-fold increase in SMHL rabbit non VLDLi cholesterol
output when compared to NZW rabbits this was not significant (98 + 28 vs 23 ± 4 ng/g 
liver/min). Non VLDLi cholesterol levels increased from 0 to 21 ± 7 and 1 ± 1 to 5 ± 2 pg/g 
liver in SMHL and NZW rabbits respectively during the three hour perfusion, reaching 
significance at 30, 90 and 150 minutes.
There were no significant differences in VLDLi triglyceride output rates in young NZW vs 
SMHL rabbits because o f the large inter-animal variability (Table 2, Figure 3C). Likewise in 
mature animals VLDLi triglyceride output was similar in the two groups (Table 2, Figure 
3D). However, VLDLi triglyceride concentration was higher in the perfusate from young 
SMHL vs NZW rabbits at 60, 90 and 150 minutes. Non VLDLi triglyceride output was 
higher in the perfused livers from young SMHL rabbits than from young NZW rabbits (153 ± 
93 vs 20 ± 6 ng/g liver/minute respectively, p < 0.05), and non VLDLi triglyceride 
concentrations were significantly higher at all time points from 60 minutes to 150 minutes. 
In mature SMHL perfused livers non VLDLi triglyceride output rates tended to be higher
14
than in those from NZW rabbits although the difference was not significant (78 ± 38 vs 30 ± 
11 ng/g liver/minute respectively). There was however a significant increase in the non 
VLDLi triglyceride concentration in the perfusate from the mature SMHL rabbits after 180 
minutes.
ApoB output from perfused livers
Apolipoprotein B was measured in the individual lipoproteins secreted into the hepatic 
perfusate. The results are shown in Table 2 and Figure 4. ApoB as a percentage o f total 
lipoprotein protein was similar in SMHL and NZW rabbits. In VLDLi it comprised 41% of 
the total protein in SMHL vs 38% in NZW rabbits, in VLDL2 60% vs 64%, in IDL 79% vs 
82% and in LDL 75% vs 76%. Individual VLDLi, VLDL2  and IDL apoB outputs were
significantly elevated in young SMHL rabbits compared to NZW controls (Table 2). In 
mature rabbits, mean VLDLi apoB output was not significantly different between the two
strains but VLDL2  and IDL apoB output were both significantly increased in SMHL 
compared to NZW rabbits. In livers from young rabbits the VLDLi apoB output was higher 
in SMHL than in NZW controls (79 vs 22 ng/g liver/minute respectively, Table 2). Non- 
VLDLi apoB output in SMHL rabbits was 80 ± 41 ng/g liver/minute vs 6 ± 3 ng/g
liver/minute in NZW rabbits (p < 0.005) (Figure 4A). The total apoB output was 
significantly higher in livers from SMHL rabbits compared to NZW (159 ± 56  vs 28 ± 7 ng/g 
liver/minute, p < 0.01). In contrast to the situation in young animals, livers from mature 
NZW rabbits released VLDLi and non-VLDLi apoB at similar rates (Table 2). There were 
no significant differences in VLDLi apoB concentrations during the perfusion in SMHL and 
NZW rabbits but non-VLDLi apoB concentrations were significantly increased in SMHL 
rabbits at all time points from 30 minutes until the end o f the experiment (Figure 4B). Non-
VLDLi apoB output was increased 6-fold in SMHL rabbits relative to NZW (36 ± 12 vs 6 ±
3 ng/g liver/minute respectively, p = 0.01). The non VLDLi apoB output accounted for 75% 
of the total apoB output. However the total apoB output in these mature rabbits was not 
significantly increased in the SMHL rabbit group (48 ± 1 4 v s l 6 ± 4  ng/g liver/minute in 
SMHL and NZW, p = 0.07).
VLDLi apoB output was significantly increased in the young NZW compared to the mature 
NZW (22 vs 10 ng/g liver/minute respectively, p = 0.04, Table 2) and in young SMHL versus 
mature SMHL rabbits (79 vs 15 ng/g liver/minute respectively, p < 0.01, Table 2). No 
differences were found between the young and mature rabbits o f either strain in non-VLDLi 
apoB output.
When both young and mature NZW and SMHL rabbits were grouped together, there was a 
highly significant correlation between the rate of apoB output by the perfused livers and 
plasma cholesterol levels at time o f sacrifice (r = 0.72, p < 0.001) (Figure 5A). Plasma 
triglyceride was also significantly correlated with total apoB output rate ( r= 0.67, p < 0.001)
i
(Figure 5B).
To examine the extent to which VLDLi was converted to denser lipoproteins during the 3 
hour perfusion, 125I labelled VLDLi was added to the perfusate o f 2 NZW rabbits 10 minutes 
prior to the beginning o f the experiment. ApoB was isolated to follow the fate o f the 
particles. At time 0, 93% of apoB radioactivity was found in the VLDLi fraction, with 6% 
in VLDL2 and 1% in IDL. After 3 hours 77% of the counts remained in VLDLi, 7.5% were 
found in VLDL2, 2.5% in DDL and 1.5% in LDL. The lack of increase in VLDL2, IDL and 
LDL radioactivity indicated that delipidation was limited in this system.
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In order to show that the lipoproteins that accumulated were derived by d e  n o v o  production 
of apoB, 3H leucine was added to the perfusate o f 2 mature NZW and 2 mature SMHL 
rabbits. By 3 hours, leucine radioactivity in VLDLi apoB rose by an average of 5-fold 
above the zero time value in NZW and 15-fold in SMHL rabbit livers, in VLDL2 it rose 2 
and 6-fold; in EDL, 2 and 2-fold and in LDL, 2 and 3-fold respectively showing that the liver 
was synthesising these lipoproteins.
Liver lipids
Hepatic lipid concentrations were measured after the perfusion experiments. Young and 
mature NZW and SMHL rabbits were found to have very similar concentrations of 
cholesterol, free cholesterol, triglyceride and phospholipids in their livers. Mature NZW 
rabbits stored more cholesterol (total and free) in their livers than did young NZW rabbits 
(total cholesterol 15.4 ± 1.9 vs 6.0 ± 1.1 mg/g wet weight liver respectively, p = 0.015 and 
free cholesterol 7.4 ± 1.3 vs 3.3 ± 0.8 mg/g wet weight liver respectively, p = 0.017). The 
lipids in the livers o f SMHL rabbits did not differ with age and were not significantly 
different to those in NZW rabbits (total cholesterol 7.9 ±2.1 vs 12.2 ± 2.3 mg/g wet weight 
liver and free cholesterol 5.0 ± 1.3 vs 8.2 ±1 .5  mg/g wet weight liver in young vs mature 
SMHL rabbits respectively). Triglyceride concentrations did not vary between the mature 
rabbits o f either strain but young NZW and SMHL rabbits showed a difference (13.0 ± 0.97 
vs 9.7 ± 0.96 mg/g wet weight o f liver, NZW vs SMHL, p = 0.05). Phospholipid 
concentrations were significantly higher in mature SMHL rabbits than mature NZW rabbits 
(17.3 ± 0.5 vs 15.4 ± 0.6 mg/g wet weight liver respectively, p = 0.046). When young and 
mature rabbits were grouped together the only difference was a significant increase in
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triglyceride concentrations in the NZW rabbits (13.4 + 0.78 vs 10.6 ± 1.2 mg/g wet weight o f 
liver, NZW vs SMHL, p < 0.05).
Discussion
Appearance o f the hyperlipidaemic phenotype o f SMHL rabbits is dependent on 
supplementing their diet with a small amount of cholesterol. NZW animals fed the same diet 
showed no change in plasma lipid levels. However, even on the chow diet, plasma VLDL2 
and DDL lipoprotein concentrations were elevated in SMHL rabbits indicating the presence of 
a lipoprotein disturbance. In the large series o f animals studied from the SMHL rabbit colony 
the plasma lipid pattern was variable with increases in both cholesterol and triglyceride being 
the most common phenotype. More detailed examination showed that all four apoB 
containing lipoprotein species were elevated in SMHL rabbits fed the cholesterol 
supplemented diet. Therefore these animals derived from the original St Thomas Hospital 
stock express a consistent mixed hyperlipidaemia compatible with their potential role as an 
animal model for FCH. The colony is inbred and as yet no attempt has been made to 
investigate the genetics o f the disorder. In examining the animals over a period o f time it 
was clear that the hyperlipidaemia in male SMHL rabbits decreased with age (Figure 1) and 
we have recently reported [22] that plasma cholesterol and triglyceride levels in male SMHL 
animals decline steadily from 8 weeks o f age reaching a plateau at 14-16 weeks. We 
therefore made the decision to study both young and mature rabbits in the perfusion 
experiments.
Rabbits used in the perfusion studies had plasma lipid levels close to the mean values o f the 
groups from which they were selected. When all rabbits studied (young and mature) were 
grouped together, triglyceride, cholesterol and apoB accumulated in the recirculating medium
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in an approximately linear manner over the 3 hour perfusion period. Output rates for 
triglyceride were similar to those previously published for perfused rabbit livers [23]. 
Comparing hepatic triglyceride output in the four apoB containing lipoproteins in SMHL and 
NZW animals revealed no difference in VLDLi despite the fact that this was the most 
abundant triglyceride carrying particle released from the liver. VLDL2 and IDL triglyceride 
output rates were significantly increased in SMHL rabbits when both young and mature 
rabbits were combined, but there was no difference in LDL triglyceride output. Cholesterol 
output however was substantially higher from SMHL vs NZW livers in VLDLi, VLDL2 and 
IDL fractions (Table 2, Figure 3). The 5-fold higher output o f cholesterol in 
VLDL2+IDL+LDL from SMHL livers was accompanied by a 9-fold increase in apoB 
released in these denser lipoprotein particles. Given that 55% o f apoB released from the 
livers o f SMHL animals appeared in the non-VLDLi density range and the finding that only a 
trivial amount o f denser lipoproteins are generated by delipidation o f VLDLi during the 
perfusion (lipase is removed from the liver during the heparin flush and little activity 
reappeared during perfusion, data not shown) we surmised that these rabbits overproduced 
these denser lipoproteins. Thus the elevation in plasma levels o f VLDLi VLDL2, IDL and 
LDL seen in Table 1 is likely to be due to increased hepatic production o f these species rather 
than decreased catabolism. In the original metabolic studies by La Ville e t  a l  [4] on St 
Thomas Hospital rabbits, no difference was seen in receptor mediated catabolism o f LDL and 
in kinetic experiments with VLDL and LDL tracers in intact animals, an increase in 
production was suggested as the basis of the hyperlipidaemia. A lower fractional catabolic 
rate was seen for LDL but this was attributed to saturation o f receptors by the expanded LDL 
pool [4]. The present perfusion experiments provide direct evidence for apoB 
overproduction as the underlying cause of the hyperlipidaemia in this animal model. The 
correlation o f apoB output with plasma cholesterol and triglyceride levels provides strong
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support that apoB output is a major determinant o f circulatory cholesterol and triglyceride 
levels (Figure 5). Despite the differences in lipoprotein production between SMHL and 
NZW rabbits there was no gross difference in the liver content of cholesterol or triglyceride 
and it may be that lipid availability was not the basis of the variation in lipoprotein 
production rates, although critical lipid pools more closely associated with lipoprotein 
assembly were not measured.
These studies demonstrate again that apoB containing lipoproteins can be generated by the 
liver across a wide spectrum of composition and size. Previous i n  v i v o  tracer studies from 
this [24, 25] and other laboratories [26] showed that not all LDL derives from VLDL 
delipidation. Rather it is necessary to postulate that small VLDL, IDL and LDL can also be 
produced directly by the liver to explain satisfactorily the findings o f kinetic studies. In 
earlier rabbit liver perfusion studies in control and Watanabe Heritable Hyperlipidaemic 
rabbits, virtually all apoB was released as VLDL, leading to the suggestion that ‘direct’ LDL 
synthesis was really due to very rapid lipolysis. In young NZW animals we can confirm 
these findings, almost all output o f triglyceride and apoB is in the form of VLDL, particularly 
VLDLi (Table 2). We found little evidence for extensive delipidation in our perfusion 
system and demonstrated also linear H leucine incorporation into the apoB of denser 
lipoproteins throughout the 3 hour period indicating that these species did not derive from 
wash out o f the space o f Disse as has been suggested previously [23]. The observation that 
up to half o f the apoB output from the liver o f mature NZW or young or mature SMHL 
rabbits was in the form of VLDL2 or DDL leads us to conclude that direct production of these 
species does occur.
SMHL rabbits therefore have a combined hyperlipidaemic phenotype compatible with their
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use as a potential animal model o f FCH. The demonstration that apoB overproduction is the 
underlying metabolic defect increases the analogy with the human situation. Our finding that 
the lipoproteins released in this inherited hyperlipidaemia can range in size across the entire 
apoB containing lipoprotein spectrum, highlights a possible mechanism to explain the inter- 
and intra-individual variability o f the lipid phenotype in FCH. An underlying overproduction 
of apoB containing lipoproteins could reveal itself as raised VLDL or raised LDL levels.
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Table 1
Effect o f 0.08% cholesterol diet on plasma lipid and lipoprotein levels
in SMHL and NZW rabbits
Cholesterol diet Chow diet
NZW SMHL NZW SMHL
Number 10 10 9 9
Cholesterol
(mmol/1)
1.6 ±0.3 3.8 ± 0.7“'6 0.8 ±0.1 1.1 ±0.2
Triglyceride
(mmol/1)
0.49 ± 0.04 1.3 + 0.46 0.8 ± 0.2 1.2 ±0.3
VLDLi mass 
(mg/dl)
16 + 4 97 ± 35° 38 ± 11 43 ± 16
VLDL2 mass 
(mg/dl)
21 ± 5 99 + 22“’* 10 ± 4 20 ± 4
DDL mass 
(mg/dl)
31 ± 10 108 ± 24“’* 7 ± 1 18 ± 3
LDL mass 
(mg/dl)
15 + 4 36 ± 6 aJ> 4 ± 1 7 ± 2
Plasma lipid and lipoprotein measurements in NZW and SMHL rabbits fed either normal 
(0.005% cholesterol) or 0.08% cholesterol diet (mean ± SEM). Significant differences p < 
0.05 using the Mann Whitney U  testa SMHL vs NZW on 0.08% cholesterol diet, b SMHL on 
0.08% cholesterol diet vs SMHL on normal diet.
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Table 2
VLDLi, VLDL2, IDL and LDL cholesterol, triglyceride and apoB output 
(ng/g liver/min) in young and mature NZW and SMHL rabbits fed a
0.08% cholesterol diet from weaning
Cholesterol Triglyceride ApoB
Young NZW SMHL NZW SMHL NZW SMHL
VLDLi 60 ± 19 237 + 68° 374 ± 93 658 ± 177 22 ± 4 79 ± 2 9 °
v l d l 2 9 ± 5 73 + 26c 17 + 3 87 + 4 4 ° 3 ± 1 36 ± 13c
IDL 3 + 2 40 + 26" 5 ± 2 55 ± 40 1 ± 1 37 ± 23*
LDL 2 + 2 10 ± 7 5 + 2 9 ± 7 2 ± 1 7 ± 5
Mature
VLDLi 160 + 45 229 + 52 408 + 97 476 ± 84 10 ± 3 15 ± 4
VLDL2 18 + 6 65 + 20 13 ± 3 56 ± 30 2 ± 1 14 ±5°
IDL 8 ± 2 26 ± 10 5 ± 2 19 ±6° 3 ± 1 16 ±6"
LDL 2 ± 1 7 ± 3 4 ± 2 8 ± 3 0 6 ± 2
VLDLi, VLDL2, IDL and LDL cholesterol, triglyceride and apoB output (ng/g liver/minute) 
in young and mature NZW and SMHL rabbits (mean ± SEM). Significant differences " p < 
0.05, * p < 0.01, c p < 0.005 between NZW and SMHL rabbits using the Mann Whitney U  
test.
28
Figure Legends
Figure 1. A. Distribution o f plasma cholesterol concentrations in male NZW and SMHL 
rabbits. Levels were determined in young SMHL rabbits (n = 60), mature SMHL rabbits (n 
= 16), young NZW rabbits (n = 11) and mature NZW rabbits (n = 18). B. Distribution of 
plasma triglyceride concentrations in NZW and SMHL rabbits. The horizontal line 
represents the median, the upper and lower limits o f the box are the 75 and 25 percentile, the 
vertical lines show the range and the asterisks represent outliers.
Figure 2. A. Mean cholesterol output from the liver o f NZW and SMHL rabbits during the 
three hours o f the perfusion study. The point missing at 180 minutes for young SMHL 
rabbits is due to insufficient data at that time. Young NZW (— ▲— ), mature NZW 
(— • — ), young SMHL (--A--), mature SMHL (—• —). Significant differences (young or 
mature NZW vs SMHL) * p < 0.05 by the Mann Whitney U  test. B. Mean output o f 
triglyceride from the livers o f NZW and SMHL rabbits during the three hours o f the 
perfusion study.
Figure 3. A. Mean VLDLi and nonVLDLi cholesterol output in young NZW and SMHL 
rabbits. NZW VLDLi (—A—), NZW nonVLDLi (— • — ), SMHL VLDLi ( -A -) , SMHL 
nonVLDLi (—• —). Significant differences (NZW vs SMHL) * p < 0.05 by the Mann
Whitney U  test. B. Mean VLDLi and nonVLDLi cholesterol output in mature NZW and
SMHL rabbits. C. Mean VLDLi and nonVLDLi triglyceride output in young NZW and
SMHL rabbits. D. Mean VLDLi and nonVLDLi triglyceride output in mature NZW and
SMHL rabbits.
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Figure 4. A. Mean VLDLi and nonVLDLi apoB output from young NZW and SMHL 
rabbits. NZW VLDLi (— A — ), NZW nonVLDLi (— • —), SMHL VLDLi (~ A - ) ,  SMHL 
nonVLDLi Significant differences (NZW vs SMHL) * p < 0.05 by the Mann
Whitney U  test. B. Mean VLDLi and nonVLDLi apoB output from mature NZW and 
SMHL rabbits.
Figure 5. Correlation of apoB output rates with plasma cholesterol (A) and triglyceride (B) 
concentrations in NZW rabbits (A ) and SMHL rabbits ( • )  at the time of sacrifice.
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